Quality assurance in rectal cancer treatment by Dulk, Marcel den
Quality assurance in rectal cancer treatment
Marcel den Dulk
Cover: The universal symbol of colorectal cancer: the Blue Star. It is a combination of a 
star and a ribbon, reflecting power, hope, and awareness.
© M. den Dulk, 2009
ISBN: 978-90-8559-551-9
Printing of this thesis was financially supported by Duo-Med NV, Covidien, CombiCare 
BV, Hollister BV, J.E. Jurriaanse Stichting, Amgen BV, B. Braun Medical BV, Coloplast BV, 
Dansac Nederland, EuroTec BV, EUSA Pharma BV, Fresenius Kabi, GlaxoSmithKline BV, 
Johnson & Johnson Medical BV, KCI Medical BV, Laprolan BV, MammaPrint, Merck Serano 
Oncology, Nestlé Healthcare Nutrition, Norgine BV, Novartis Oncology, Nycomed BV, 
Olympus Nederland BV, Pfizer BV, sanovi-aventis, Taureon, and Roche Nederland BV.
Layout and print: Optima Grafische Communicatie, Rotterdam, The Netherlands
Quality assurance in rectal cancer treatment
Proefschrift
ter verkrijging van
de graad Doctor aan de Universiteit Leiden,
op gezag van de Rector Magnificus prof. mr. P.F. van der Heijden,
volgens besluit van het College van Promoties
te verdedigen op woensdag 9 september 2009
klokke 15.00 uur
door
Marcel den Dulk
geboren te Leidschendam
in 1976.
ProMotiecoMMissie
Promotoren: prof. dr. C.J.H. van de Velde
 prof. dr. C.A.M. Marijnen
Overige leden: prof. dr. R.A.E.M. Tollenaar
 prof. dr. T. Wiggers (Universitair Medisch Centrum Groningen, Groningen)
 dr. H.J.T. Rutten (Catharina-ziekenhuis, Eindhoven)
 dr. W.H. Steup (HagaZiekenhuis, Den Haag)
The research described in this thesis was conducted at the department of Surgery of the 
Leiden University Medical Center, Leiden, the Netherlands and the department of Sta-
tistics, European Organisation for Research and Treatment of Cancer. The author of this 
thesis was supported by a Fellowship from the European Society of Surgical Oncology.
contents
1 General introduction and outline of the thesis.
In part published as: Quality assurance in surgical oncology: the tale of the 
Dutch rectal cancer TME trial.
M. den Dulk, C.J.H. van de Velde
J Surg Oncol 2008; 97: 5-7.
7
2 Improved overall survival for patients with rectal cancer since 1990: the 
effects of TME surgery and preoperative radiotherapy.
M. den Dulk, P. Krijnen, C.A.M. Marijnen, H.J.T. Rutten, L.V. van de 
Poll-Franse, H. Putter, E. Meershoek-Klein Kranenbarg, M.L.E.A. Jansen-
Landheer, J.W.W. Coebergh, C.J.H. van de Velde.
Eur J Cancer 2008; 44: 1710-1716.
19
3 Survival of elderly rectal cancer patients not improved: analysis of 
population-based data on the impact of TME surgery.
H.J.T. Rutten, M. den Dulk, V.E.P.P. Lemmens, G.A.P. Nieuwenhuijzen, P. 
Krijnen, M.L.E.A. Jansen-Landheer, L.V. van de Poll Franse, J.W.W. Coebergh, 
H. Martijn, C.A.M. Marijnen, C.J.H. van de Velde.
Eur J Cancer 2007; 43: 2295-2300.
33
4 Controversies of total mesorectal excision for rectal cancer in elderly 
patients.
H.J.T. Rutten, M. den Dulk, V.E.P.P. Lemmens, C.J.H. van de Velde, C.A.M. 
Marijnen.
Lancet Oncol 2008; 9: 494-501.
47
5 The abdominoperineal resection itself is associated with an adverse 
outcome: the European experience based on a pooled analysis of five 
European randomised clinical trials on rectal cancer.
M. den Dulk, H. Putter, L. Collette, C.A.M. Marijnen, J. Folkesson, J. F. Bosset, 
C. Rödel, K. Bujko, L. Påhlman, C.J.H. van de Velde.
Eur J Cancer 2009; 45: 1175-1183.
65
6 Risk factors for adverse outcome in patients with rectal cancer treated 
with an abdominoperineal resection in the total mesorectal excision trial.
M. den Dulk, C.A.M. Marijnen, H. Putter, H.J.T. Rutten, G.L. Beets, T. Wiggers, 
I.D. Nagtegaal, C.J.H. van de Velde.
Ann Surg 2007; 246: 83-90.
81
6 Contents
7 Quality of surgery in T3-4 rectal cancer: involvement of circumferential 
resection margin not influenced by preoperative treatment. Results from 
EORTC trial 22921.
M. den Dulk, L. Collette, C.J.H. van de Velde, C.A.M. Marijnen, G. Calais, L. 
Mineur, P. Maingon, L. Radosevic-Jelic, A. Daban, J.F. Bosset.
Eur J Cancer 2007; 43: 1821-1828.
97
8 Patients with curative resection of cT3-4 rectal cancer after preoperative 
radiotherapy or radiochemotherapy: does anybody benefit from adjuvant 
fluorouracil-based chemotherapy? A trial of the European Organisation for 
Research and Treatment of Cancer Radiation Oncology Group.
L. Collette, J.F. Bosset, M. den Dulk, F. Nguyen, L. Mineur, P. Maingon, L. 
Radosevic-Jelic, M. Piérart, G. Calais.
J Clin Oncol 2007; 25: 4379-4386.
113
9 The association between diverting stomas and symptomatic anastomotic 
leakage after low anterior resection for rectal cancer.
M. den Dulk, C.A.M. Marijnen, L. Collette, H. Putter, L. Påhlman, J. 
Folkesson, J.F. Bosset, C. Rödel, K. Bujko, C.J.H. van de Velde.
Br J Surg 2009, accepted.
129
10 Improved diagnosis and treatment of anastomotic leakage after colorectal 
surgery.
M. den Dulk, S.L. Noter, E.R. Hendriks, M.A.M. Brouwers, C.H. van der Vlies, 
R.J. Oostenbroek, A.G. Menon, W.H. Steup, C.J.H. van de Velde.
Eur J Surg Oncol 2009; 35: 420-426.
145
11 A multivariate analysis of limiting factors for stoma reversal in patients 
with rectal cancer entered into the total mesorectal excision (TME) trial: a 
retrospective study.
M. den Dulk, M. Smit, K.C.M.J. Peeters, E. Meershoek-Klein Kranenbarg, 
H.J.T. Rutten, T. Wiggers, H. Putter, C.J.H. van de Velde.
Lancet Oncol 2007; 8: 297-303.
159
12 General discussion 175
Summary 185
Nederlandse samenvatting 193
13 Acknowledgements 203
Curriculum Vitae 205
List of publications 207
chapter 1
General introduction and outline of the thesis
Published in part in: 
J Surg Oncol 2008; 97: 5-7.

General introduction and outline of the thesis 9
introDuction
The incidence of cancer is increasing in Europe.1,2 With an estimated 3.2 million new 
cases of cancer and 1.7 million deaths due to cancer in 2006 in Europe, it is an important 
health problem.1 Colorectal cancer is the cancer with the second highest incidence and 
accounts for 412,900 (12.9%) new cases a year.1 Besides, it is the second cause of cancer 
death with an estimated 207,400 deaths a year in Europe.1 In the Netherlands, 10,851 pa-
tients were diagnosed with colorectal cancer in 2005.3 In general, rectal cancer accounts 
for roughly 35% of colorectal cancers; currently over 3,000 patients are diagnosed with 
rectal cancer a year.
Quality assurance in surgical oncology
For almost all solid organ cancers, randomised trials have been performed to study new 
treatment protocols. It is recognised that variability in treatment could influence treat-
ment outcome and consequently this confounder should be minimised. In radiotherapy, 
several actions have been taken to reduce variation, such as dosimetry or a pre-trial 
dummy run.4-10 Moreover, also for systemic treatment such as chemotherapy, several cri-
teria were defined which were used to asses treatment variation in oncological trials.11-13
In contrast to drugs, which are reproducible entities, a characteristic of operations 
is the large variability making it difficult to reproduce the results. A major variable re-
sponsible for this variability is the skills of the surgeon. In 1991, McArdle and Hole wrote 
that “some surgeons perform less than optimal surgery… If by meticulous attention to 
detail the results of surgery could be improved, and our results suggest that this would 
not be difficult, the impact on survival might be greater than that of any of the adjuvant 
treatment therapies currently under study”.14 The skill level of surgeons will not only 
vary among surgeons, but will increase as a surgeon gains experience. Besides, surgeons 
with specific interests will perform better and develop more new techniques.14,15 These 
new techniques are often tested and analysed in their own centre. This partly explains 
why so many non-randomised single centre or personal series are reported in surgery.
It is a prerequisite for a randomised trial that the participating surgeons are equally 
skilled in both techniques. Differences in performances between individual surgeons are 
rather the rule than the exception. To solve this problem one group of surgeons could 
only perform the conventional procedure and another group only the experimental 
operation: a so-called expertise based randomised trial.16 Another option is to train all 
surgeons to perform the procedure in the same way and at a similar level. Quality assur-
ance aims at reducing variability and can be defined as the systematic measures required 
to achieve a treatment result that meets a certain standard. It is a process in which con-
tinuous quality improvement is a central issue. Surgical quality assurance measurements 
were used in the Dutch D1-D2 gastric cancer trial and later in the Dutch TME trial.17-21
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Quality control in gastric cancer surgery
From August 1989 to June 1993 the Dutch D1-D2 Gastric cancer trial was performed.17 
This trial randomised patients between a limited D1 and an extended D2 lymph node 
dissection. In the design of this trial, quality assurance measures for both surgery and 
pathology were incorporated.17,18,21 Participating surgeons received videotapes and book-
lets about the technique and were instructed in the operating room by a gastric-cancer 
surgeon from Japan.21 This instructing surgeon was present during the first 4 months of 
the trial, which served as an instruction period. He was also present regularly thereafter. 
Eight surgeons, from 8 regions, had been specially trained in D2 dissection. These spe-
cially trained consulting surgeons attended all operations involving D2 dissections. The 
study coordinator attended nearly all D1 dissections. The consulting surgeons and the 
study coordinator monitored the technique and the extend of the lymph node dissec-
tion, and after the operation, they divided the perigastric tissue into the proper lymph 
node stations. Regular meetings about the technique were held with the consulting 
surgeons, the study coordinator, and the instructing surgeon.18
Quality control was also used for pathological examination in the Dutch D1-D2 
trial. The number and location of lymph nodes detected at pathological examination 
were related to the guidelines of the study protocol.22 If at pathological examination 
lymph nodes were detected in stations other than those specified by the protocol, this 
violation of the protocol was called “contamination”. If, however, the pathologist could 
not detect lymph nodes in stations that should have been dissected, this violation was 
called “non-compliance”. These violations could occur in both D1 and D2 dissections. 
Contamination in the D1 group and non-compliance in the D2 group could blur the 
distinction between the 2 types of dissection. To account for biological variation, one 
missing station was allowed.18
At the start of the trial, historical data was used to calculate the expected 5-year 
survival rates after dissection with curative intent: 20% for patients who had a D1 dis-
section and 32% for patients who had a D2 dissection.18,23 Although the trial could not 
demonstrate a difference in overall survival, the 5-year survival rates were much higher 
than expected: 45% after a D1 dissection and 47% after a D2 dissection.24 Part of this im-
proved outcome could be explained by an unexpectedly high proportion of pathologi-
cal T1 (26%) and T2 (47%) tumours, but it could not account for the complete difference. 
The process of instructing surgeons by videotapes, booklets and instruction sessions, in 
combination with supervision of dissections by instructor surgeons to standardise the 
procedure also paid off.
General introduction and outline of the thesis 11
Quality control in rectal cancer surGery
Background
Before the introduction of TME (total mesorectal excision) surgery, blunt digital resec-
tion was used, resulting in local recurrence rates of about 20%.25 In the Swedish Rectal 
Cancer trial, for example, which included patients from 1987 until 1990, the 5-year lo-
cal recurrence rate was 27% for patients treated with surgery alone. If the patient was 
treated with preoperative 5 x 5 Gy radiotherapy, local recurrence rates dropped to 11%.25
In the 1990s, the Dutch Colorectal Cancer Group designed a trial using standardised 
surgery to reduce local recurrence rates: the Dutch TME trial.19 The surgical procedure 
used in this trial was new at that time, involving a complete and sharp excision of the 
mesorectum under direct vision, with preservation of the hypogastric plexus (TME 
procedure). The approach was advocated by Heald and Enker and resulted in a 5-year 
local recurrence rate below 10%.26,27 These rates were almost similar to the recurrence 
rate found in the Swedish Rectal Cancer trial for conventional surgery combined with 
preoperative radiotherapy.25 After the Swedish Rectal Cancer trial had demonstrated the 
beneficial effect of radiotherapy, the remaining question was whether radiotherapy was 
still beneficial in combination with standardised, good, TME surgery.25,28 To standardise 
treatment and reduce variation, extensive quality control was included in the TME trial 
for radiotherapy, surgery and pathology.19,20
Quality control
Results from a questionnaire which was mailed to all 21 Dutch radiotherapy depart-
ments showed that the use of the 5 x 5 Gy scheme, as used in Sweden,29 was accepted by 
most institutes. Treatment details, like volume and fields were described meticulously in 
the protocol, including a mandatory stimulation procedure. All institutes had to use a 3 
or 4 fields portal box technique in order to avoid serious non-surgical morbidity which 
was observed in the Stockholm trial using less fields.30
The TME procedure provides an excellent specimen and therefore the pathologist 
was able to check whether the procedure had been performed according to the pro-
tocol, using the transverse slicing method of Quirke.31 For the pathologists, this way of 
analysing the specimen was very different from their daily practice. In addition to the 
TME study protocol, a special pathology protocol was written and distributed to 43 pa-
thology laboratories. A pathology workshop was organised in December 1995 with the 
attendance of Dr. Quirke. A step-to-step protocol was produced, usable at the dissection 
table. In addition, the pathology coordinator had set up a Pathology Review Committee 
to discuss problems and review the slides, reports, and photographs of the specimen.32
In the TME trial, a new surgical technique was used by all participating surgeons. For 
the TME trial, an expertise based randomised controlled trial design was not possible, 
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as TME surgery was used in both randomisation arms. Besides, due to such a design the 
change outside the trial would occur at a slower pace, because only part of the surgeons 
is able to perform the new procedure. Different modalities were used to train the partici-
pating surgeons. First, a videotape on radicality and autonomic nerve preservation was 
produced, with operations performed by professor Moriya. Dr. Heald from Basingstoke 
(United Kingdom) performed almost 30 operations throughout the Netherlands and 
produced two videotapes, which were distributed to all participating hospitals. Besides, 
he has attended all seven workshops, which were organised all over the country from 
May 1996 to April 2000. A total of 21 instructor surgeons were selected. Their task was 
to introduce, teach and control the TME operations in their region. In each hospital, the 
first 5 TME procedures had to be supervised by an instructor surgeon.
results
A total of 1861 patients were included in the study between January 1996 and December 
1999, of whom 1530 from 84 Dutch hospitals.33 During the TME trial the pathology data 
were checked.32 Pathology data from case record forms were compared with hospital 
pathology reports. Three independent audits were carried out. Special attention was 
given to the accuracy of parameters, which are important for prognosis and treatment 
decisions. These quality checks revealed that only one third of the forms were complete 
and correct. Missing values were most prominent in the number of lymph nodes exam-
ined, whereas most errors were made in relation to the circumferential margin. Incorrect 
and missing data were corrected during these audits. By performing quality checks on 
all pathology data, the accuracy and completeness of these data were increased, which 
improved reliability of future analyses.
In the TME trial, the first 5 procedures in each hospital were supervised by an instruc-
tor surgeon. This requirement meant that 66% of the TME operations were attended by 
instructor surgeons during the first year and 58% during the first 500 TME procedures.19 
The pathologist was able to give feedback on the surgical quality of the resection to the 
surgeon: macroscopic completeness and microscopic circumferential resection margin 
(CRM) involvement were shown to be good predictors of local recurrence and overall 
survival.33,34
The 5-year local recurrence rates were 5.6% and 10.9% respectively for the group 
treated with preoperative radiotherapy and for the group treated with surgery alone (P 
< 0.0001), and overall survival rates were 64.2% and 63.5% respectively (P = 0.90; median 
follow up 6.1 years).33 Compared with historical data derived from trials in which con-
ventional, blunt, non-standardised surgery was used, local recurrence rates were halved 
and the 5-year overall survival rate improved from 48% to 64% after surgery alone.25,34 
Also in other reports the improved results with standardised surgery for rectal cancer 
are shown.35
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The association between CRM involvement and outcome in terms of local recurrence 
and overall survival, demonstrates the importance of assessing surgical variation: with 
CRM involvement the 5-year local recurrence rate was 19.7% for patients preoperatively 
treated with radiotherapy, compared to 3.4% for patients with a negative CRM.33 If such 
a parameter of surgical quality is not assessed and used as adjustment in the interpreta-
tion of the trial results, drawn conclusions might be made erroneously. Moreover, CRM 
involvement should be determined in daily clinical practice, as it is an important param-
eter of outcome and essential for feedback to the individual surgeon.
Quality assurance in recent years
Nowadays, there is a focus on quality assurance. Newspapers publish ranked lists of 
hospitals with the best care36,37 and health care insurance companies advertise that they 
only contract hospitals that provide a certain standard of care. Quantifiable parameters 
which could be used to determine the quality of care provided are called performance 
indicators. The Netherlands Health Care Inspectorate has used such performance indi-
cators to protect and promote health and healthcare. An example of interference of 
the Health Care Inspectorate can be found for oesophageal resections. In literature, an 
association between volume and postoperative morbidity and mortality was shown: the 
more oesophageal resections performed in a hospital per year, the lower the complica-
tion rate.38-40 As a result, the Netherlands Health Care Inspectorate nowadays only allows 
hospitals to perform an oesophageal resection if, annually, 10 or more of these proce-
dures are done. However, to guarantee a certain (high) level of quality of care, it remains 
important that medical professionals themselves are actively involved in quality assur-
ance. The European Society of Surgical Oncology (ESSO) has recognised the importance 
of quality assurance and the author of this thesis has received the first Quality Assurance 
Fellowship. This thesis focuses on quality assurance of rectal cancer treatment, in par-
ticular of the surgical treatment. Both oncological short-term and long-term outcome 
parameters such as circumferential resection margin involvement, local recurrence, and 
overall survival are studied, but also other end-points which are important for quality 
assurance are investigated, such as anastomotic leakage and stoma reversal.
outline of the thesis
chapter 2 describes the overall survival for resected rectal cancer in the Netherlands be-
fore, during and after the TME trial. TME surgery was nationwide introduced during the 
TME trial in the Netherlands. In the trial, the effects of preoperative 5 x 5 Gy radiotherapy 
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were studied. In this chapter both the effects of the nationwide introduction of the TME 
technique and preoperative radiotherapy are investigated.
Chapter 3 and chapter 4 focus on the elderly patients. These patients are under-
represented in most rectal cancer trials, whereas they form the majority of the rectal 
cancer patient population. It could be questioned whether it is reasonable to apply the 
guidelines based on relatively younger patients to the elderly. chapter 3 discusses this 
problem, based on analyses of overall survival for elderly patients with rectal cancer. As 
overall survival failed to improve in the subset of elderly patients since the introduction 
of TME surgery, in chapter 4, postoperative complications and mortality are explored to 
get more insight in the problems involved.
Apart from the issue of the elderly patients, several studies showed that the type of 
surgical procedure does also influence outcome: patients treated with an abdomino-
perineal resection (APR) have a reduced overall survival compared to patients treated 
with a low anterior resection (LAR).41-43 In chapter 5 is studied whether the factors as-
sociated with the decision to perform an APR or the APR procedure itself were related 
to circumferential resection margin involvement, local control, and overall survival. 
chapter 6 describes an in depth analysis in patients treated with an APR in the TME trial 
to identify tumour and patient related risk factors that contributed to CRM involvement, 
local recurrence, and reduced overall survival. In both chapters methods which could 
improve outcome for patients treated with an APR are discussed.
The importance of a resection without involved resection margins or R0 resection has 
been shown in several studies.44,45 EORTC trial 22921 compared adjuvant fluorouracil-
based chemotherapy to no adjuvant treatment in a 2 x 2 factorial trial with randomisa-
tion for preoperative (chemo)radiotherapy in patients with resectable T3-4 rectal cancer. 
This trial started in April 1993. In 1999, the recommendation to perform a TME procedure 
was included. In chapter 7 CRM involvement is investigated in EORTC trial 22921. Fur-
thermore, the effects of CRM involvement on local recurrence and overall survival rates 
are shown. In chapter 8, the same EORTC trial is used to study which subset of patients 
benefits significantly from adjuvant treatment.
After a resection of the primary rectal tumour, surgeons often create an anastomosis 
to restore the continuity of the bowel. chapter 9 describes a feared complication: anas-
tomotic leakage. Apart from the focus on short-term morbidity, in this chapter long-
term end-points are considered including local recurrence, overall survival, disease-free 
survival, and cancer-specific survival. In chapter 10, a protocol for postoperative sur-
veillance after colorectal resection with continuity restoration is described and tested. 
This protocol aimed at reducing delay in the diagnosis of anastomotic leakage and 
subsequently at reducing mortality associated with this complication.
Recently, it was shown that the creation of a stoma reduces the rate of symptom-
atic anastomotic leakage.46 However, not all stomas that are created with a temporary 
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intention are reversed. chapter 11 describes stoma reversal in the TME trial. Specific 
attention is given to determine limiting factors for stoma reversal.
Finally, the results of all studies will be summarised and discussed in chapter 12.
16 Chapter 1
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aBstract
aim
The aim was to study the effects of the introduction of TME surgery and preoperative 
radiotherapy on overall survival (OS) by comparing patients treated in the period before 
(1990-1995), during (1996-1999) and after (2000-2002) the TME trial.
Patients and methods
Patients diagnosed with rectal carcinoma in the region of Comprehensive Cancer Cen-
tres South and West were used (n = 3179).
results
Five-year OS was, respectively, 56%, 62% and 65% in the pre-trial, trial and post-trial 
periods (P < 0.001). Preoperative RT was increasingly used over time and significantly 
related to OS in the post-trial period (P = 0.002), but not in the pre-trial and trial periods.
conclusions
Population-based OS improved markedly since the introduction of TME surgery. With 
standardised TME surgery, preoperative RT improved OS, whereas withholding pre-
operative RT was associated with a poorer prognosis. The present study supports that 
preoperative RT was correctly introduced as a standard treatment before TME surgery in 
our national guideline.
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introDuction
Since the early 1990s, there have been changes in rectal cancer treatment towards bet-
ter surgery and/or preoperative radiotherapy (RT). With conventional, blunt dissection 
of the rectum 5-year local recurrence rates used to be above 20%.1 However, after total 
mesorectal excision (TME), which is a sharp dissection under direct vision of the rectum 
with its mesorectum and the visceral pelvic fascia,2 local recurrence rates can be less 
than 10%.3,4 Moreover, 5-year overall survival (OS) improved from 48% after conventional 
surgery as performed in the Swedish Rectal Cancer trial to >60% after TME surgery.1,5,6
In the Netherlands, a trial was performed between 1996 and 1999 to study the effects 
of preoperative RT on local control and OS in patients that underwent TME surgery.7 Dur-
ing this trial, all participating surgeons were trained in the TME technique.6,8 Instructions 
were given during workshops, at the dissection table, with booklets and a video tape. 
Besides, the first five procedures of each participating surgeon were attended by an 
instructor surgeon. Moreover, RT and pathology examination were also standardised to 
reduce the variability.7 The trial resulted in a 5-year local recurrence rate of 5.6% with and 
10.9% without preoperative RT, and a 5-year OS rate of 64% in both groups.6
TME is now accepted as the golden standard for the curative treatment of rectal car-
cinoma. In the present study, OS was evaluated in the time periods before, during and 
after the TME trial to study the effects of the introduction of TME surgery in combination 
with preoperative RT in the region of Comprehensive Cancer Centres South and West in 
the Netherlands.
Patients anD MethoDs
Patients
Data were derived from the cancer registry of the population-based Comprehensive 
Cancer Centres South and West. Registration is based on notification of all newly diag-
nosed malignancies after which data are obtained from clinical records in hospitals. The 
Dutch regional Cancer Registries have shown to attain a completeness of data exceed-
ing 95%.9 Patients who underwent a resection for cancer located in the rectum (Inter-
national Classifications of Diseases-9 154.1) and diagnosed between January 1990 and 
December 2002 were selected for analysis. Patients with prior invasive adenocarcinoma 
or with distant metastases diagnosed prior to or during surgery were not included, as 
were patients who underwent a local excision such as polipectomy or TEM (transanal 
endoscopic microsurgery). In the Dutch TME trial, patients with T1-T3 and patients with 
mobile T4 tumours were included. In the registry no details were available on mobility 
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of the tumour, so all T4 tumours were excluded to limit the current analysis to tumours 
which could be curatively resected.
The period of study was divided into three periods: 1990-1995 (pre-trial period), 
1996-1999 (trial period) and 2000-2002 (post-trial period). Age was categorised into 
<60 years, 60-74 years and ≥75 years. Data on tumour stage and data on preoperative 
and postoperative treatment were obtained from the Cancer Registries. Preoperative RT 
consisted of both the short, 5 x 5 Gy, schedule and the long schedule, such as 25 x 2 Gy. 
TNM-classification 4 (UICC,1987) was used before 1999.10 Since 1999, TNM-classification 
5 (UICC, 1997) was used, which classifies node negative patients with less than 12 exam-
ined lymph nodes as Nx.11 Survival data were obtained from hospitals, general practitio-
ners and the Central Bureau for Genealogy, which registers all the deceased persons in 
the Netherlands.
statistical analysis
Data were analysed with the SPSS package (SPSS 14.0 for Windows; SPSS Inc., Chicago, 
IL). Univariate comparisons of categorical variables were performed by a χ2 test. The 
following variables were considered as potential confounders for period in the analysis 
for OS: pathological T-stage, lymph node status, age, gender, (neo)adjuvant treatment, 
and Comprehensive Cancer Centre region. Potential confounder variables were first 
univariately tested in a Cox regression model. Confounders with a P-value ≤ 0.10 in the 
univariate analysis were selected and entered in a multivariate Cox regression model 
together with period of diagnosis. Besides, the model was tested for an interaction be-
tween period and statistically significant confounders. To test whether the hazard ratios 
(HR) were constant across time, the assumption of proportional hazards was studied 
univariately, and subsequently variables with a significant interaction in these analyses 
(age, pathological T-stage, nodal status, and (neo)adjuvant treatment) were entered in 
the previously described multivariate Cox regression model. As the estimates of the HR 
and P-values for >6 months post-surgery in the model with time-dependency were com-
parable to the model without time-dependency, we chose to report the results without 
time-dependency. Two-sided P-values ≤0.05 were considered statistically significant.
results
Patient characteristics
In total, 3179 patients were included in the analysis. In the pre-trial period 1150 patients, 
in the trial period 1084 patients and in the post-trial period 945 patients were analysed. 
In the trial period, 421 patients (39%) were included in the TME trial. All hospitals in 
both Comprehensive Cancer Centre regions South and West participated in the TME 
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trial. Median follow-up of patients alive was 144 (range 108-191), 86 (range 60-119) 
and 46 months (range 24-72 months), for the pre-trial, trial and post-trial periods, 
respectively. Patient characteristics are shown in Table 1. In the pre-trial period more 
patients were included in the region of Comprehensive Cancer Centre West, whereas in 
the trial and post-trial periods relatively more patients were included from the region 
of Comprehensive Cancer Centre South. The patients diagnosed in the three periods 
differed significantly with respect to (neo)adjuvant treatment: over time less patients 
were treated with postoperative RT, whereas more patients were preoperatively treated 
with RT (P < 0.001). In the trial and post-trial period more patients were diagnosed with 
N+ disease compared with the pre-trial period.
table 1. Patient characteristics by period of diagnosis.
Variable Pre-trial 
period (%)
n = 1150
Trial period 
(%)
n = 1084
Post-trial 
period (%)
n = 945
Total (%)
n = 3179
P-value
Gender
 Female
 Male
495 (43)
655 (57)
451 (42)
633 (58)
370 (39)
575 (61)
1316 (41)
1863 (59)
 0.195
Age
 < 60  years
 60-74 years
 > 74  years
296 (26)
535 (47)
319 (28)
305 (28)
512 (47)
267 (25)
268 (28)
426 (45)
251 (27)
 869 (27)
1473 (46)
 837 (26)
 0.369
pT-stage
 T1
 T2
 T3
110 (10)
392 (34)
648 (56)
 96  (9)
386 (36)
602 (56)
 74  (8)
350 (37)
521 (55)
 280  (9)
1128 (36)
1771 (56)
 0.525
Lymph node status
 N0/Nx
 N+
825 (72)
325 (28)
720 (66)
364 (34)
640 (68)
305 (32)
2185 (69)
 994 (31)
 0.019
(Neo)adjuvant treatment
 No perioperative treatment
 Preoperative RT
 Preoperative CRT
 Preop. RT and postop. CT
 Postoperative RT
 Postoperative CRT
 Postoperative CT
705 (61)
  1  (0)
  0  (0)
  0  (0)
403 (35)
 27  (2)
 14  (1)
591 (55)
329 (30)
 17  (2)
  9  (1)
116 (11)
  5  (0)
 17  (2)
241 (26)
555 (59)
 50  (5)
 35  (4)
 36  (4)
  5  (1)
 23  (2)
1537 (48)
 885 (28)
  67  (2)
  44  (1)
 555 (17)
  37  (1)
  54  (2)
<0.001
Region
 CCC South
 CCC West
527 (46)
623 (54)
701 (65)
383 (35)
556 (59)
389 (41)
1784 (56)
1395 (44)
<0.001
Pre-trial period (1990-1995), trial period (1996-1999) and post-trial period (2000-2002). Percentages may 
not add up to 100% due to rounding. RT = radiotherapy; CRT = chemoradiotherapy; CT = chemotherapy; 
CCC = Comprehensive Cancer Centre.
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overall survival
Five-year OS in the pre-trial period was 56% (95% confidence interval (CI) 53%-59%), 
compared to 62% (95% CI 60%-65%) and 65% (95% CI 60%-69%) for the trial and post-
trial periods respectively (P < 0.001). The increase in OS in the trial period compared 
with the pre-trial period was significant (P < 0.001) and did not change significantly 
thereafter (P = 0.31).
The results of the univariate analyses to select confounding variables for OS are 
shown in Table 2. In this analysis, only region was not found to be associated with OS (P = 
0.993) and was not entered in the multivariate analysis. All other variables were entered 
in the multivariate analysis: the results are presented in Table 3. The effects of period, 
gender, age, pT-stage, lymph node status, and (neo)adjuvant treatment were found 
to be independently related to the risk of dying. Furthermore, a significant interaction 
between period and (neo)adjuvant treatment was found (P < 0.001). Consequently, the 
table 2. Results of the univariate Cox regression analyses for overall survival.
Variable Hazard ratio 95% CI P-value
Period of diagnosis
 Pre-trial
 Trial
 Post-trial
1.00
0.81
0.74
0.72-0.91
0.64-0.86
<0.001
<0.001
<0.001
Gender
 Female
 Male
1.00
1.16 1.05-1.29
 0.005
Age
 < 60  years
 60-74 years
 > 74  years
1.00
1.60
3.14
1.39-1.84
2.72-3.63
<0.001
<0.001
<0.001
pT-stage
 T1
 T2
 T3
1.00
1.31
2.44
1.04-1.65
1.96-3.03
<0.001
 0.021
<0.001
Lymph node status
 N0/Nx
 N+
1.00
1.89 1.70-2.09
<0.001
(Neo)adjuvant treatment
 No (neo)adjuvant treatment
 Preoperative RT
 Preoperative CRT
 Preoperative RT and postoperative CT
 Postoperative RT
 Postoperative CRT
 Postoperative CT
1.00
0.77
1.35
0.86
1.27
0.84
1.21
0.67-0.89
0.93-1.96
0.51-1.47
1.12-1.43
0.52-1.36
0.84-1.76
<0.001
<0.001
 0.111
 0.586
<0.001
 0.478
 0.311
Region
 CCC South
 CCC West
1.00
1.00 0.90-1.11
 0.993
RT = radiotherapy; CRT = chemoradiotherapy; CT = chemotherapy; CCC = Comprehensive Cancer Centre; 
CI = confidence interval.
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effect of (neo)adjuvant treatment is presented separately for each period in Table 3. 
Moreover, period of treatment itself was significantly associated with OS. Adjusted OS in 
the trial period was significantly improved compared to the pre-trial period (OR 0.66, P 
< 0.001). In contrast, adjusted OS was lower in the post-trial period compared with the 
trial period although not statistically significant (OR = 1.20, P = 0.141 for post-trial period 
compared to trial period). Adjusted Cox regression curves for OS are shown in Figure 1.
table 3. Results of the multivariate Cox regression analysis for overall survival.
Variable Hazard ratio 95% CI P-value
Period of diagnosis
 Pre-trial
 Trial
 Post-trial
1.00
0.66
0.79
0.56-0.77
0.63-1.00
<0.001
<0.001
 0.049
Gender
 Female
 Male
1.00
1.26 1.13-1.40
<0.001
Age
 < 60  years
 60-74 years
 > 74  years
1.00
1.71
3.44
1.48-1.97
2.96-4.00
<0.001
<0.001
<0.001
pT-stage
 T1
 T2
 T3
1.00
1.22
2.02
0.96-1.54
1.61-2.54
<0.001
 0.094
<0.001
Lymph node status
 N0/Nx
 N+
1.00
1.88 1.68-2.10
<0.001
(Neo)adjuvant treatment, pre-trial period *
 No (neo)adjuvant treatment
 Postoperative RT
 Postoperative CRT
 Postoperative CT
1.00
0.80
0.58
0.99
0.68-0.94
0.33-1.04
0.51-1.92
 0.046
 0.005
 0.069
 0.972
(Neo)adjuvant treatment, trial period
 No (neo)adjuvant treatment
 Preoperative RT
 Preoperative CRT
 Preoperative RT and postoperative CT
 Postoperative RT
 Postoperative CRT
 Postoperative CT
1.00
1.11
2.38
0.60
1.35
1.99
1.14
0.90-1.36
1.24-4.44
0.19-1.84
1.02-1.75
0.75-5.46
0.62-2.10
 0.040
 0.315
 0.007
 0.376
 0.032
 0.174
 0.683
(Neo)adjuvant treatment, post-trial period
 No (neo)adjuvant treatment
 Preoperative RT
 Preoperative CRT
 Preoperative RT and postoperative CT
 Postoperative RT
 Postoperative CRT
 Postoperative CT
1.00
0.64
1.30
0.84
1.59
0.41
0.82
0.49-0.86
0.80-2.17
0.45-1.58
0.97-2.68
0.06-2.95
0.41-1.63
 0.001
 0.002
 0.282
 0.590
 0.066
 0.375
 0.562
RT = radiotherapy; CRT = chemoradiotherapy; CT = chemotherapy; CI = confidence interval. * Results for 
preoperative RT in the pre-trial period not shown (n = 1).
26 Chapter 2
the effects of period and treatment on overall survival
In the pre-trial period only one patient is treated with preoperative RT, therefore this 
patient is not included in the following analyses. Unadjusted, 5-year survival rates per 
period and treatment are shown in Table 4. In Figure 2, Cox regression curves for OS 
are shown adjusted for gender, age, pT-stage, and lymph node status. The curves are 
presented separately for patients treated without (neo)adjuvant treatment (Figure 2A), 
with preoperative RT (Figure 2B) and with postoperative RT (Figure 2C). In the pre-trial 
period, OS was better for patients treated with postoperative RT compared with patients 
treated without (neo)adjuvant treatment (P = 0.005, Table 3). In the trial period, in which 
39% of patients were included in the TME trial and randomised between preoperative 
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figure 1. Cox regression curves for overall survival (OS) for resectable rectal cancer by period adjusted 
for gender, age, pT-stage, lymph node status, (neo)adjuvant treatment, and the interaction between 
treatment and period.
table 4. Unadjusted 5-year overall survival rate (%) per period for patients treated with no (neo)adjuvant 
treatment, preoperative radiotherapy (RT), and postoperative RT.
Period No (neo)adjuvant treatment
% (95% CI)
Preoperative RT
% (95% CI)
Postoperative RT
% (95% CI)
Pre-trial
Trial
Post-trial
57.9 (54.2-61.6)
65.0 (61.1-68.9)
59.5 (66.8-52.2)
n.a.*
62.3 (57.0-67.6)
70.5 (65.6-75.4)
52.6 (47.7-57.5)
54.3 (45.3-63.3)
49.8 (33.3-66.3)
n.a. = not available. *Results for preoperative RT in the pre-trial period not shown (n = 1).
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figure 2. Cox regression curves for overall survival (OS) shown separately for patients treated without 
(neo)adjuvant treatment (A), with preoperative radiotherapy (RT) (B) and with postoperative RT (C) in the 
pre-trial, trial and post-trial period. The curves are adjusted for gender, age, pT-stage, and lymph node 
status. The results for preoperative RT in the pre-trial period is not shown (n = 1).
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RT followed by TME surgery and TME surgery alone (no (neo)adjuvant treatment), both 
treatments were comparable, whereas patients treated with postoperative RT did worse. 
In the post-trial period, preoperative RT was standard treatment, although the treating 
physician of surgeon could adapt the treatment for each patient. In this period, patients 
treated with preoperative RT had the best outcome and patients treated with postopera-
tive RT the worst outcome. Moreover, the influence of the introduction of TME surgery 
can be seen by the improvement of OS in the TME period, which is stable in the post-trial 
period. Patients treated with preoperative RT did better in the post-trial period compared 
with the trial period. Patients treated with postoperative RT did worse in both the trial pe-
riod and post-trial period compared with the pre-trial period. Overall, the lowest survival 
rate is found for patients in the post-trial period treated with postoperative RT and the 
highest survival rate is found for patients treated in the same period with preoperative RT.
The relationship between age and (neo)adjuvant treatment per period is shown in 
Table 5. In general, less (neo)adjuvant treatment is given to patients aged ≥ 80 years. 
However, over time in all age groups more preoperative RT was given: 47% of patients 
aged ≥ 80 years and 62% of patients aged <75 years in the post-trial period.
Discussion
Between 1996 and 1999, the TME trial was conducted in the Netherlands, resulting in a 
nationwide standardised and quality-controlled introduction of TME surgery.12 Inciden-
tally, preoperative short course RT was already in use in some parts of the Netherlands. 
In the TME trial, the effects of the addition of preoperative 5 x 5 Gy RT in combination 
with standardised TME surgery were studied. This cohort study demonstrates that pop-
table 5. (Neo)adjuvant treatments shown separately for patients aged < 75 years, 75-79 years and ≥ 80 
years.
Period (Neo)adjuvant treatment Age < 75 years
n (%)
Age 75-79 years
n (%)
Age ≥ 80 years
n (%)
Pre-trial No (neo)adjuvant treatment
Preoperative RT
Postoperative RT
Other (neo)adjuvant treatment
465 (56.0)
  1  (0.1)
326 (39.2)
 39  (4.7)
192 (65.8)
  0  (0.0)
 51 (32.9)
  2  (1.6)
138 (84.1)
  0  (0.0)
 26 (15.9)
  0  (0.0)
Trial No (neo)adjuvant treatment
Preoperative RT
Postoperative RT
Other (neo)adjuvant treatment
403 (49.3)
269 (32.9)
 97 (11.9)
 48  (5.9)
 95 (66.4)
 37 (25.9)
 11  (7.7)
  0  (0.0)
 93 (75.0)
 23 (18.5)
  8  (6.5)
  0  (0.0)
Post-trial No (neo)adjuvant treatment
Preoperative RT
Postoperative RT
Other (neo)adjuvant treatment
133 (19.2)
431 (62.1)
 26  (3.7)
104 (15.0)
 53 (37.9)
 72 (51.4)
  6  (4.3)
  9  (6.4)
 55 (49.5)
 52 (46.8)
  4  (3.6)
  0  (0.0)
RT = radiotherapy.
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ulation-based OS of patients with rectal cancer improved over time. An earlier study of 
Comprehensive Cancer Centre South showed that, compared to the period 1980-1989, 
OS in this region had already improved in the period 1990-1994, and continued to im-
prove during the study period of the TME trial.13 Interestingly, the present cohort study 
shows that the OS improved in the period 1996-1999 and 2000-2002 compared with the 
period 1990-1995, suggesting that the introduction of TME surgery has improved sur-
vival further. Moreover, after adjusting for gender, age, pT-stage, nodal status, and (neo)
adjuvant treatment, OS in the post-trial period mainly increased for patients treated with 
preoperative RT. In other words: with good quality TME surgery survival improves and 
with good surgery preoperative RT does matter for outcome. In the remaining discus-
sion, we will use the adjusted OS when mentioning OS, unless indicated differently.
Several studies found that preoperative RT resulted in better local control compared 
with postoperative RT.14,15 Besides, compliance to postoperative treatment was only 
about 50% which was often related to surgical complications.14-16 In a meta-analysis, it 
was concluded that preoperative RT could be safely used and resulted in a better local 
control compared to postoperative treatment (37% less local recurrences, P = 0.002).17 In 
addition, the authors of the meta-analysis found that fewer patients who had preopera-
tive RT died from rectal cancer than did those who had surgery alone (45% versus 50%, 
respectively, P = 0.0003). In the Dutch TME trial, it was found that local recurrence rates 
could be further reduced with the addition of preoperative RT to TME surgery, whereas 
OS remained the same.6,12 These findings resulted in the adjustment of the national 
treatment guidelines for rectal cancer in the Netherlands: the National Committee on 
Gastrointestinal Cancer decided to implement 5 x 5 Gy preoperative RT in combina-
tion with TME surgery as standard practice in the treatment of resectable T2-4 rectal 
carcinoma in 2001. The present analysis also showed that patients who were treated 
with preoperative RT had a better outcome than patients treated with postoperative 
treatment.
The effect of RT on survival changed over time. In the trial period, 39% of patients 
were treated within the trial and randomly assigned to preoperative RT followed by TME 
surgery or TME surgery alone. Similar to the findings in the TME trial,6,12 treatment with 
preoperative RT did not significantly improve OS in this period (P = 0.315). In contrast, 
in the post-trial period, preoperative RT was significantly related to OS (P = 0.002). In 
this period, preoperative RT was the standard, although for some patients preoperative 
RT was omitted according to the judgement of the treating physician or surgeon. For 
example, preoperative RT was more frequently used in younger patients than in older 
patients. However, the multivariate analysis showed that after adjustment for age, gen-
der, pT-stage, and lymph node status, preoperative RT was associated with an increased 
survival in the post-trial period. According to the results, preoperative RT was withheld 
in 32% (305/945) of patients in the post-trial period, resulting in a poorer prognosis in 
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this subset of patients. Unfortunately, no information on comorbidity was available in 
this study. Also for patients treated without preoperative RT but with postoperative RT 
survival was less, although for these patients selection of tumour related parameters 
could have played a role. It should be noted that postoperative radiotherapy has been 
used differently over time: in the trial and post-trial periods it was mainly indicated for 
patients with a positive circumferential resection margin (CRM), whereas in the pre-
trial period it was used for more patients such as patients with pT3 disease or positive 
lymph nodes. Due to these differences in selection, comparisons between the periods 
should be done with caution. Nevertheless, the question arises whether patients treated 
without preoperative RT did receive the most optimal treatment. We think that the aim 
should be to treat all patients with preoperative RT, although for the elderly patients the 
effect of preoperative treatment on survival is less clear than for younger patients.18,19
Circumferential resection margin (CRM) involvement has been found to be associated 
with an increased risk of local recurrence and decreased OS in several trials.20-22 However, 
not only involvement of the CRM, commonly defined as tumour within 1 mm of the 
CRM, but even tumour within 1 cm of the CRM is associated with increased local recur-
rence rates and decreased survival.22 Therefore, it is necessary to preoperatively identify 
patients with a tumour that is located in proximity to the mesorectal fascia, the surgical 
border of the TME resection. The MERCURY study group reported recently that magnetic 
resonance imaging (MRI) is accurate in predicting whether the CRM will be clear or af-
fected by tumour.23 Burton et al. showed that if only a MRI-scan is performed but not 
discussed in a multidisciplinary team meeting, poor prognostic factors were missed in 
50% of patients.24 Therefore, preoperative MRI-based multidisciplinary team meetings 
are necessary to select patients in whom the treatment plan should be adapted to a more 
extended resection and/or to a long schedule of (chemo)radiotherapy to downstage or 
downsize the tumour to perform a curative resection with an uninvolved CRM.25,26
In conclusion, population-based OS of patients with curatively resected rectal cancer 
improved since the nationwide introduction of TME surgery. The training of surgeons in 
this new technique was done successfully, with lasting effects. Furthermore, after TME 
surgery, preoperative RT resulted in an increased survival rate, whereas withholding of 
preoperative RT was associated with a poorer prognosis. In the latest Dutch national 
guideline, a preoperative MRI scan is recommended as standard preoperative work-up 
for all patients with a >T1 tumour. Besides, all patients should be discussed preopera-
tively in a multidisciplary team meeting. Preoperative short-course RT is advised for all 
patients with a >T1 curable rectal tumour. If all future patients will be treated according 
to these recommendations, it is likely that further improvements in OS are within reach.
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aBstract
introduction
The incidence of rectal cancer is the highest in elderly patients. However, these patients 
are often underrepresented in randomised studies. Therefore, it is not clear whether re-
sults of rectal cancer studies are equally applicable to both elderly and younger patients.
In this paper, the Dutch Total Mesorectal Excision (TME) study is revisited, focused on 
patients aged 75 years and above. The rectal cancer databases of the Comprehensive 
Cancer Centres (CCC) South and West were combined to analyse the effect of the TME 
study in three different periods: before (1990-1995), during (1996-1999) and after (2000-
2002) the trial.
results
Implementation of preoperative radiotherapy, as investigated in the TME trial, and the 
introduction of TME surgery resulted in improved 5-year survival during the subsequent 
periods in patients younger than 75 years, of 60% (1990-1995) to 67% (1996-1999) and 
70% (2000-2002) (P < 0.0001, log-rank). The older patients did not improve and remained 
at 41%, 40% and 43% at 5 years in the respective periods.
Furthermore, mortality during the first 6-month period after treatment is signifi-
cantly raised compared to younger patients: 14% in the elderly, compared to 3.9% in the 
younger TME study patient (P < 0.0001, χ2). In the CCC database these figures were 
confirmed at 16% and 3.9% (P < 0.0001, χ2).
conclusion
Overall survival was not improved in the elderly rectal cancer patient after introduc-
tion of preoperative radiotherapy and TME surgery. Non-cancer related mortality is a 
significant problem in the first 6 months after surgery.
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introDuction
Few data are available about the proper treatment of elderly patients with rectal can-
cer. The median age of patients that are enrolled in rectal cancer studies is around the 
mid-60s. Often patients are excluded either because they are too old: i.e. older than 75 
years, or they are excluded as a result of co-morbidity or high ASA (American Society of 
Anaesthesiology) classification. Despite the fact that surgery is the only proven curable 
treatment for rectal cancer there are no randomised studies focusing on the improve-
ment of rectal cancer surgery in the elderly. The introduction of TME (Total Mesorectal 
Excision) surgery has led to a major decrease of the local recurrence rate and an improve-
ment in survival rate.1,2 TME surgery is an explicit improvement of the quality of surgery 
and therefore not suitable to be investigated in randomised trials: it is impossible to 
compare ‘good’ surgery with ‘bad’ surgery in a randomised fashion. In the Netherlands, 
a randomised study comparing TME surgery alone to TME surgery preceded by 5 x 5 
Gy short course of radiotherapy led to the introduction of this new technique.3 This 
introduction happened almost instantaneously in 1996; within 6 months, surgeons in 
80 Dutch hospitals were trained through workshops and the attendance of a referent 
surgeon at the first five procedures. This relative short transition period to TME surgery 
creates the opportunity to study population-based databases from the Comprehensive 
Cancer Centres (CCC) South (Eindhoven Cancer Registry) and West in periods before, 
during and after introduction of TME surgery. The findings of the randomised study 
can be correlated with the population-based databases. In the CCC databases all older 
patients are included. Therefore, it was a challenge to research if findings from the TME 
study permeated equally into the younger and older rectal cancer population.
The authors of this paper were involved in accumulating data of rectal cancer 
treatment without the exclusion of older patients: the first database being used is the 
combined population-based database of two Comprehensive Cancer Centres (South 
and West) in the Netherlands; the second is the database from the Dutch TME study.
Several questions have to be answered. The most important question remains 
whether it is reasonable to apply the guidelines based on relatively younger patients to 
the elderly. Secondary questions are: do the same risk-factors apply to the elderly and 
do subsequent adjuvant treatments yield the same response? And lastly, must special 
circumstances be taken into account?
Patients anD MethoDs
Data were derived from the cancer registry of the population-based Comprehensive 
Cancer Centres (CCC) South and West. Registration is based on notification of all newly 
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diagnosed malignancies after which data is obtained from clinical records in hospitals. 
The Dutch regional Cancer Registries have been shown to attain a completeness of data 
exceeding 95%.4 Patients that underwent a resection for cancer located in the rectum 
(International Classifications of Diseases-9 154.1) and diagnosed between January 1990 
and December 2002 were selected for analysis. Patients with prior invasive adenocarci-
noma or with distant metastases diagnosed prior to or during surgery were discarded, 
as well as patients who underwent polypectomy or transanal endoscopic microsurgery.
The period of study was divided into three periods: 1990-1995 (pre-trial period), 
1996-1999 (trial period) and 2000-2002 (post-trial period). Age was categorised into 
younger than 75 years and 75 years or older. A total number 4567 patients, of which 
28% was 75 years or older, was included. Data on tumour stage and data on preopera-
tive RT were also obtained from the cancer registries. Survival data were obtained from 
hospitals, general practitioners and the Central Bureau for Genealogy, which registers all 
deceased persons in the Netherlands. 
The other dataset used came from the Dutch TME study. From January 1996 until 
December 2000, 1861 patients were randomly assigned to either preoperative radio-
therapy (5 x 5 Gy) followed by TME or TME alone in a large, international, multicentre trial. 
Details of the TME study have been described elsewhere.5,6 All patients were required 
to give informed consent before randomisation. Only Dutch patients (n = 1530) were 
considered in the present analysis because collection and verification of data were, for 
logistical reasons, feasible for these patients only. Patients with concomitant metastases 
or who were not resected were excluded. For the underlying study, 1356 patients were 
selected. Of all the patients in this database, 230 were 75 years or older (17%).
statistical analysis
Data were analysed with the SPSS package (SPSS 15.0 for Windows; SPSS Inc., Chi-
cago, IL). Univariate comparisons of categorical variables were performed by a χ2 test. 
Preoperative treatment, gender, distance, TNM stage, type of resection, preoperative 
complications, postoperative infectious, general or surgical complications were first 
univariately analysed for their association with hospital mortality, defined as mortality 
during the admission in which the TME procedure was performed, and 180-day mortal-
ity. All variables with a P-value of ≤ 0.10 were tested in a multivariate logistic regression 
analysis. Kaplan-Meier curves for overall survival of patients were compared using the 
log-rank test. All survival data are presented at 5 years. Two-sided P-values ≤ 0.05 were 
considered statistically significant.
Prognostic groups were created based on significant variables and analysed and 
presented using a Cox regression survival model.
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results
The combined database of the Comprehensive Cancer Centres South and West showed 
that survival of rectal cancer patients has improved over time.7 Interestingly, this 
improvement was observed in patients younger than 75 years (Figure 1). For younger 
patients, TME surgery and preoperative radiotherapy were introduced in the second 
observation period (1996-1999) in the frame of a randomised study, which led to a 
significant decrease of the hazard ratio to 0.81, and rise of the 5-year survival rate from 
60% in the first period to 67% in the second period. After general introduction of TME 
surgery and 5 x 5 Gy preoperative radiotherapy, the expected survival rate of younger 
patients increased to 70% and the relative risk decreased further to 0.70 when compared 
to the first period (P < 0.0001). For the elderly rectal cancer patient, the expected 5-year 
survival rate was 41% in the first period, but it remained 40% and 43% in the respective 
second and third periods.
Compared to people of the same age from the general population, the relative risk of 
dying from rectal cancer increased 5.2 times in younger and 1.6 times in older patients 
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figure 1. Cox regression overall survival curves in the Comprehensive Cancer Centres combined 
database. Improved survival over the subsequent periods in the younger patients (P < 0.0001), but no 
improvement in the subsequent periods for the elderly patients.
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(data not shown). In the Dutch population, men and women still have a life expectancy 
of 5 years at the ages of 84 and 87 respectively (Central Bureau of Statistics: www.stat-
line.cbs.nl).
The proportion of patients receiving preoperative radiotherapy in the TME study 
did not differ between the younger and elderly (younger < 75 years 50% radiotherapy 
plus TME versus 49% in the elderly, P = 0.70). Sex distribution did differ between the 
age groups: in the younger patients, 65% were male compared to 56% in the elderly (P 
= 0.006). More sphincter conserving procedures were performed in the younger, 66% 
versus 60% in the elderly (P < 0.001). TNM stage distribution also differed: in the young 
27% stage 2 and 39% stage 3 whereas in the elderly these figures were 36% and 33% 
respectively (P = 0.021). T-stage distribution differed slightly: 6.0% T1, 34% T2, and 55% 
T3 in the younger patients versus 2.6%, 33%, and 59% in the elderly (P = 0.038). N-stage 
did not differ between age groups. No patients in this study had metastatic disease. 
Therefore, mortality during the first month or first 6 months cannot be contributed to 
cancer progression, but is rather treatment-related. During the first month, the elderly 
had a significant higher mortality rate, 7.8% versus 2.5% (P < 0.0001). However, this dif-
ference exaggerates in the ensuing months. The 6-month mortality rate for the elderly 
was 14% versus 3.3% for the younger patients (P < 0.0001). In the TME plus preoperative 
radiotherapy arm, the 6-month mortality rate for the elderly was 17% compared to 12% 
in the surgery-alone arm; these figures do not reach statistical significance (P = 0.27).
The 6-month mortality rate was also significantly raised in the CCC database: 16% 
for age 75 and above and 3.9% in the younger patients. For 1-month mortality, these 
figures were 4.5% and 0.8% respectively. Six-month mortality rates did not decline dur-
ing the study period. These figures are lower than in the TME study, because the primary 
date is the date of diagnosis and not the date of surgery, which was unfortunately not 
recorded in the CCC registries. For the elderly, 6-month mortality was 15%, 18%, and 
16% in the consecutive periods. For the younger patients, these figures were 3.9%, 4.1% 
and 3.6%. No influence on 6-month mortality was found with regard to TNM, T-stage, N-
stage, preoperative versus no radiotherapy or type of surgical procedure. Interestingly, 
those older patients who received postoperative radiotherapy experienced significantly 
less 6-month mortality, despite the fact that their overall survival was the worst: 37% 
(postoperative radiotherapy), 40% (no radiotherapy at all) and 48% (preoperative radio-
therapy). In younger patients, similar findings were encountered: 6-month mortality was 
5.1%, 3.3% and 1.4% (P < 0.0001) for no radiotherapy, preoperative radiotherapy and 
postoperative radiotherapy respectively. Again, an inverse relation with overall survival 
was noticed: 68%, 68%, and 53% (P < 0.0001) for no, preoperative and postoperative 
radiotherapy.
In the Dutch TME study, patients aged 75 years and older showed a better response in 
the study arm when compared to younger patients. Younger patients have a significantly 
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lower local recurrence rate of 5.2% after preoperative 5 x 5 Gy radiotherapy versus 11% 
for patients without preoperative radiotherapy (P = 0.001). However, overall survival at 
5 years (respectively 72% and 72%, P = 0.30), distant metastases free survival (74% vs. 
72%, P = 0.70) and cancer-free survival (81% versus 69%, P = 0.44) were not improved. 
Whereas in the elderly, apart from local recurrence rate (5.4% versus 14%, P = 0.02), also 
distant metastases free survival (81% versus 69% P = 0.07) and cancer-free survival (81% 
versus 66%, P = 0.03) were improved. The 5-year overall survival rate in the elderly (48% 
versus 43%, P = 0.27), much like in the younger patients, was only slightly improved in 
the study arm that received 5 x 5 Gy preoperative radiotherapy (Figures 2 and 3).
Complications occurred more frequently in older patients: any postoperative (infec-
tious, general or surgical) complication occurred in 42% of patients aged younger than 
75 years compared with 51% in older patients (P = 0.008). Pulmonary, renal, neurologi-
cal, and cardiac complications, and thrombo-embolism, hypertension, line sepsis, and 
cholecystitis were scored as general complications. Wound infection, abscess, sepsis/
febris eci, and haematoma were the infectious complications, and abdominal wound 
dehiscence, perineal wound dehiscence, intestinal necrosis, ileus, leakage, bleeding, 
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figure 2. Cox regression overall survival curve in the TME study. A significant increase of the risk of dying 
for the elderly (P < 0.0001), but randomisation within the same age-category was of no influence.
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fistula, stoma complications, and perforation were considered surgical complications. 
Six-month mortality was significantly influenced by general (odds ratio (OR) = 3.74, P 
= 0.002) and surgical postoperative complications (OR = 4.93, P < 0.001). Radiotherapy, 
sex, distance, TNM stage, and perioperative complications were not independent 
contributors. Type of surgical resection was borderline significant (P = 0.059). Besides, 
infectious postoperative complications were not associated with 6-months mortality.
Complications had a greater impact among elderly patients compared to younger 
patients, i.e. if an anastomotic leakage occurs, the probability of fatal outcome is 50.0% 
compared to 7.1% in younger patients (P < 0.001). However, the overall occurrence of 
anastomotic leakage is not increased in the elderly: 10% in the elderly compared to 12% 
in the younger (P = 0.63, low anterior resected patients only).
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figure 3. Cox regression survival curve of cancer-specific survival in the TME study. Cancer-specific 
survival was significantly decreased in the elderly, not receiving preoperative radiotherapy (P < 0.045, 
hazard ratio 1.76). No difference among the other three groups.
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Discussion
From the population-based registries of the Comprehensive Cancer Centre South and 
Comprehensive Cancer Centre West it is evident that the prognosis of patients with 
rectal cancer has improved over the last 15 years.7,8 In Sweden, having the same history 
of introducing 5 x 5 Gy preoperative radiotherapy and TME surgery, these findings were 
also made.9 The major change in the treatment of rectal cancer was the introduction of 
TME surgery and the introduction of 5 x 5 Gy preoperative radiotherapy for stage 2 and 
stage 3 rectal cancers. From the registry-based results, it is also obvious that younger pa-
tients have more benefited more from the change in cancer treatment than the 75 years 
and older patients. There is a very evident paradox, as it seems that from the results of 
the Dutch TME study it can be concluded, that the biological behaviour of rectal cancer 
in the elderly in response to treatment is better than in the younger patients. Not only 
is local recurrence rate decreased by the addition of 5 x 5 Gy preoperative radiotherapy, 
but also the distant metastatic rate and the cancer-specific survival. Unfortunately, 
this favourable responsiveness comes with a price. The impact of complications in the 
elderly is more severe. However, neoadjuvant treatment does not lead to statistically 
significant more complications in the elderly, but this may be due to a power effect. The 
elderly are a small group within the Dutch TME study and in the whole group of patients 
treated in the Dutch TME study neoadjuvant treatment did lead to more complications.10 
In the elderly, complications more often have a fatal course. Significant mortality occurs 
not only during stay in hospital, but is present until 6 months after surgery. Even in the 
Dutch TME study where elderly patients constitute a highly selected group of patients 
fit enough to undergo treatment, approximately one out of six will die within 6 months 
after the treatment.
In the combined CCC database, 6-month mortality was equally high in all periods 
around 16%, indicating that the changes in therapeutical approach had little impact, 
and that the surgical trauma by itself, being non-TME or TME, is the most important fac-
tor for postoperative mortality. In the general rectal cancer population, the elderly suffer 
more often from multiple comorbidity, which causes more complications during treat-
ment.11 Elderly were underrepresented in the Dutch TME study. Age was no exclusion 
criterion but poor performance status was, and most elderly suffer from comorbidity, 
influencing performance status. From previous epidemiological studies it is known that 
older people are less likely to receive adjuvant or neoadjuvant treatment. When elderly 
are not considered to receive adjuvant or neoadjuvant treatment, they are considered 
even less for participation in a study investigating (neo-)adjuvant treatment.
Rectal cancer is a disease of the elderly. The chance of developing a rectal cancer 
increases with age and is highest at the age of 80.12 The fact that survival did not im-
prove in the older rectal cancer patients casts some doubt as to whether the approach 
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to rectal cancer in the elderly should be the same as in younger patients. Despite the 
fact that older patients respond very well to neoadjuvant treatment, the intercurrent 
mortality not related to cancer obscures any beneficial effect. In the elderly, not only is 
cancer-related mortality an outcome parameter, but also mortality which is not cancer-
related. The relative risk of dying from rectal cancer is 1.6 in the elderly compared to 5.2 
in younger patients. Therefore, it can be argued that the focus of treatment should be on 
preventing non-cancer-related mortality.
Theoretically, two approaches can be followed to achieve reduction of mortality. 
The first is to optimise the condition of the patient; making him or her more fit for the 
operation. This approach requires thorough preoperative assessment of amongst others 
the nutritional, metabolic, cardiac, and pulmonary status of the patient. Standardising 
risk assessments by the routine use of scorings systems like the P-possum may be a step 
forward.13,14 However, this is beyond the scope of this article. The other approach is to 
reduce the risk or the toxicity of the treatment. This does not mean that a palliative treat-
ment instead of a curative treatment should be offered. If the life expectancy exceeds 
1 year, an initially palliative treatment will lead to death from progressive rectal cancer. 
Moreover, radiotherapy without surgery in potentially curative patients limits the pallia-
tive options in case of local progression and secondary curative surgery will certainly be 
more hazardous. Therefore, curative treatment is the better option.
Combined treatment is more effective than surgery alone, but also carries greater 
risks. Heald, who has published his excellent personal series, argues that in patients with 
perfect mesorectal excision, preoperative radiotherapy may be omitted.15 However, 
results from the CRO7 study show that even in perfect surgery there is added value of 
preoperative radiotherapy.16 An ongoing Scandinavian study investigates the effect of 
delaying surgery after a short course of radiotherapy.17 The study goal is to see whether 
delay leads to downsizing and staging of the tumour. Other effects could be that after 
a waiting period of 6-12 weeks, the patient recovers from the radiotherapy and avoids 
the double jeopardy of radiotherapy and a major surgical trauma. Nutritional, metabolic, 
cardiac, or pulmonary disorders may be optimised in the waiting period.
The surgical approach must also be tailored to the patient. The keywords are opti-
misation of the patient and individualisation of the treatment to the patient. One of 
the most feared and life-threatening complications can be avoided by not restoring the 
continuity of the bowel. However, anastomotic leakage does not occur more often in 
the elderly.18 The subsequent complications of anastomotic failure are more serious. 
Postoperative mortality after complications is substantially higher among the elderly. 
In addition, this increased mortality persists at least for the first 6 months after surgery.
Apart from a risk factor for recovery, restoration of continuity requires secondary 
surgery (closure of the temporary colostomy or ileostomy) with its implicit morbidity. 
Removal of the rectal ampulla and replacing it with the low anterior anastomosis re-
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sults in a serious handicap. Most patients will experience a longer period of increased 
frequency, urge, soiling, fragmented and less solid defecation.19-21 This often leads to 
incontinence and subsequently more dependency for care and inclination to social 
isolation. In a period of life with less mobility, loss of relatives and friends, threats of 
social isolation must be taken very seriously. Despite this fear, the TME study did not pro-
vide data that older patients more often experience worse incontinence than younger 
ones. At least with regard to the number of patients aged 75 years and older included 
in the TME study, the 10% difference in worse incontinence did not reach statistical 
significance.22 The only finding in the elderly that reached statistical difference was the 
fact that 21% of the elderly versus 8% of the younger patients had no reversal of their 
temporary stoma.23
The role of local excision after neoadjuvant treatment or even treatment solely with 
chemoradiotherapy and omitting surgery has not been explored. The elderly patient, 
especially, is a good candidate for these sorts of studies that focus on reducing the surgi-
cal trauma.24
conclusion
The paradox in the treatment of rectal cancer in elderly patients is that the treatment is 
even more effective than in younger patients, but that overall survival is obscured by an 
increase in non-cancer-related mortality. Improvement of outcome in elderly patients 
can be realised if non-cancer-related mortality is reduced. This objective can be realised 
by optimising the condition of the patient or by reducing the toxicity of the treatment. 
Ideally, randomised studies for elderly patients should be performed. Extrapolation of 
results of younger patients may not be appropriate. Postoperative or post-treatment 
mortality should be recorded for at least up to 6 months after the primary treatment. 
The (in)capacities to take care of themselves and the social environment must bear more 
weight than the technical possibilities in proposing certain surgical procedures.
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aBstract
The cornerstone of treatment for rectal cancer is resectional treatment according to the 
principles of total mesorectal excision (TME). However, population-based registries show 
that improvements in outcome after resectional treatment occur mainly in younger 
patients. Furthermore, 6-month postoperative mortality is significantly increased in 
elderly patients (≥ 75 years of age) compared with younger patients (< 75 years of age). 
Several confounding factors, such as treatment-related complications and comorbidity, 
are thought to be responsible for these disappointing findings. Thus, major resectional 
treatment is not advantageous for all older patients with rectal cancer. However, the 
Dutch TME trial showed a good response to a short course of neoadjuvant radiotherapy 
in the elderly patients. Biological responses to cancer treatment seem to change with 
age, and, therefore, individualised cancer treatments should be used that take into ac-
count the heterogeneity of ageing. For elderly patients who retain a good physical and 
mental condition, treatment that is given to younger patients is deemed appropriate, 
whereas for those with diminished physiological reserved and comorbid conditions, 
alternative treatments that keep surgical trauma to a minimum and optimise the use of 
radiotherapy might be more suitable.
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introDuction
The effectiveness of surgery for rectal cancer in the elderly (≥ 75 years of age) can be 
measured by survival, postoperative morbidity and mortality, and the ability of the 
patient to regain the independence they had before the surgery. The incidence of rectal 
cancer is highest at around 80 years of age. However the incidence of comorbidity, 
which renders the patient vulnerable to postoperative complications, is also highest 
after this age (Figure 1).1-3
Population-based studies have shown that the prognosis of patients with rectal 
cancer has improved over the past few decades. The Danish Nationwide Cancer Registry, 
a population-based registry with almost complete ascertainment, showed that between 
1977 and 1999, 5-year survival gradually improved in all age groups, with the biggest 
improvement seen in the period between 1977 and 1989. In elderly patients, 30-day 
and 6-month mortality decreased substantially over time. Better anaesthesia, improved 
health awareness leading to earlier stage diagnoses, less emergency procedures (sur-
gery within 24 h after first onset of symptoms), improved access to health-care services, 
and greater availability of effective treatments were considered factors responsible for 
these findings.4 In the Netherlands, Dutch cancer registries also noted an improvement 
in outcome after surgery for rectal cancer, which accelerated in the 1990s.5
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figure 1. Prevalence of comorbidity and incidence of age-specific rectal cancer.
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An explanation for the improvement in the 1990s might be the introduction of total 
mesorectal excision (TME), which has become the standard for resectional treatment. 
Heald and colleagues6 introduced this technique, in which the rectum is removed envel-
oped within its mesorectal fascia, and Quirke and co-workers7 provided the anatomical 
basis for this concept by showing that an uninvolved circumferential margin is the most 
important independent factor for avoiding local recurrence.
In the Netherlands, TME surgery was introduced as a result of a trial done in 1996 that 
compared TME surgery with and without a short course of preoperative radiotherapy (5 
fractions of 5 Gy).8 On the basis of the findings of this trial, TME combined with preop-
erative radiotherapy was rapidly accepted as the standard treatment for rectal cancer. 
However, the mean age of the patients included in the trial was 63 years, and, although 
no upper age limit was used, there is concern that the elderly population was under-
represented. In most population-based studies, the mean age of patients with rectal 
cancer is 70 years and the relative incidence increases with age, reaching a maximum 
at 80 years of age.9 Therefore, whether the findings of the TME trial are applicable to the 
elderly population is unclear.
Other reports of under-representation of the elderly in clinical trials also exist.10,11 
The opinion that geriatric patients do not tolerate cancer treatment well might be a 
reason for why they are not always included in prospective randomised studies. Other 
possible explanations are exclusion criteria for comorbidity, which is increasingly pres-
ent in older patients, and the reluctance of investigators to include frail patients in such 
trials. Despite this issue, the findings from most studies are presented irrespective of 
participant age. The exclusion of older populations from these trials leaves important 
questions unanswered - i.e., are biological behaviour and responsiveness to treatment 
independent from age; and how do cancer treatments interact with the vulnerability of 
ageing people? In this paper, we will address the above mentioned topics and propose 
alternatives for the treatment of elderly patients with rectal cancer.
MethoDs
Two datasets were used for our analyses: data from the Dutch TME study and data from 
the Dutch Comprehensive Cancer Centres (CCC) South and West combined. Both datas-
ets have been published before.12,13 However, for this review new, unpublished analyses 
have been done. In the TME study 1356 patients had curative resection (1126 patients 
aged < 75 years and 230 patients aged ≥ 75 years). 99% of patients had complete follow-
up. In this dataset, we focused on mortality in elderly patients. In the Dutch CCC South 
and West combined dataset, 4567 patients had curative resection during the period 
1990-2002, of whom 28% were aged 75 years or more.12
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Data were analysed with the SPSS package (version 15.0 for Windows; SPSS Inc., 
Chicago, IL, USA), and SAS (version 9; SAS Institute Inc., Cary, NC, USA). Forest plots were 
drawn with software from Biostat (Comprehensive Meta-analysis Version 2; Biostat, 
Englewood, NJ, USA).
The prevalence of comorbidity, including hypertension, in the area of the Compre-
hensive Cancer Centre South was recorded according to a slightly adapted version of 
the Charlson Index.1,2 Patients with missing data were excluded from the comorbidity 
analysis. European standardised incidence rates of rectal cancer in the Netherlands were 
downloaded from the website of the Dutch Comprehensive Cancer Centres.3 Age-
specific life expectancy tables were used from the Dutch Central Bureau of Statistics to 
calculate relative risks of dying for patients with rectal cancer compared with the general 
population, by means of Cox regression. P-values lower than 0.05 were considered sig-
nificant. All eligible Dutch patients from the Dutch TME trial who underwent a resection 
and had no evidence of distant metastasis at the time of surgery were included in the 
analysis of the relative risk of dying from a complication within 6 months of surgery for 
patients aged 75 years or more compared with those aged less than 75 years.13 95% 
confidence intervals (CIs) not including 1 were considered to indicate significant differ-
ences between the respective age groups. No imputation methods of missing values 
were used because completeness of data in the TME trial exceeded 99%.
Findings from the analyses were compared with the published work. We searched 
Medline, Scopus, and the Cochrane database for articles published in English back to 
January 1997. The following search terms were used: “rectal cancer and elderly (ageing)”, 
“preoperative irradiation”, “local excision”, and “chemoradiation”. Reference lists were 
used for further search.
results
The combined cancer registries of the CCC South and West failed to show a beneficial 
effect of the use of TME surgery in elderly patients (Figure 2). Table 1 provides the rela-
tive risk of dying of rectal cancer according to 3-year age groups compared with the 
general population, and shows that age is an independent risk factor. Therefore, the 
effectiveness of TME surgery for rectal cancer in the overall population cannot be simply 
derived from the findings of studies that involve a predominantly younger age group. 
In a younger patient group with a high relative risk of dying from cancer, a small treat-
ment benefit might be worthwile. However, in elderly patients, such a benefit might 
be overshadowed by their increased vulnerability and decreased tolerance, resulting in 
greater postoperative mortality than in younger patients.
Table 1 also shows postoperative 30-day mortality and 6-month mortality for each 
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age group after curative surgery for rectal cancer. An increase can be seen in both 30-
day mortality and 6-month mortality in elderly patients, representing one of the major 
drawbacks of surgery for rectal cancer in this population. In patients above 75 years of 
age, 6-month mortality increases compared with patients aged 75 years or younger. This 
proportion increases to almost 40% in patients older than 90 years of age. Unfortunately, 
the introduction of TME surgery has not resulted in a decrease in 6-month mortality.12 
Figure 3 shows 30-day and 6-month mortality per age group for the CCC South and West 
combined dataset and the Dutch TME trial dataset.
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figure 2. Overall survival per age group before and after the introduction of total mesorectal excision 
(TME) in the Netherlands. Data from the Dutch Comprehensive Cancer Centres South and West combined 
database. CI = confidence interval.
table 1. Relative risk of dying after curative rectal cancer surgery compared with the general population.
Data from the Dutch Comprehensive Cancer Centres South and West. CI = confidence interval.
Age (years) n Relative risk 95% CI P-value 30-day 
mortality (%)
6-month 
mortality (%)
<  61 1179 123 56-275  0.0001  1.1  2.1
61-63  354 127 20-806 <0.0001  1.1  3.1
64-66  401   9.0  6.4-12 <0.0001  2.0  4.7
67-69  481   4.7  3.7-6.1 <0.0001  2.5  6.2
70-72  428   3.1  2.5-3.9 <0.0001  1.6  4.9
73-75  452   2.8  2.2-3.4 <0.0001  3.5  8.0
76-78  423   1.8  1.5-2.2 <0.0001  6.9 13.0
79-81  329   1.6  1.3-2.0 <0.0001  7.9 14.9
82-84  321   1.2  0.9-1.6  0.17 10.4 17.7
85-87  169   2.4  1.7-3.2 <0.0001 14.8 27.2
88-90   71   1.5  0.9-2.5  0.09 18.3 26.8
>  90   31   1.5  0.5-2.5  0.14 25.8 38.7
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Discussion
Rectal cancer surgery is a major procedure, highlighted by the number of postoperative 
complications. The occurrence of complications is associated with a higher postopera-
tive mortality, which, in elderly patients, persists for at least 6 months, compared with a 
few weeks after surgery in younger patients.
Table 2 presents the complications that occurred in elderly patients in the Dutch 
TME trial (unpublished), showing that elderly patients are liable to more complications 
than their younger counterparts. Furthermore, these complications were associated 
with higher mortality. Even complications in elderly that occurred at a similar or lower 
frequency compared with younger patients were associated with more severe conse-
quences. The best example of such a complication is anastomotic leakage. This leakage 
occurred at a similar rate in younger and elderly patients, but the ensuing mortality in 
elderly patients was 57% compared with just 8.2% in younger patients. Furthermore, 
complications including abscesses, sepsis, and postoperative pulmonary and cardiac 
problems were related to a significantly increased risk of dying within 6 months post-
surgery in elderly patients compared with younger patients.
Several studies have addressed the issue of why elderly patients benefit less than 
younger patients from surgical treatment for rectal cancer. Shahir and colleagues14 
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figure 3. 1-month and 6-month mortality per age group in the Dutch TME study and the population-
based Comprehensive Cancer Centres (CCC) database.
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showed in a regional setting that older patients (≥ 70 years) were at higher risk of 
developing treatment-related complications than younger patients (< 70 years). They 
noted that age, comorbidity, and the number of postoperative complications were sig-
table 2. Relation between morbidity and 6-month mortality in the Dutch TME trial.
Variable Prevalence
n (%)
6-month mortality
n (%)
Relative 
risk*
95% CI
< 75 years ≥ 75 years < 75 years ≥ 75 years
Postoperative infections 208 (18.5)  49 (21.3)  19  (9.1) 11  (22.4)  2.46 1.25-  4.82
 Abdominal wound infection  69  (6.1)  17  (7.4)   3  (4.3)  2  (11.8)  2.71 0.49- 14.94
  Perineal wound infection (APR 
only)
 35 (10.1)  13 (19.4)   1  (2.9)  0   (0.0)  0 ----
 Urinary tract infection  96  (8.5)  27 (11.7)   2  (2.1)  3  (11.1)  5.33 0.94- 30.31
 Abscess  37  (3.3)  11  (4.8)   1  (2.7)  3  (27.3) 10.09 1.16- 87.57
 Sepsis  69  (6.1)  11  (4.8)  15 (21.7)  7  (63.6)  2.93 1.56-  5.51
 Fever without known cause   9  (2.0)   0  (0.0)   1 (11.1)  0   (0.0)  0 ----
 Other   9  (0.8)   1  (0.4)   1 (11.1)  0   (0.0)  0 ----
General postoperative complications 163 (14.5)  49 (21.3)  19 (11.7) 15  (30.6)  2.63 1.45-  4.77
 Pulmonary complications  78  (6.9)  27 (11.7)   5  (6.4)  7  (25.9)  4.04 1.40- 11.69
 Renal complications   8  (0.7)   2  (0.9)   3 (37.5)  1  (50.0)  1.33 0.26-  6.94
 Neurological complications  18  (1.6)   3  (1.3)   2 (11.1)  0   (0.0)  0 ----
 Venous thrombosis   6  (0.5)   0  (0.0)   0  (0.0)  0    (n.a.)  0 ----
 Embolism  17  (1.5)   2  (0.9)   5 (29.4)  1  (50.0)  1.70 0.35-  8.17
 Cardiac complications  35  (3.1)  20  (8.7)   6 (17.1) 10  (50.0)  2.92 1.25-  6.82
 Line sepsis  18  (1.6)   1  (0.4)   2 (11.1)  0   (0.0)  ---- ----
 Cholecystitis  13  (1.2)   2  (0.9)   1  (7.7)  1  (50.0)  6.50 0.63- 67.35
Postoperative surgical complications 302 (26.8)  61 (26.5)  25  (8.3) 19  (31.1)  3.76 2.22-  6.39
 Abdominal wound dehiscence  35  (3.1)   5  (2.2)   3  (8.6)  2  (40.0)  4.67 1.02- 21.43
  Perineal wound dehiscence 
(APR only)
 34  (9.5)  10 (14.9)   1  (2.9)  2  (20.0)  6.80 0.69- 67.46
 Intestinal necrosis  10  (0.9)   1  (0.4)   4 (40.0)  1 (100.0)  2.50 1.17-  5.34
 Ileus  64  (5.7)  18  (7.8)   6  (9.4)  2  (11.1)  1.19 0.26-  5.38
 Anastomotic leakage (LAR only)  85 (11.5)  14 (10.1)   7  (8.2)  8  (57.1)  6.94 2.99- 16.11
 Fistula  20  (1.8)   0  (0.0)   3 (15.0)  0    (n.a.)  0 ----
 Perforation  14  (1.2)   0  (0.0) 6 (42.9)  0    (n.a.)  0 ----
 Haematoma   9  (0.8)   0  (0.0) 0   (n.a.)  0    (n.a.)  0 ----
 Bleeding  42  (3.7)   8  (3.5) 6 (14.3)  3  (37.5)  2.63 0.82-  8.39
 Stoma complications  23  (2.0)   3  (1.3) 1  (4.3)  2  (66.7) 15.33 1.92-122.39
 Other  52  (4.6)  15  (6.5)   3  (5.8)  3  (20.0)  3.47 0.78- 15.44
Any postoperative complications 471 (41.8) 118 (51.3)  33  (7.0) 27  (22.9)  3.27 2.05-  5.21
* Relative risk of 6-month mortality for patients aged ≥ 75 years compared with those aged < 75 years. APR 
= abdominoperineale resectie; LAR = low anterior resection; CI = confidence interval; n.a. = not available.
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nificantly related with worse outcome. In a subset of patients, the presence of chronic 
obstructive pulmonary disease and deep vein thrombosis led to a higher occurrence of 
perioperative complications.15 An extended study2 of the Comprehensive Cancer Centre 
South showed that 65% of patients aged 65-79 years and 70% of patients aged 80 years 
or over had one or more comorbid conditions, and about half of these patients had 
two or more comorbid conditions. Additionally, comorbidity was shown to significantly 
decrease the chance of being treated with TME surgery and was strongly associated 
with diminished survival.
Similarly, in a systematic review by the Colorectal Cancer Collaborative Group,16 age 
was noted to be an important risk factor for 30-day mortality, with a 3.2 times increased 
risk in the 75-84-year age group and a 6.2 times increased risk in the 85-years-and-older 
age group compared with younger patients. Although all types of general complications 
were significantly increased in the older age groups (i.e., pneumonia, thromboembolism, 
and cerebrovascular complications), anastomotic leakage was not correlated with age.16
In addition to the risks of anastomotic leakage, functional outcome after bowel res-
toration should also be taken into account. When confronted with the choice between a 
permanent colostomy and restoration of bowel continuity, most patients will opt for the 
latter choice. Technically, the restoration of bowel continuity is feasible in most patients 
with rectal cancer. With the protection of a diverting stoma, more than 90% of the anas-
tomoses at the pelvic floor level or lower will heal, and, in elderly patients, the number 
of anastomotic failures is similar to that in younger patients.17 However, there are several 
disadvantages of this procedure. In addition to an increased risk of mortality in case of 
anastomotic failure, 20% of diverting stomas in elderly patients will not be reversed for 
many reasons.18 Furthermore, a return of manageable bowel function is not guaranteed. 
After removal of the rectal ampulla, bowel function will change and can take up to 2 
years before an end stage is reached. Side studies of the Dutch TME trial have shown 
that, in most patients, a high frequency of defecation, fractionated defecation, urge, and 
incontinence will occur, at least temporarily. If the anal sphincter was included in the 
radiation field, incontinence will be a problem in almost all patients.19 The consequences 
of the changes in defecation patterns can be grave in elderly patients. The increase 
and urge of bowel movements can prevent patients from leaving their home and can, 
therefore, lead to social isolation. Loss of functionality, which is a threat to the delicate 
balance between living an independent life and depending on others, often leads to a 
depersonalised, institutionalised life. Several researchers have shown that quality of life 
can be better with a stoma than with a low anastomosis.20,21 Multidimensional assess-
ment of individual cases is needed for deciding whether an anastomosis is technically 
feasible, safe, but above all desirable.
56 Chapter 4
future perspectives
The current evidence shows that findings from randomised studies on the treatment of 
rectal cancer cannot be automatically applied to elderly patients, in whom treatment 
of rectal cancer is a multidimensional issue. Apart from being an oncological problem, 
this issue is also associated with the physiological changes caused by aging, whereby 
patients become more vulnerable to noxious effects, which are often exaggerated by 
comorbid conditions. Population-based studies often claim that elderly patients, who 
undergo the same cancer treatment as their younger counterparts, have a more favour-
able outcome than elderly patients who do not have these treatments,22 and under-
treatment of the elderly has been suggested as the reason for decreased rectal-cancer-
specific survival in this population.23 However, these studies do not provide convincing 
evidence that elderly patients should have the same treatment as younger patients. The 
factors responsible for the obvious selection bias when recruiting elderly patients into 
clinical trials are not well explained. Sufficient evidence exists to support the statement 
that cancer-specific survival after major resection is not age dependent.24-29 However, 
all researchers agree that postoperative mortality is at least doubled in elderly patients 
after resection compared with younger patients after resection and that careful selec-
tion should be made. None of the studies provided data for 6-month mortality, but, as 
can be noted from our analysis presented in Table 1, a further doubling of postoperative 
mortality at 6 months and thereafter is very likely.
Thus, major surgical treatment might not be the best option for all elderly patients 
with rectal cancer. However, biological age is not the only factor to be taken into account 
when including patients in this at-risk group, and more reliable parameters are mandatory 
when selecting patients for certain treatments. Obviously, in the very fit (i.e., American 
Society of Anesthesiologists (ASA) grade I) and the very ill (ASA IV-V) the decision to treat 
with curative intent or to provide palliative care is not difficult to make. The Association of 
Coloproctology of Great Britain and Ireland (ACPGBI) has developed an excellent scoring 
system for 30-day mortality on the basis of a prospective survey of more than 8077 pa-
tients with colorectal cancer in 79 hospitals (ACPGBI Colorectal Cancer Study).30,31 Several 
other scoring systems (i.e., Possum, P-Possum, and CR-Possum) have also been developed, 
which take into account physiological status and the extent of the procedure, and have 
produced similar findings. Validation studies have confirmed the usefulness of these 
systems to predict mortality.32 For example, the operative mortality risk for patients aged 
75-95 years with ASA II-III ranges from 5.4% to 13.5%, as shown in Figure 4 on the basis 
of the ACPGBI score for resected rectal cancer (Tumour Node Metastasis stage 2 and 3).
Although these scoring systems can help to identify and quantify the risk associated 
with resectional treatment for a given physiological performance status, they cannot 
be used as a definite decision aid. A 20% operative mortality risk might be acceptable 
for a disease that leads to debilitating symptoms if left untreated, but is probably not 
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acceptable for a small, well-differentiated tumour. Furthermore, the most important 
question for older patients is not whether they will survive, but, rather, how their quality 
of life will be affected after surgery - i.e., will their functional status deteriorate and will 
an independent life still be possible? Mortality scoring systems do not help to answer 
these questions.
alternatives for tMe surgery for elderly patients
The standardised approach of TME is certainly the best way to avoid local recurrence. 
However, with the extremely high 6-month postoperative mortality associated with this 
procedure in elderly patients, the search for safer alternatives is imperative.
In a paper describing the effects of introducing TME surgery in the general popula-
tion,12 we showed that radiotherapy was not responsible for the increased mortality in 
elderly patients and that surgical trauma remained the heaviest burden on mortality. 
Figure 5 shows cancer-specific survival in the Dutch TME trial. Cancer-specific survival 
in elderly patients was significantly improved in the study group that received five 
fractions of 5 Gy preoperative radiotherapy, whereas this improvement did not occur in 
younger patients.
Future research should take advantage of this finding. The important question is 
whether radiotherapy can have a more prominent role in the treatment of rectal can-
cer in the elderly and, thus, avoid the morbidity and mortality associated with major 
resectional treatments. A concern of omitting mesorectal excision in these patients is 
the possibility of leaving positive lymph nodes behind, which might cause local recur-
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58 Chapter 4
rence. However, Read and colleagues33 showed that in patients whose tumours were 
downstaged to T0-1 after neoadjuvant radiotherapy and chemoradiotherapy, nodal 
metastases were rare. Furthermore, publications by Hughes and colleagues34 and Ratto 
and colleagues35 confirm that good responders to neoadjuvant treatment have little 
chance of persisting nodal metastases. On the basis of these findings, we now discuss 
several alternative treatment options for rectal cancer in elderly patients.
chemoradiotherapy alone
In a study by Habr-Gama and colleagues,36 which included patients with mainly T3 rectal 
cancers, 71 patients who had a complete clinical response after chemoradiotherapy 
were closely observed and not operated on. With a mean follow up of 57 months, two 
patients developed a local recurrence, of which one underwent a successful salvage 
operation. An additional three patients developed distant metastases. Up to now, no 
other studies to our knowledge have confirmed these findings.
radiotherapy in combination with local excision
Less invasive surgical techniques than TME, such as local excision or transanal endo-
scopic microsurgery (TEM), have resulted in promising findings in the treatment of early 
rectal cancer, especially in terms of low morbidity and mortality. However, the benefits 
of these less invasive treatments should be carefully weighed against the increased risk 
of local recurrence.
For early-stage rectal cancer (T1N0), a trial that randomly assigned patients to either 
TEM or anterior resection showed significantly less blood loss in the TEM group than in 
the anterior resection group (143 mL versus 745 mL) and shorter hospitalisation times 
(5.7 days versus 15.4 days). Local control in the anterior resection group was 100% com-
pared with 95.8% in the TEM group.37-43 On the basis of these findings, TEM has become 
a widely accepted treatment modality for T1N0 rectal cancers.
Hazard ratio and 95% CIHazard
ratio 
Lower
limit 
Upper
limit 
Z-Value P-Value
1.076 0.785 1.474 0.456 0.648
0.725 0.492 1.068 -1.626 0.104
0.563 0.323 0.982 -2.023 0.043
1.000 0.063 15.930 0.000 1.000
0.851 0.681 1.063 -1.423 0.155
< 65   years
65-74 years
75-84 years
≥ 85   years
Overall
0.1 0.2 0.5 1 2 5 10
Favours TME + RT Favours TME only
figure 5. Cancer-specific mortality per age group in the Dutch TME trial. TME = total mesorectal excision; 
RT = radiotherapy; CI = confidence interval.
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For T2 and T3 tumours, the findings for TEM surgery are less satisfactory, even when 
combined with postoperative radiotherapy of chemoradiotherapy. Local recurrence of 
these tumours varies from 10% to 36%,44-50 suggesting that postoperative radiotherapy 
or chemoradiotherapy is incapable of eradicating possible lymph node involvement. 
However, the combination of preoperative radiotherapy or chemoradiotherapy with 
TEM seems to be more promising.51 Only one small randomised trial to our knowledge 
has been done for low T2N0 tumours (situated in the distal rectum), which showed no dif-
ference in local control between patients who underwent local excision or laparoscopic 
resection after chemoradiotherapy.51 In accordance with this finding, several researchers 
have reported local control between 90% and 95% for patients with T2 or T3 tumours 
treated with this approach.52-56 However, the addition of chemotherapy to radiotherapy, 
which has produced promising findings in younger patients for downsizing tumours, 
might become a problem in elderly patients who are unfit for resectional treatment. By 
contrast, elderly patients respond well to radiotherapy alone, and this might also be an 
option to be investigated, in terms of a short or long course radiotherapy, without che-
motherapy, followed by a longer waiting period before re-evaluation for local excision.
radiotherapy as radical treatment option
In this context, the role of radiotherapy is limited to the (neo)adjuvant or palliative set-
ting, because a very high dose of radiation (at least 60 Gy, but probably more than 80 Gy) 
needs to be given for control of rectal carcinomas by radiotherapy alone.57,58 However, 
external-beam radiotherapy doses higher than 50 Gy will result in increased late toxic 
effects, which are the limiting factor for dose escalation in external-beam radiotherapy. 
To overcome this dose limitation, intracavity irradiation, either by contact X-rays or by 
intraluminal brachytherapy, which enables the delivery of a high dose of radiation to the 
tumour with low doses to the surrounding normal tissue, might be explored.
Papillon and Berard59 described the value of contact X-rays for early rectal cancers (T1 
and favourable T2 lesions) and reported 4.5% local failure and 74% survival after 5 years. 
Several other investigators have confirmed these findings in studies with contact X-rays 
for patients with T1N0 and small T2N0 rectal cancer.60-66
For patients with more advanced tumours, the risk of nodal involvement is high and 
a combination of contact treatment or interstitial brachytherapy with external-beam 
radiotherapy is needed to address this problem. Several publications have shown that 
the combination of local and external radiotherapy leads to 63%-85% local recurrence 
in T2 and T3 tumours.66,67
These findings show that radical radiotherapy might be a good alternative to TME, 
especially for elderly patients who are unable to undergo any surgical procedure. For 
patients with small tumours with a low likelihood of nodal involvement, locally applied 
radiotherapy might be appropriate, as long as the total dose to the tumour is about 
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80 Gy. For larger tumours with possible lymph node involvement, a combination of 
external-beam radiotherapy and brachytherapy can be an option.
conclusion
After major resectional treatment, elderly patients with rectal cancer have an increased 
30-day and 6-month mortality compared with younger patients. Treatment-related 
mortality is an important competitive risk factor, which obscures the positive effect 
of modern rectal cancer treatment in those aged 75 years and above. Easy and appli-
cable physiological and clinical scoring systems have been developed and validated as 
instruments for the identification of those with a high operative risk. Additionally, in 
frail patients, a multidimensional assessment of the relevant medical, functional, social, 
and mental parameters is necessary to define an appropriate treatment goal. In such 
an individualised treatment plan, the optimum oncological outcome might not be the 
most important objective.68 Less invasive treatment options for rectal cancer in the 
elderly patients are gaining increased interest. Furthermore, elderly patients seem to 
respond well to radiotherapy, and might, therefore, become the main beneficiaries from 
the use of radical radiotherapy in this setting. As such, the elderly population might be 
a suitable patient group for research in this field.
Despite the fact that we have limited knowledge of the biology of rectal cancer in 
the elderly patients, treatment options for this population need to be explored, and 
individualised treatment approaches should be considered in order to maintain a good 
quality of life for each patient. Such treatment needs to involve specialised services that 
are capable of obtaining optimum outcomes for this multifactorial issue.
Controversies of total mesorectal excision for rectal cancer in elderly patients 61
references
 1.  Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comor-
bidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
 2.  Lemmens VE, Janssen-Heijnen ML, Verheij CD, Houterman S, Repelaer van Driel OJ, Coebergh JW. 
Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal 
cancer. Br J Surg 2005; 92: 615-623.
 3.  NKR cijfers. http://www.ikcnet.nl/cijfers/index.php?taal=nl&frequentiemaat=1 (accessed 28 March 
2008).
 4.  Iversen LH, Pedersen L, Riis A, Friis S, Laurberg S, Sorensen HT. Age and colorectal cancer with 
focus on the elderly: trends in relative survival and initial treatment from a Danish population-
based study. Dis Colon Rectum 2005; 48: 1755-1763.
 5.  Martijn H, Voogd AC, van de Poll-Franse LV, Repelaer van Driel OJ, Rutten HJ, Coebergh JW. Im-
proved survival of patients with rectal cancer since 1980: a population-based study. Eur J Cancer 
2003; 39: 2073-2079.
 6.  Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 
1986; 327: 1479-1482.
 7.  Quirke P, Dixon MF, Durdey P, Williams NS. Local recurrence of rectal adenocarcinoma due to inad-
equate surgical resection. Histopathological study of lateral tumour spread and surgical excision. 
Lancet 1986; 328: 996-999.
 8.  Kapiteijn E, Putter H, van de Velde CJ. Impact of the introduction and training of total mesorectal 
excision on recurrence and survival in rectal cancer in the Netherlands. Br J Surg 2002; 89: 1142-
1149.
 9.  Matanoski G, Tao XG, Almon L, Adade AA, Davies-Cole JO. Demographics and tumor characteris-
tics of colorectal cancers in the United States, 1998-2001. Cancer 2006; 107: 1112-1120.
 10.  Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients 
with cancer onto clinical trials. J Clin Oncol 2005; 23: 3112-3124.
 11.  Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, et al. Participation of pa-
tients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003; 21: 1383-1389.
 12.  Rutten H, den Dulk M, Lemmens V, Nieuwenhuijzen G, Krijnen P, Jansen-Landheer M, et al. Survival 
of elderly rectal cancer patients not improved: analysis of population based data on the impact of 
TME surgery. Eur J Cancer 2007; 43: 2295-2300.
 13.  Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radio-
therapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 
345: 638-646.
 14.  Shahir MA, Lemmens VE, van de Poll-Franse LV, Voogd AC, Martijn H, Janssen-Heijnen ML. Elderly 
patients with rectal cancer have a higher risk of treatment-related complications and a poorer 
prognosis than younger patients: a population-based study. Eur J Cancer 2006; 42: 3015-3021.
 15.  Lemmens VE, Janssen-Heijnen ML, Houterman S, Verheij KD, Martijn H, Poll-Franse L, et al. Which 
comorbid conditions predict complications after surgery for colorectal cancer? World J Surg 2007; 
31: 192-199.
 16.  Colorectal Cancer Collaborative Group. Surgery for colorectal cancer in elderly patients: a system-
atic review. Lancet 2000; 356: 968-974.
 17.  Peeters KC, Tollenaar RA, Marijnen CA, Klein Kranenbarg E, Steup WH, Wiggers T, et al. Risk factors 
for anastomotic failure after total mesorectal excision of rectal cancer. Br J Surg 2005; 92: 211-216.
62 Chapter 4
 18.  den Dulk M, Smit M, Peeters KC, Klein Kranenbarg E, Rutten HJ, Wiggers T, et al. A multivariate 
analysis of limiting factors for stoma reversal in patients with rectal cancer entered into the total 
mesorectal excision (TME) trial: a retrospective study. Lancet Oncol 2007; 8: 297-303.
 19.  Lange MM, den Dulk M, Bossema ER, Maas CP, Peeters KC, Rutten HJ, et al. Risk factors for faecal 
incontinence after rectal cancer treatment. Br J Surg 2007; 94: 1278-1284.
 20.  Marijnen CA, van de Velde CJH, Putter H, van den BM, Maas CP, Martijn H, et al. Impact of short-
term preoperative radiotherapy on health-related quality of life and sexual functioning in primary 
rectal cancer: report of a multicenter randomized trial. J Clin Oncol 2005; 23: 1847-1858.
 21.  Vironen JH, Kairaluoma M, Aalto AM, Kellokumpu IH. Impact of functional results on quality of life 
after rectal cancer surgery. Dis Colon Rectum 2006; 49: 568-578.
 22.  Kiran RP, Pokala N, Dudrick SJ. Long-term outcome after operative intervention for rectal cancer 
in patients aged over 80 years: analysis of 9,501 patients. Dis Colon Rectum 2007; 50: 604-610.
 23.  Chang GJ, Skibber JM, Feig BW, Rodriguez-Bigas M. Are we undertreating rectal cancer in the 
elderly? An epidemiologic study. Ann Surg 2007; 246: 215-221.
 24.  Law WL, Choi HK, Ho JW, Lee YM, Seto CL. Outcomes of surgery for mid and distal rectal cancer in 
the elderly. World J Surg 2006; 30: 598-604.
 25.  Endreseth BH, Romundstad P, Myrvold HE, Bjerkeset T, Wibe A. Rectal cancer treatment of the 
elderly. Colorectal Dis 2006; 8: 471-479.
 26.  Larsen SG, Wiig JN, Tretli S, Giercksky KE. Surgery and pre-operative irradiation for locally ad-
vanced or recurrent rectal cancer in patients over 75 years of age. Colorectal Dis 2006; 8: 177-185.
 27.  Vironen JH, Sainio P, Husa AI, Kellokumpu IH. Complications and survival after surgery for rectal 
cancer in patients younger than and aged 75 years or older. Dis Colon Rectum 2004; 47: 1225-
1231.
 28.  Barrier A, Ferro L, Houry S, Lacaine F, Huguier M. Rectal cancer surgery in patients more than 80 
years of age. Am J Surg 2003; 185: 54-57.
 29.  Puig-La Calle J, Jr., Quayle J, Thaler HT, Shi W, Paty PB, Quan SH, et al. Favorable short-term and 
long-term outcome after elective radical rectal cancer resection in patients 75 years of age or 
older. Dis Colon Rectum 2000; 43: 1704-1709.
 30.  Heriot AG, Tekkis PP, Smith JJ, Cohen CR, Montgomery A, Audisio RA, et al. Prediction of postop-
erative mortality in elderly patients with colorectal cancer. Dis Colon Rectum 2006; 49: 816-824.
 31.  Tan E, Tilney H, Thompson M, Smith J, Tekkis PP. The United Kingdom National Bowel Cancer 
Project - Epidemiology and surgical risk in the elderly. Eur J Cancer 2007; 43: 2285-2294.
 32.  Ramkumar T, Ng V, Fowler L, Farouk R. A comparison of POSSUM, P-POSSUM and colorectal POS-
SUM for the prediction of postoperative mortality in patients undergoing colorectal resection. 
Dis Colon Rectum 2006; 49: 330-335.
 33.  Read TE, Andujar JE, Caushaj PF, Johnston DR, Dietz DW, Myerson RJ, et al. Neoadjuvant therapy 
for rectal cancer: histologic response of the primary tumor predicts nodal status. Dis Colon Rectum 
2004; 47: 825-831.
 34.  Hughes R, Glynne-Jones R, Grainger J, Richman P, Makris A, Harrison M, et al. Can pathological 
complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for 
T3-T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence 
and the appropriateness of local excision? Int J Colorectal Dis 2006; 21: 11-17.
 35.  Ratto C, Ricci R, Valentini V, Castri F, Parello A, Gambacorta MA, et al. Neoplastic mesorectal micro-
foci (MMF) following neoadjuvant chemoradiotherapy: clinical and prognostic implications. Ann 
Surg Oncol 2007; 14: 853-861.
Controversies of total mesorectal excision for rectal cancer in elderly patients 63
 36.  Habr-Gama A, Perez RO, Nadalin W, Nahas SC, Ribeiro U, Jr., Silva e Sousa AH Jr, et al. Long-term 
results of preoperative chemoradiation for distal rectal cancer correlation between final stage 
and survival. J Gastrointest Surg 2005; 9: 90-101.
 37.  Winde G, Nottberg H, Keller R, Schmid KW, Bunte H. Surgical cure for early rectal carcinomas (T1). 
Transanal endoscopic microsurgery vs. anterior resection. Dis Colon Rectum 1996; 39: 969-976.
 38.  Mellgren A, Sirivongs P, Rothenberger DA, Madoff RD, Garcia-Aguilar J. Is local excision adequate 
therapy for early rectal cancer? Dis Colon Rectum 2000; 43: 1064-1071.
 39.  Nascimbeni R, Nivatvongs S, Larson DR, Burgart LJ. Long-term survival after local excision for T1 
carcinoma of the rectum. Dis Colon Rectum 2004; 47: 1773-1779.
 40.  Lee W, Lee D, Choi S, Chun H. Transanal endoscopic microsurgery and radical surgery for T1 and 
T2 rectal cancer. Surg Endosc 2003; 17: 1283-1287.
 41.  Bentrem DJ, Okabe S, Wong WD, Guillem JG, Weiser MR, Temple LK, et al. T1 adenocarcinoma of 
the rectum: transanal excision or radical surgery? Ann Surg 2005; 242: 472-477.
 42.  Endreseth BH, Myrvold HE, Romundstad P, Hestvik UE, Bjerkeset T, Wibe A. Transanal excision vs. 
major surgery for T1 rectal cancer. Dis Colon Rectum 2005; 48: 1380-1388.
 43.  Langer C, Liersch T, Suss M, Siemer A, Markus P, Ghadimi BM, et al. Surgical cure for early rectal 
carcinoma and large adenoma: transanal endoscopic microsurgery (using ultrasound or elec-
trosurgery) compared to conventional local and radical resection. Int J Colorectal Dis 2003; 18: 
222-229.
 44.  Benson R, Wong CS, Cummings BJ, Brierley J, Catton P, Ringash J, et al. Local excision and postop-
erative radiotherapy for distal rectal cancer. Int J Radiat Oncol Biol Phys 2001; 50: 1309-1316.
 45.  Russell AH, Harris J, Rosenberg PJ, Sause WT, Fisher BJ, Hoffman JP, et al. Anal sphincter conserva-
tion for patients with adenocarcinoma of the distal rectum: long-term results of radiation therapy 
oncology group protocol 89-02. Int J Radiat Oncol Biol Phys 2000; 46: 313-322.
 46.  Paty PB, Nash GM, Baron P, Zakowski M, Minsky BD, Blumberg D, et al. Long-term results of local 
excision for rectal cancer. Ann Surg 2002; 236: 522-529.
 47.  Steele GD, Jr., Herndon JE, Bleday R, Russell A, Benson A, III, Hussain M, et al. Sphincter-sparing 
treatment for distal rectal adenocarcinoma. Ann Surg Oncol 1999; 6: 433-441.
 48.  Bouvet M, Milas M, Giacco GG, Cleary KR, Janjan NA, Skibber JM. Predictors of recurrence after 
local excision and postoperative chemoradiation therapy of adenocarcinoma of the rectum. Ann 
Surg Oncol 1999; 6: 26-32.
 49.  Chakravarti A, Compton CC, Shellito PC, Wood WC, Landry J, Machuta SR, et al. Long-term follow-
up of patients with rectal cancer managed by local excision with and without adjuvant irradia-
tion. Ann Surg 1999; 230: 49-54.
 50.  Mendenhall WM, Morris CG, Rout WR, Zlotecki RA, Lind DS, Hochwald SN, et al. Local excision and 
postoperative radiation therapy for rectal adenocarcinoma. Int J Cancer 2001; 96 Suppl: 89-96.
 51.  Lezoche E, Guerrieri M, Paganini AM, D’Ambrosio G, Baldarelli M, Lezoche G, et al. Transanal 
endoscopic versus total mesorectal laparoscopic resections of T2-N0 low rectal cancers after neo-
adjuvant treatment: a prospective randomized trial with a 3-years minimum follow-up period. 
Surg Endosc 2005; 19: 751-756.
 52.  Bonnen M, Crane C, Vauthey JN, Skibber J, Delclos ME, Rodriguez-Bigas M, et al. Long-term results 
using local excision after preoperative chemoradiation among selected T3 rectal cancer patients. 
Int J Radiat Oncol Biol Phys 2004; 60: 1098-1105.
 53.  Kim CJ, Yeatman TJ, Coppola D, Trotti A, Williams B, Barthel JS, et al. Local excision of T2 and T3 
rectal cancers after downstaging chemoradiation. Ann Surg 2001; 234: 352-358.
64 Chapter 4
 54.  Ruo L, Guillem JG, Minsky BD, Quan SH, Paty PB, Cohen AM. Preoperative radiation with or without 
chemotherapy and full-thickness transanal excision for selected T2 and T3 distal rectal cancers. 
Int J Colorectal Dis 2002; 17: 54-58.
 55.  Schell SR, Zlotecki RA, Mendenhall WM, Marsh RW, Vauthey JN, Copeland EM, III. Transanal exci-
sion of locally advanced rectal cancers downstaged using neoadjuvant chemoradiotherapy. J Am 
Coll Surg 2002; 194: 584-590.
 56.  Lezoche E, Guerrieri M, Paganini AM, Baldarelli M, De Sanctis A, Lezoche G. Long-term results in 
patients with T2-3 N0 distal rectal cancer undergoing radiotherapy before transanal endoscopic 
microsurgery. Br J Surg 2005; 92: 1546-1552.
 57.  Ahmad NR, Marks G, Mohiuddin M. High-dose preoperative radiation for cancer of the rectum: 
impact of radiation dose on patterns of failure and survival. Int J Radiat Oncol Biol Phys 1993; 27: 
773-778.
 58.  Fortier GA, Constable WC, Meyers H, Wanebo HJ. Preoperative radiation therapy for rectal cancer. 
An effective therapy in need of a clinical trial. Arch Surg 1986; 121: 1380-1385.
 59.  Papillon J, Berard P. Endocavitary irradiation in the conservative treatment of adenocarcinoma of 
the low rectum. World J Surg 1992; 16: 451-457.
 60.  Sischy B. The use of endocavitary irradiation for selected carcinomas of the rectum: ten years 
experience. Radiother Oncol 1985; 4: 97-101.
 61.  Rauch P, Bey P, Peiffert D, Conroy T, Bresler L. Factors affecting local control and survival after treat-
ment of carcinoma of the rectum by endocavitary radiation: a retrospective study of 97 cases. Int 
J Radiat Oncol Biol Phys 2001; 49: 117-124.
 62.  Gerard JP, Ayzac L, Coquard R, Romestaing P, Ardiet JM, Rocher FP, et al. Endocavitary irradiation 
for early rectal carcinomas T1 (T2). A series of 101 patients treated with the Papillon’s technique. 
Int J Radiat Oncol Biol Phys 1996; 34: 775-783.
 63.  Kovalic JJ. Endocavitary irradiation for rectal cancer and villous adenomas. Int J Radiat Oncol Biol 
Phys 1988; 14: 261-264.
 64.  Schild SE, Martenson JA, Gunderson LL. Endocavitary radiotherapy of rectal cancer. Int J Radiat 
Oncol Biol Phys 1996; 34: 677-682.
 65.  Coatmeur O, Truc G, Barillot I, Horiot JC, Maingon P. Treatment of T1-T2 rectal tumors by contact 
therapy and interstitial brachytherapy. Radiother Oncol 2004; 70: 177-182.
 66.  Aumock A, Birnbaum EH, Fleshman JW, Fry RD, Gambacorta MA, Kodner IJ, et al. Treatment of rec-
tal adenocarcinoma with endocavitary and external beam radiotherapy: results for 199 patients 
with localized tumors. Int J Radiat Oncol Biol Phys 2001; 51: 363-370.
 67.  Gerard JP, Chapet O, Ramaioli A, Romestaing P. Long-term control of T2-T3 rectal adenocarcinoma 
with radiotherapy alone. Int J Radiat Oncol Biol Phys 2002; 54: 142-149.
 68.  Maas HA, Janssen-Heijnen ML, Olde Rikkert MG, Machteld Wymenga AN. Comprehensive geriat-
ric assessment and its clinical impact in oncology. Eur J Cancer 2007; 43: 2161-2169.
chapter 5
the abdominoperineal resection itself is associated 
with an adverse outcome: the european experience 
based on a pooled analysis of five european 
randomised clinical trials on rectal cancer
Marcel den Dulk, Hein Putter, Laurence Collette, Corrie A.M. Marijnen, 
Joakim Folkesson, Jean-Francois Bosset, Claus Rödel, Krzysztof Bujko, Lars Påhlman, 
Cornelis J.H. van de Velde
Eur J Cancer 2009; 45: 1175-1183
66 Chapter 5
aBstract
Purpose
The aim of this study is to identify factors associated with the decision to perform an 
abdominoperineal resection (APR) and to assess if these factors or the surgical proce-
dure itself is associated with circumferential resection margin (CRM) involvement, local 
recurrence (LR), overall survival (OS), and cancer-specific survival (CSS).
Patients and methods
The Swedish Rectal Cancer trial (SRCT), TME trial, CAO/ARO/AIO-94 trial, EORTC 22921 
trial, and Polish Rectal Cancer trial (PRCT) were pooled. A propensity score was calcu-
lated, which indicated the predicted probability of undergoing an APR given gender, 
age and distance, and used in the multivariate analyses.
results
An APR procedure was associated with an increased risk of CRM involvement (odds ratio 
(OR) 2.52, P < 0.001), increased LR rate (hazard ratio (HR) 1.53, P = 0.001) and decreased 
CSS rate (HR 1.31, P = 0.002), whereas the propensity score was not.
conclusion
The results suggest that the APR procedure itself is a significant predictor for nonradical 
resections and increased risk of LR and death due to cancer for patients with advanced 
rectal cancer.
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introDuction
At the end of the 1980s, the 5-year overall survival (OS) rate for curatively treated rectal 
cancer was around 50%.1 During the early 1990s it became clear that the previously used 
bowel margin of 5 cm distal from the tumour could be safely reduced to 2 cm or less.2 
In the same time period, the total mesorectal excision (TME) technique was introduced 
as the standard of care for rectal cancer.1,3,4 As a result, less abdominoperineal resections 
(APR) were performed.5,6
Although the general OS improved since the introduction of the TME technique, 
several studies showed that patients treated with a low anterior resection (LAR) had a 
10% better survival rate than patients treated with an APR.7-10 Recently, Påhlman and 
colleagues reported the results from 1995 to 2003 of the Swedish Rectal Cancer Registry, 
a large nationwide Swedish audit.10 They showed that after the introduction of the TME 
technique in Sweden, the APR procedure was less frequently performed. However, the 
APR was still associated with a reduced OS compared to the LAR procedure: 59.8% 5-year 
survival for patients treated with an APR compared with 70.1% for patients treated with 
a LAR.10
It is not clear if the observed worse outcome of patients undergoing an APR is a result 
of the surgical procedure itself or solely related to patient- and tumour-related factors 
that drove the decision to perform an APR in the first place. The aim of the present analy-
ses is first to identify patient- and tumour-related factors associated with the decision 
to perform an APR, and next, to assess if these patient- and tumour-related risk factors 
or the type of surgery itself is independently associated with circumferential resection 
margin (CRM) involvement, local recurrence (LR), OS, and cancer-specific survival (CSS) 
in a pooled database of treatment variables of five large European trials in rectal cancer.
Patients anD MethoDs
trials and patients
The individual patient data of the following five trials were collated: Swedish Rectal Can-
cer trial (SRCT)11, Dutch TME trial3, German CAO/ARO/AIO-94 trial12, EORTC 22921 trial13, 
and the Polish Rectal Cancer trial (PRCT)14. The SRCT randomised 1180 patients between 
surgery alone and 5 x 5 Gy preoperative radiotherapy followed by surgery (1987-1990).11 
The Dutch TME trial (n = 1861, 1996-1999) randomised patients between TME alone 
and 5 x 5 Gy preoperative radiotherapy followed by TME.3 The German trial compared 
preoperative chemoradiotherapy with postoperative chemoradiotherapy (1995-2002, n 
= 823).12 In EORTC trial 22921 (1993-2003), 1011 patients were randomised in one of four 
arms: (1) preoperative 45 Gy radiotherapy, (2) preoperative chemoradiotherapy, (3) pre-
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operative radiotherapy and postoperative chemotherapy, and (4) preoperative chemo-
radiotherapy and postoperative chemotherapy.13 In the PRCT (n = 312), that recruited 
from 1999 to 2002, preoperative 5 x 5 Gy radiotherapy was compared with preoperative 
chemoradiotherapy.14 From this pooled database, all eligible patients, without distant 
metastases at the time of surgery, treated with LAR or APR were selected. Patients who 
were treated with a Hartmann’s procedure (a LAR in which instead of an anastomosis an 
endcolostomy is performed) were included in the LAR group. Unless indicated differ-
ently, both types of resections will be referred to as a LAR. Because only patients with an 
advanced tumour stage were included in the German CAO/ARO/AIO-94, EORTC 22921, 
and PRCT, only the patients with a T3-4 tumour were selected from the SRCT and the 
Dutch TME trial, and the patients with a T1 or T2 tumour who were entered into these 
two trials were excluded (TNM classification of malignant tumours fifth edition15). As 
the distance between the tumour and the anal verge was used in the calculations of the 
propensity score, patients in whom the distance was unknown were excluded. To adjust 
the survival analyses for different age limits allowed in the various trials, those analyses 
were restricted to only patients aged 75 year or less.
end-points, variables and statistics
First, the following factors were studied in a multivariate logistic regression analysis for 
their association with the decision for an APR by preference over an LAR: gender, age, 
and distance of the tumour to the anal verge. These factors were considered as they were 
available at the time of the surgical procedure. A propensity score was then calculated 
from the logistic regression as the predicted likelihood to undergo an APR given gender, 
age and distance between the tumour and the anal verge; a low score corresponds to 
a low probability of undergoing an APR and a high score corresponds to a high prob-
ability of undergoing an APR. This propensity score was then categorised into quartiles. 
Second, both the propensity score and the type of surgical resection actually performed 
were assessed as predictors in four multivariate models predicting, respectively, the risk 
of CRM involvement (logistic regression), LR, OS, and CSS (Cox regression). The analysis 
for CRM was adjusted, and the analyses for LR, OS, and CSS were stratified for trial and 
randomisation arm. A positive CRM was defined as microscopic or macroscopic tumour 
in the resection margin. The information about CRM was not available for the SRCT, thus 
patients from this trial were excluded of the analysis of CRM. For the calculation of LR 
and OS, the time from surgery to, respectively, LR and death was used. CSS was defined 
as the time from surgery to death due to rectal cancer. LR probabilities are reported as 
cumulative incidences with death as a competing risk; CSS is reported as one minus 
cumulative incidence with death due to other causes as competing risk.16
Data were analysed with the SPSS package (SPSS 14.0 for Windows; SPSS Inc., Chicago, 
IL, USA). Statistical significance was claimed at the two-sided 0.05 significance level.
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results
Patients
In total, 5187 patients were included in the SRCT, Dutch TME trial, German CAO/ARO/
AIO-94 trial, EORTC 22921 trial, and the PRCT. Of these, 124 were ineligible (2.4%). Be-
sides, 1142 patients with a T1-2 tumour from the SRCT and TME trial were excluded. 
Another 148 patients had distant metastasis at the time of surgery; 70 patients had 
other procedures than LAR, Hartmann’s procedure or APR. The distance between the 
tumour and the anal verge was unknown in 70 patients. Therefore, 3633 patients (70.0%) 
were included in the analyses of the type of surgery and LR. Patient and tumour char-
acteristics are shown in Table 1 separately for patients treated with a LAR (including 
Hartmann’s procedure) and an APR. The median follow-up of patients alive was 5.4 years 
(range 0.2-14.9 years). The analysis of CRM involvement was restricted to 2760 of these 
3633 patients for whom the CRM status was known. OS and CSS were studied in 3330 
of 3633 patients who were aged 75 years or less. In all the presented analyses, patients 
treated with a Hartmann’s procedure were included. If, however, patients treated with 
a Hartmann’s procedure were excluded from the analyses, the results of the following 
analyses were similar (data not shown).
type of surgery
The following factors were independently associated with the decision to perform an 
APR: male gender, age above 60 years, and a tumour located within 7 cm from the anal 
verge (Table 2A). This model was used to calculate the propensity score: the predicted 
likelihood to undergo an APR or LAR given gender, age, and distance (range 0.053-0.900). 
The regression coefficients determining the propensity score are shown in Table 2A. 
Patients were then classified by quartiles of the propensity score and this grouping was 
used in all further analyses (patients in the lowest quartile have the lowest probability 
of being selected for an APR, given their age, gender, and tumour localisation; Table 2B).
circumferential resection margin
Tumour cells were found in the CRM in 188 patients of 2760 (6.8%). In 93 of 1863 pa-
tients (5.0%) treated with a LAR and 95 of 897 patients (10.6%) with an APR, the CRM 
was tumour positive. The multivariate prognostic factor analysis for the end-point CRM 
involvement is displayed in Table 3: Table 3A shows the model with type of surgical pro-
cedure and propensity score; Table 3B shows the impact of the separate variables. The 
type of the surgical procedure predicted significantly for the risk of CRM involvement. In 
contrast, neither the propensity score nor any of the individual factors, distance, gender 
or age, was significantly associated with CRM involvement.
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table 1. Patient and tumour characteristics given separately for patients treated with a LAR including 
Hartmann’s procedure and an APR.
Variable LAR
n (%)
APR
n (%)
Sex
 Female  816 (66)  416 (34)
 Male 1464 (61)  937 (39)
Age
 ≤ 60  years  886 (68)  410 (32)
 61-70 years  829 (61)  540 (39)
 > 70  years  565 (58)  403 (42)
Trial
 Swedish Rectal Cancer trial
  Surgery only  150 (42)  209 (58)
  5 x 5 Gy RT + surgery  155 (47)  175 (53)
 TME trial
  TME surgery only  413 (75)  136 (25)
  5 x 5 Gy RT + TME surgery  384 (73)  142 (27)
 CAO/ARO/AIO-94 trial
  Preoperative CRT  235 (68)  109 (32)
  Postoperative CRT  243 (72)   93 (28)
 EORTC 22921 trial
  Preoperative 45 Gy RT  257 (57)  197 (43)
  Preoperative CRT  267 (59)  185 (41)
 Polish Rectal Cancer trial
  Preoperative CRT   85 (60)   57 (40)
  Preoperative 5 x 5 Gy RT   91 (65)   50 (35)
Distance of tumour to anal verge
 ≤ 3.0    cm   99 (15)  563 (85)
 3.1-7.0 cm  818 (55)  661 (45)
 > 7.0    cm 1363 (91)  129  (9)
pN-status a
 N0/Nx 1290 (63)  754 (37)
 N+  990 (62)  599 (38)
pT-stage b
 Tis/T1/T2  641 (61)  404 (39)
 T3/T4 1630 (64)  934 (36)
CRM involvement
 No 1770 (69)  802 (31)
 Yes   93 (49)   95 (51)
 Unknown  417 (48)  456 (52)
LAR = low anterior resection; APR = abdominoperineal resection; RT = radiotherapy; CRT = chemoradio-
therapy. a Missing for 178 patients. b Missing for 24 patients.
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table 2. Multivariate logistic regression analysis for the type of surgery (LAR including Hartmann’s 
procedure versus APR) (A) and number of patients with patients’ characteristics (gender, age, and distance 
from the tumour to the anal verge) shown for each quartile of the propensity score (B).
A
Variable Odds ratio 95% CI P-value Regression coefficient 
for propensity score
Gender  0.001
 Female  1.00
 Male  1.35  1.13- 1.61 0.301
Age <0.001
 ≤ 60  years  1.00
 61-70 years  1.42  1.17- 1.72 <0.001 0.349
 > 70  years  1.90  1.54- 2.36 <0.001 0.643
Distance from the anal verge <0.001
 > 7.0    cm  1.00
 3.1-7.0 cm  8.82  7.15-10.88 <0.001 2.177
 ≤ 3.0    cm 63.13 47.57-83.79 <0.001 4.145
An odds ratio (OR) >1 indicates an increased likelihood for an APR and decreased likelihood for a LAR/
Hartmann’s procedure. CI = confidence interval.
B
Propensity score Gender Age Distance from tumour to anal verge
≤ 3 cm 3-7 cm > 7 cm
Lowest quartile Male ≤ 60  years 346
Female ≤ 60  years 202
61-70 years 171
> 70  years 144
25-49% Male 61-70 years 358
> 70  years 271
Female ≤ 60  years 176
50-74% Male ≤ 60  years 353
Female 61-70 years 174
> 70  years 148
Highest quartile Male ≤ 60  years 143
61-70 years 191 400
> 70  years 111 228
Female ≤ 60  years  76
61-70 years  75
> 70  years  66
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In the presented multivariate model for CRM involvement, no interaction between 
distance and surgical procedure could be demonstrated. Figure 1 depicts the observed 
percent of patients with CRM involvement by distance between the tumour and the anal 
verge (in centimetres) separately for patients treated with a LAR and an APR. The APR 
procedure appears to be associated with more frequent CRM involvement for almost all 
distances.
table 3. Multivariate logistic regression analyses, adjusted for trial and randomisation arm, for 
circumferential resection margin (CRM) involvement: with the propensity score for the type of surgery (A) 
and for all variables given separately (B).
A
Variable Odds ratio 95% CI P-value
Surgical procedure <0.001
 LAR 1.00
 APR 2.52 1.69-3.76
Propensity score  0.513
 Lowest quartile 1.00
 25-49% 0.68 0.41-1.15  0.153
 50-74% 0.90 0.54-1.48  0.667
 Highest quartile 0.80 0.50-1.31  0.374
B
Variable Odds ratio 95% CI P -value
Surgical procedure <0.001
 LAR 1.00
 APR 2.53 1.70-3.78
Gender  0.474
 Female 1.00
 Male 1.12 0.82-1.55
Age  0.574
 ≤ 60  years 1.00
 61-70 years 0.83 0.58-1.18  0.295
 > 70  years 0.93 0.64-1.37  0.732
Distance from the anal verge  0.919
 > 7.0    cm 1.00
 3.1-7.0 cm 1.01 0.68-1.52  0.946
 ≤ 3.0    cm 0.93 0.55-1.58  0.790
An odds ratio (OR) >1 indicates an increased likelihood for CRM involvement and an OR < 1 indicates 
a decreased likelihood for CRM involvement. CI = confidence interval; LAR = low anterior resection, 
including Hartmann’s procedure; APR = abdominoperineal resection.
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local recurrence
In Figure 2A, the cumulative incidence function for LR is shown separately for LAR and 
APR with death as competing risk. Five-year local recurrence rates were 11.4% (95% 
confidence interval (CI) 10.0-12.8%) after LAR and 19.7% (95% CI 17.3-22.1%) after APR 
(P < 0.001). The multivariate model for local control is displayed in Table 4. The type of 
surgical procedure actually performed, the presence of lymph node metastasis and CRM 
involvement independently predicted for the risk of LR, but not the propensity score 
itself. If the analysis was repeated with the component variables of the propensity score 
(age, gender, and distance) instead of the propensity score, none of these variables 
predicted for LR (data not shown).
overall survival
The Kaplan-Meier curves for OS for patients with a LAR and an APR are presented in Figure 
2B; 5-year OS rate was 70.1% (95% CI 67.9-72.3%) for patients treated with a LAR and 
59.5% for patients treated with an APR (95% CI 56.6-62.4%; P < 0.001). The multivariate 
analysis for OS in Table 4 shows that lymph node metastasis, CRM involvement, surgical 
procedure, and propensity score were all associated with OS. The results indicate that a 
higher propensity score (i.e. higher probability to be selected for an APR) was associated 
with a shorter OS. Studying separately the variables used for the calculation of the pro-
pensity score, the three individual variables (gender, age, and distance) all predicted OS 
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figure 1. CRM involvement in relation to distance of the tumour to the anal verge, shown separately for 
patients treated with an abdominoperineal resection (grey bar) and low anterior resection, including 
Hartmann’s procedure (white bar).
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figure 2. Local recurrence (A), overall survival (B), and cancer-specific survival (C) shown as cumulative 
incidence (A), Kaplan-Meier survival (B), and one minus cumulative incidence (C) curves separately for 
patients treated with a LAR (including Hartmann’s procedure) and an APR.
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independently of lymph node status, CRM involvement, and type of surgical procedure 
(data not shown).
cancer-specific survival
The results for CSS, defined as the time from surgery to death due to rectal cancer, are 
shown in Table 4: lymph node status, CRM involvement and the type of surgical proce-
dure were independently associated with CSS, whereas the propensity score was not. 
Focusing on the separate variables, gender (P = 0.010) and distance of the tumour to the 
anal verge (P = 0.042) were independently associated with CSS (data not shown). For age 
such an association could not be found (P = 0.704). The estimated cumulative incidences 
as survival curves with death due to other causes as competing risk are depicted in 
Figure 2C; 5-year CSS rate was 76.6% (95% CI 74.6-78.6%) for patients treated with a LAR 
and 65.1% for patients treated with an APR (95% CI 62.0-68.2%; P < 0.001).
table 4. Multivariate Cox regression analyses for local recurrence, overall survival, and cancer-specific 
survival with the propensity score for the type of surgery, stratified for trial and randomisation arm.
Variable Local recurrence Overall survival Cancer-specific survival
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
LN status <0.001 <0.001 <0.001
 N0 1.00 1.00 1.00
 N+ 2.26 1.86-2.75 1.99 1.78-2.24 2.97 2.57-3.44
CRM <0.001 <0.001 <0.001
 Negative 1.00 1.00 1.00
 Positive 3.11 2.26-4.30 <0.001 1.75 1.39-2.19 <0.001 1.84 1.43-2.38 <0.001
 Unknown 1.32 0.86-2.04  0.206 1.36 1.05-1.74  0.021 1.36 1.01-1.84  0.043
Surgical procedure  0.011  0.030  0.002
 LAR 1.00 1.00 1.00
 APR 1.36 1.07-1.72 1.17 1.02-1.34 1.31 1.11-1.56
Propensity score  0.440 <0.001  0.101
 Lowest quartile 1.00 1.00 1.00
 25-49% 1.02 0.77-1.36  0.887 1.36 1.16-1.60 <0.001 1.20 0.98-1.47  0.076
 50-74% 0.94 0.68-1.30  0.706 1.09 0.90-1.32  0.364 1.04 0.83-1.30  0.754
 Highest quartile 1.17 0.87-1.57  0.308 1.40 1.17-1.67 <0.001 1.24 1.00-1.53  0.052
HR = hazard ratio; CI = confidence interval; LN = lymph node; CRM = circumferential resection margin; LAR 
= low anterior resection, including Hartmann’s procedure; APR = abdominoperineal resection.
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Discussion
Several studies have documented that patients treated with an APR have a worse local 
control, and OS than patients treated with a LAR.8,9 Based on these studies one could 
debate whether the APR procedure by itself or the difference in the clinical factors that 
affect the choice to perform an APR in patients is responsible for this adverse outcome. 
The results of our exploration of a large database of patients treated in five prospective 
randomised trials suggest that there is an association between the APR procedure itself 
and a higher risk of CRM involvement, decreased local control and CSS compared to a 
LAR for patients with advanced rectal cancer, whereas for OS the factors associated with 
the choice of an APR (age, gender, and distance) seem at least as relevant as the surgical 
procedure itself. We combined treatment variables of five different European trials on 
rectal cancer. All of these studies were designed to study the effects of (neo)adjuvant 
treatments on LR and OS, although in the PRCT these were secondary end-points. The 
present analyses should thus be interpreted with caution, as the separate trials were not 
designed to study the effects of different surgical procedures on LR or OS. Moreover, the 
time-periods of patient recruitment were different. In the mid-1980s when the SRCT was 
run, 5 cm distal bowel margin below the tumour was considered to be appropriate, re-
sulting in more patients with a mid-rectal tumour to be treated with an APR. Nowadays, a 
distal margin of 2 cm or less is considered sufficient.2 Consequently, in comparison more 
patients were treated with an APR procedure in the SRCT than in the trials that were run 
later. However, differences between the trials was not the subject of the study. The large 
number of patients in this study strengthens our conclusion and could be considered 
representative of a common European experience since patients in our database come 
from several European countries and were treated over a relatively long period of time.
In this study, distance of the tumour to the anal verge, gender, and age were the 
factors that influence the choice of the surgical procedure. However, it must be stressed 
that some other factors, that were not available in the present study because they were 
not collected in any or some of the trials, may also have influenced the selection of the 
surgical procedure. Moreover, patients’ or surgeons’ preferences could have affected the 
type of surgical resection actually performed: variability between surgeons and patients 
exists.17 The variables that were considered in the present analysis for propensity score 
were known at the time of surgery, as otherwise they could not have affected the choice 
for a certain surgical procedure: pathological T-stage and nodal status were therefore 
not considered as variables for this end-point. It is important to note that the decision 
to perform an APR is influenced by multiple factors. The worse outcome for the APR 
procedure after adjustment for the propensity score in the current analyses is therefore 
also multi-factorial. However, the analyses for LR, OS and CSS are adjusted for the factors 
involved in the propensity score, lymph node status, and CRM involvement. Therefore, 
The abdominoperineal resection itself is associated with an adverse outcome 77
in our opinion the quality of the surgical procedure is a crucial factor contributing to the 
poor results of patients treated with an APR.
The APR procedure is still associated with a high risk for a nonradical resection. Due 
to changes in time, such as the changed thoughts about a free distal margin, nowadays 
less patients are treated with an APR than many years ago. For very distal tumours, 
however, an APR will remain the only treatment of choice and therefore further im-
provement of this technique is necessary. Several groups have studied the surgical APR 
specimen.8,9,18 Marr and colleagues reported on 190 patients who were operated on in 
Leeds and described that with an APR less tissue was removed around the tumour than 
after a LAR.8 Similarly, in the TME trial, the high rate of CRM involvement after an APR was 
ascribed to the surgical resection plane: the plane of surgical resection most frequently 
followed the mesorectal fascia and then passed over the surface or into the sphincter 
muscles providing little in the way of tissue to protect the surgical margin from direct 
spread of tumour circumferentially.9 Furthermore, the plane of surgical resection was as-
sociated with LR and OS.9,18 These results indicate that a more anatomical and selectively 
widened resection should be performed in order to improve CRM negativity.
Holm and colleagues described a different surgical approach for the APR resulting 
in a lower risk of bowel perforation and CRM involvement, used in a selected group of 
patients: the extended posterior perineal approach.19 The main differences with the con-
ventional approach are that the mesorectum is not dissected off the levator muscles, the 
perineal part of the operation is done with the patient in the prone jack-knife position 
and the entire levator muscle is resected en block with the anal canal and lower rectum.19 
The result is a more cylindrical resection with more tissue covering and surrounding the 
tumour in low rectal cancer. To reduce the rate of local complications observed after 
primary closure, a gluteus maximus flap is used to reconstruct the pelvic floor. Holm and 
colleagues selected the following patients: patients in whom a MRI scan indicated a T3-4 
tumour within 6 cm of the anal verge or a low tumour fixed or tethered at rectal exami-
nation.19 In practice, the APR is more difficult in the smaller pelvis of male patients and 
in tumours growing anteriorly where the distance to the mesorectal fascia is smallest. 
Although neither in the pooled database (Table 3B) nor in a previous analysis in the TME 
trial an association between gender and CRM involvement in the multivariate analysis 
could be shown, anteriorly located tumours were indeed found to be more frequently 
associated with an involved CRM in the TME trial independent from confounders such 
as T-stage.20 With the cylindrical technique, the amount of tissue present anteriorly 
beyond the internal sphincter or muscularis propria almost doubled compared to the 
conventional APR.21 Therefore, we feel that even patients with an anteriorly located T1-2 
tumour might benefit from a cylindrical resection.
Apart from a more cylindrical resection, preoperative treatment with radiotherapy or 
chemoradiotherapy and delayed surgery may be an alternative option to reduce CRM 
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involvement and to improve both local control and OS. Chemoradiotherapy and delayed 
surgery have been shown to downstage and downsize tumours.14,22 Short course 5 x 5 Gy 
radiotherapy followed by immediate surgery does not result in downstaging or downsiz-
ing,23 whereas if 5 x 5 Gy is used with delayed surgery, the effect is probably of the same 
magnitude as found for chemoradiotherapy.24,25 Unfortunately, the present pooled data-
base cannot be used to study the question which preoperative treatment is associated 
with more radical resections: observed differences could also be explained by differences 
between the several trials instead of solely a treatment effect. However, in the PRCT, 
preoperative chemoradiotherapy is compared with 5 x 5 Gy radiotherapy. Bujko and col-
leagues reported that CRM involvement was 4.4% after chemoradiotherapy compared 
with 12.9% after 5 x 5 Gy radiotherapy followed by immediate surgery (P = 0.017).14,26 
Despite this difference in CRM involvement, no statistically significant difference in local 
control or OS could be found.26 The reason for this finding might be due to the short 
interval between radiotherapy and surgery in the 5 x 5 Gy group. It should, however, 
be noted that the PRCT did not had LR or OS as a primary end-point. The absence of 
statistical significance in this study regarding LR or OS may be related to the relatively 
small number of patients to study these end-points. Nevertheless, downstaging and 
downsizing are not the only contributors to free resection margins. In the EORTC 22921 
trial, with the same delay in all groups between preoperative treatment and surgery, it 
was shown that no significant difference in CRM involvement was obtained after preop-
erative chemoradiotherapy compared to preoperative radiotherapy despite an impact 
on tumour stage and size.27 Therefore, improving the surgical procedure to reduce CRM 
involvement remains necessary to structurally improve the number of R0 resections.
In conclusion, the results suggest that the APR procedure itself is associated with 
nonradical resections, and later reduced local control, OS, and CSS for patients with ad-
vanced rectal cancer. For many patients an APR is the only and best surgical option, and 
therefore we should focus on how to improve treatment outcome for these patients. 
The debate about the optimal (preoperative) treatment for patients who undergo an 
APR is still ongoing. At present there is no official guideline to advise preoperative treat-
ment with a long schedule of chemoradiotherapy for all patients who have planned 
to undergo an APR or to advise that an extended resection should be performed to 
prevent CRM involvement. One can speculate whether patients subjected to an APR 
should not have delayed surgery independent from the type of preoperative treatment 
given. Nevertheless, our exploratory study supports the view that the quality of the 
APR procedure needs improvement and stresses the importance to find other means 
to improve the outcome of patients treated with an APR procedure. Until the debate is 
ended, preoperative imaging and multidisciplinary team meetings should be used to 
discuss the optimal treatment for each individual patient.
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aBstract
objective
This study was performed to identify tumour- and patient-related risk factors for distal 
rectal cancer in patients treated with an abdominoperineal resection (APR) associated 
with positive cirumferential resection margin (CRM), local recurrence (LR), and overall 
survival (OS).
Background
The introduction of total mesorectal excision (TME) has improved the outcome of pa-
tients with rectal cancer. However, survival of patients treated with an APR improved less 
than of those treated with a low anterior resection (LAR). Besides, an APR is associated 
with a higher LR rate.
Methods
Patients were selected from the TME trial, which is a randomised, multicentre trial, study-
ing the effects of preoperative radiotherapy (RT) in 1861 patients. Of the Dutch patients, 
455 underwent an APR. Location of the bulk of the tumour was scored with surgery, 
pathology, or other reports. CRM was available from pathology reports.
results
A positive CRM was found in 29.6% of all patients, 44% for anterior, 21% for lateral, 23% 
for posterior, and 17% for (semi)circular tumour location (P < 0.0001). In a multivariate 
analysis, T-stage, N-stage, and tumour location were independent risk factors for CRM. If 
a (partial) resection of the vaginal wall was performed in women, 47.8% of patients still 
had a positive CRM. T-stage, N-stage, and CRM were risk factors for LR and age, T-stage, 
N-stage, CRM, and distance of the inferior tumour margin to the anal verge for OS.
conclusion
Age, T-stage, N-stage, CRM, distance of the tumour to the anal verge, and tumour lo-
cation were independent risk factors for adverse outcome in patients treated with an 
APR for low rectal cancer. Anterior location, specifically in women, more often requires 
downstaging and/or more extended resection to obtain free margins.
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introDuction
The change from digital, blunt dissection of the rectum to total mesorectal excision 
(TME) in rectal cancer patients has played a major role in reducing local recurrence (LR) 
rates and improving overall survival (OS).1-3 The TME procedure aims at free circumfer-
ential resection margins (CRM), which has been found to be an acceptable surrogate 
end-point for LR and disease-free survival.4-6 LR rates have dropped by 50% with TME 
surgery compared with conventional surgery (respectively, 11% and 27% at 5 years).2,7
With the introduction of the TME technique, a decline in the ratio of abdominoperineal 
resections (APR) compared with low anterior resections (LAR) was observed, without a 
rise in hospital mortality.8 LR and OS rates for rectal cancer have improved.7,9 However, 
several groups have shown that the improvement for APR was less than for LAR.10,11 In 
LAR, 12% of excisions had a positive CRM compared to 29% after APR.11 Radiotherapy 
(RT) was not effective in patients with a positive CRM.12 Five-year OS rates in patients 
with a positive CRM after LAR and APR were, respectively, 57.6% and 38.5% (P = 0.008).11
In the standard TME technique for APR, the mesorectal fascia is followed onto the 
sphincter complex. The anterior mesorectum below prostate and vesicles is thin. In 
theory, this area is at risk for nonradical resections. In women, the tumour could grow 
ventrally in the vagina. This study aimed to determine whether tumour location or 
other tumour and patient related characteristics were risk factors for CRM, LR, or OS. We 
evaluated this in the Dutch TME trial.2 This trial included 1861 patients and examined the 
effects of short-course (5 x 5 Gy) preoperative RT.
Patients anD MethoDs
study population
The Dutch TME trial included 1861 patients from January 1996 to December 1999.2 This 
randomised multicentre trial evaluated TME surgery with or without preoperative RT (5 
x 5 Gy). Patients with clinically resectable adenocarcinoma of the rectum were included 
and were subsequently randomly assigned to either RT followed by TME surgery or to 
TME surgery alone. Stratification was used for institution and expected operation type. 
RT, surgery, and pathology were standardised and strictly quality controlled. Follow-up 
of all patients was conducted according to trial protocol. Outcome measures included 
local and distant recurrences. The study was approved by all institutes and ethics com-
mittees. All patients gave informed consent.
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Patient selection
For the current study, data of eligible patients who underwent an APR were analysed.13 
Only Dutch patients were selected because detailed information about the CRM was 
available for these patients. Patients with distant metastases at surgery and patients 
who died during the admission for the TME procedure were excluded from analyses for 
LR and OS. Patients with macroscopic nonradical resections (R2) were excluded from 
analyses for LR.
Preoperative radiotherapy
Patients assigned to preoperative RT received a total dose of 25 Gy in 5 fractions over 5 
to 7 days. The irradiated volume included the primary tumour and the mesentery with 
vascular supply containing perirectal, presacral, and the internal iliac nodes.
surgery
All patients underwent surgery according to the principles of TME, as previously de-
scribed.1 The main principles of this technique involve sharp dissection of the rectum 
and mesorectum within the true pelvis around the endopelvic fascia under direct vision 
with nerve preservation.
Pathological procedure
Standardised pathology examination was performed in the pathology laboratories of 
referring hospitals using the protocol of Quirke et al.6,14,15 Pathologists from referring 
hospitals recorded pathologic information of the resected tumour on a standard 
form for all patients. A pathology quality manager and a pathology review committee 
were installed to ensure consistent quality of all pathology data and procedures. The 
lateral resection margin of the fresh received specimen was inked and subsequently 
the specimen was fixated for 48 hours. After fixation, the resected specimen was sliced 
transversely to provide multiple coronal sections through the tumour and the mesorec-
tum. The macroscopic CRM was measured using a ruler. Sufficient blocks of the primary 
tumour and lymph nodes in relation to the CRM were taken; and when the tumour or 
a suspected lymph node approached the margin (i.e., distance from the margin <1 cm) 
measurements were repeated microscopically. Any specimen that had tumour (i.e., pri-
mary tumour or lymph node metastasis) ≤ 1 mm from the CRM was recorded as having 
tumour margin involvement. If the tumour was more than 1 mm but less than 2 mm 
from the CRM, deeper levels were cut to exclude involvement.
Data collection
During the trial, T-, N-, M-stage, and maximum tumour size were recorded. Information 
on tumour location was collected retrospectively from surgery reports. The investiga-
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tor who studied the reports was blinded for the outcome. If no information could be 
found related to the location, the pathology report was examined, and if necessary, 
reports from radiologic, digital, or endoscopic examination were studied. A tumour was 
scored as located anterior if the bulk of the tumour was located anterior or anterolateral. 
Similarly, if the bulk of the tumour was located either posterior or posterolateral, the 
tumour was scored as posterior. If the tumour was located lateral or (almost) circular, 
these locations were used. The variables were analysed for their relation with CRM, LR, 
and OS, which were collected prospectively during the follow-up of the trial.
statistical analyses
Data were analysed with the SPSS package (SPSS 12.0 for Windows; SPSS Inc., Chicago, IL). 
Unless indicated differently, univariate analyses with categorical variables were performed 
with a χ2 test, whereas continuous variables were analysed with an unpaired t-test. LR and 
OS were univariately tested with log-rank tests. The following variables were studied for 
CRM, LR, and OS: assigned treatment, sex, age, body mass index, T-stage, N-stage, maxi-
mum tumour diameter, distance of the tumour to the anal verge, and location of the tu-
mour. CRM was included as variable in analyses for LR and OS. Only variables with a P-value 
≤ 0.10 in the univariate analyses were selected and studied in the multivariate analyses. 
Multivariate analyses were performed with logistic regression analyses for CRM and with 
Cox regression analyses for LR and OS. Assigned treatment was always in the multivariate 
analysis to adjust for trial design. A P-value of ≤ 0.05 was considered statistically significant.
results
Patient characteristics
The median follow up was 7.1 year (range 2.5-9.8 years). In total, 455 Dutch patients 
underwent an APR, of whom 441 were eligible at randomisation. Seven patients had no 
invasive tumour at the time of surgery, leaving 434 patients evaluable. Twenty-seven 
patients with distant metastases at surgery and 10 patients who died during the admis-
sion for the TME procedure were excluded from analyses on LR and OS. Two patients 
with macroscopic nonradical resections (R2) were excluded for analyses from LR.
Patient characteristics are summarised in Table 1 for the selected APR patients in 
comparison to patients that had a LAR or Hartmann’s procedure. A significant differ-
ence was found in maximum tumour size, which was larger in APR operated patients 
(P = 0.01). Significantly more lymph nodes were examined after a LAR or Hartmann’s 
procedure (median 8; range 0-60) than after an APR (median 7; range 0-36; P < 0.001, 
Mann-Whitney U test). Slightly more APR patients were node negative (P = 0.04). In men, 
significantly more often an APR was performed (P = 0.02).
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location of the tumour
The bulk of the tumour was located anteriorly in 172 patients (40%), laterally in 53 
patients (12%), and posteriorly in 103 patients (24%). In 47 patients (11%), the tumour 
was described as (semi)circular. In 59 patients (14%), the location of the tumour was not 
specified. Location of the tumour was not significantly different between the randomi-
sation groups (P = 0.69).
table 1. Patient characteristics of studied eligible patients who had a LAR or Hartmann’s procedure in 
comparison with patients who underwent an APR.
Variable LAR and Hartmann’s 
procedure (%)
APR (%) Total P-value
Total 978 (69.3) 434 (30.7) 1412
Radiotherapy 0.80
 No 484 (49.5) 218 (50.2)  702
 Yes 494 (50.5) 216 (49.8)  710
Sex 0.02
 Female 372 (38.0) 137 (31.6)  509
 Male 606 (62.0) 297 (68.4)  903
Age
 Mean
 Standard deviation
64.0
11.0
64.5
11.1
0.82
BMI a 0.20
 < 25  kg/m2 341 (46.5) 127 (40.7)  468
 25-29 kg/m2 322 (43.9) 148 (47.4)  470
 ≥ 30  kg/m2  71  (9.7)  37 (11.9)  108
T-stage 0.10
 T1  59  (6.0)  15  (3.5)   74
 T2 307 (31.4) 155 (35.7)  462
 T3 579 (59.2) 246 (56.7)  825
 T4  33  (3.4)  18  (4.1)   51
N-stage b 0.04
 N0 563 (57.6) 265 (61.2)  828
 N1 258 (26.4)  88 (20.3)  346
 N2 156 (16.0)  80 (18.5)  236
Maximum tumour diameter c
 Median
 Range
4.0
0.3-13.0
4.0
1.0-10.5
0.01*
Distance of tumour from 
anal verge d
 ≤ 2.0    cm
 2.1-4.0 cm
 > 4.0    cm
 12  (1.2)
 60  (6.2)
893 (92.5)
159 (41.3)
143 (37.1)
 83 (21.6)
 171
 203
 976
<0.001
a Missing for 366 patients. b According to UICC TNM stage 1997; data missing for 2 patients. c Missing for 7 
patients. d Missing for 62 patients. * Mann-Whitney test. BMI = body mass index.
Risk factors for adverse outcome in patients treated with an abdominoperineal resection 87
sex differences
Table 1 demonstrates that men relatively more frequently were subjected to an APR 
than women (P = 0.02). Low rectal tumours for which an APR was performed in women 
were significantly more often T4 tumours (P = 0.01). For N-stage, no significant difference 
could be found (P = 0.23). Of all Dutch women in the TME trial who had an APR, 33.6% 
(46 of 137) had a partial resection of the vaginal wall. If the vaginal wall was included 
in the resection, 47.8% (22 of 46) of these patients had a positive CRM. In Table 2, the 
association between T-stage, partial resection of the vaginal wall and CRM is shown. 
In 10 out of 50 female patients (20%) with a T1 or T2 tumour, a resection of the vaginal 
wall was performed. The indicated reasons for vaginal wall resection in these patients 
were: suspicion of infiltrating tumour growth (n = 1), adhesions (n = 2), adjacent tumour 
location (n = 3) and unspecified (n = 4). Of the patients with a T3 or T4 tumour in whom 
a partial resection of the vaginal wall was performed, 62% and 50%, respectively, still 
had a positive CRM. Surprisingly, in most patients, CRM involvement was not located at 
the resection margin of the vagina, but in the surrounding tissue. The rate of positive 
CRM after partial resection of the vaginal wall did not differ significantly between the 
randomisation groups (P = 1.00; data not shown). In contrast to the results in women, 
a (partial) resection of the prostate was only performed in 8 of 297 (2.7%) men who 
underwent an APR, of whom 3 (37.5%) had a positive CRM.
table 2. Number and percentage of circumferential resection margin (CRM) involvement per T-stage for 
female patients who underwent an APR without and with (partial) resection of the vaginal wall.
T1 + T2
n (%)
T3
n (%)
T4
n (%)
Total
No (partial) resection of vagina CRM negative 33 (83) 25 (51)  0   (0) 58 (64)
CRM positive  7 (18) 24 (49)  1 (100) 32 (36)
Total 40 49  1 90
(Partial) resection of vagina CRM negative  9 (90) 10 (39)  5  (50) 24 (52)
CRM positive  1 (10) 16 (62)  5  (50) 22 (48)
Total 10 26 10 46
CRM status was missing for 1 female patient. P = 0.003 for women without a resection of the vaginal wall, 
and P = 0.02 for patients with a (partial) resection.
circumferential resection margin
CRM status was available for 433 of 434 patients. The results of the univariate analyses 
are shown in Table 3. In total 29.6% (128 of 433) patients had a positive CRM. Of the ante-
riorly located tumours, 44% (75 of 171) of patients had a positive CRM. The frequency of 
positive CRM was significantly lower in tumours located laterally, posteriorly, circularly 
or with unspecified location, respectively, 21% (11 of 53), 23% (24 of 103), 17% (8 of 47), 
and 17% (10 of 59) (P < 0.001). In a multivariate analysis (Table 4), advanced T-stage, 
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higher N-stage, and anterior tumour location were independent risk factors for a posi-
tive CRM. Although sex was significant in the univariate analysis, after adjustment for 
T-stage, N-stage, and tumour location, no significant difference could be found.
table 3. Univariate analyses for circumferential resection margin (CRM) involvement.
Variable Positive CRM
n (%)
Negative CRM
n (%)
OR (95% CI) P-value
Radiotherapy
 No
 Yes
 66 (30.3)
 62 (28.8)
152 (69.7)
153 (71.2)
1.00
0.93 (0.62-1.41)
0.74
Sex
 Female
 Male
 54 (39.7)
 74 (24.9)
 82 (60,3)
223 (75.1)
1.00
0.50 (0.33-0.78)
0.002
Age
 ≤ 50   years
 51 – 70 years
 > 70   years
 10 (20.0)
 76 (29.7)
 42 (33.1)
 40 (80.0)
180 (70.3)
 85 (66.9)
1.00
1.69 (0.80-3.55)
1.98 (0.90-4.34)
0.11+
BMI
 < 25  kg/m2
 25-29 kg/m2
 ≥ 30  kg/m2
 31 (24.4)
 48 (32.7)
 13 (35.1)
 96 (75.6)
 99 (67.3)
 24 (64.9)
1.00
1.50 (0.88-2.56)
1.68 (0.76-3.69)
0.24
T-stage
 T1 + T2
 T3 + T4
 17 (10.0)
111 (42.2)
153 (90.0)
152 (57.8)
1.00
6.57 (3.76-11.5)
<0.001
N-stage
 N0
 N1
 N2
 46 (17.4)
 27 (30.7)
 54 (67.5)
218 (82.6)
 61 (69.3)
 26 (32.5)
1.00
2.10 (1.21-3.65)
9.84 (5.59-17.3)
<0.001
Maximum tumour diameter
 ≤ 3.0    cm
 3.1-4.0 cm
 4.1-5.0 cm
 5.1-6.0 cm
 > 6.0    cm
 30 (31.9)
 29 (22.1)
 22 (24.7)
 21 (36.8)
 21 (38.2)
 64 (68.1)
102 (77.9)
 67 (75.3)
 36 (63.2)
 34 (61.8)
1.00
0.61 (0.33-1.10)
0.70 (0.37-1.34)
1.24 (0.62-2.48)
1.32 (0.66-2.64)
0.14+
Distance of tumour from 
anal verge
 ≤ 2.0    cm
 2.1-4.0 cm
 > 4.0    cm
 45 (28.5)
 44 (30.8)
 20 (24.1)
113 (71.5)
 99 (69.2)
 63 (75.9)
1.00
1.12 (0.68-1.83)
0.80 (0.43-1.47)
0.59+
Tumour location
 Anterior
 Lateral
 Posterior
 Circular
 Unspecified
 75 (43.9)
 11 (20.8)
 24 (23.3)
  8 (17.0)
 10 (16.9)
 96 (56.1)
 42 (79.2)
 79 (76.7)
 39 (83.0)
 49 (83.1)
1.00
0.34 (0.16-0.70)
0.39 (0.23-0.67)
0.26 (0.12-0.60)
0.26 (0.12-0.55)
<0.001
+ χ2 test for trends. OR = odds ratio; BMI = body mass index; CI = confidence interval.
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local recurrence
The results of the univariate analysis for LR are shown in Table 5. Randomisation, sex, 
T-stage, N-stage, distance of the tumour to the anal verge, and CRM had a P-value ≤ 
0.10 in the univariate analysis and were entered in the multivariate analysis (Table 6). 
Significantly higher LR rates were found for higher T-stage, positive lymph node status, 
and positive CRM.
overall survival
Similar to LR, OS was studied (univariate Table 5, multivariate Table 6). A P-value of ≤ 0.10 
was found in the univariate analyses for sex, age, T-stage, N-stage, distance of the tumour 
to the anal verge, CRM, and tumour location. Increased age, advanced T-stage, positive 
lymph node status, distal location of the tumour, and positive CRM were independent 
risk factors for OS in the multivariate analysis.
Discussion
This study investigated risk factors associated with positive CRM, increased LR rates, and 
decreased OS rates in abdominoperineal resected patients in whom TME surgery was 
table 4. Results of the multivariate logistic regression analysis for positive circumferential resection 
margin (CRM).
Variable OR 95% CI P-value
Radiotherapy
 No
 Yes
1.00
0.97 0.59 – 1.59
0.90
Sex
 Female
 Male
1.00
0.65 0.38 – 1.10
0.11
T-stage
 T1 + T2
 T3 + T4
1.00
4.93 2.68 – 9.06
<0.001
N-stage
 N0
 N1
 N2
1.00
1.55
8.31
0.85 – 2.85
4.39 – 15.7
<0.001
0.15
<0.001
Tumour location
 Anterior
 Lateral
 Posterior
 Circular
 Unspecified
1.00
0.26
0.46
0.17
0.32
0.11 – 0.63
0.25 – 0.88
0.06 – 0.45
0.14 – 0.74
<0.001
0.003
0.02
<0.001
0.008
All variables with a P-value of ≤ 0.10 in the univariate analysis were included in the multivariate analysis. 
OR = odds ratio; CI = confidence interval.
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table 5. Results of the univariate analyses for local recurrence and overall survival.
Variable Local recurrence Overall survival
  HR 95% CI P-value HR 95% CI P-value
Radiotherapy
 No
 Yes
 1.00
 0.57 0.31-1.05
0.07
1.00
0.91 0.67-1.23
0.53
Sex
 Female
 Male
 1.00
 0.48 0.27-0.87
0.01
1.00
0.75 0.55-1.03
0.07
Age
 ≤ 50  years
 50-70 years
 > 70  years
 1.00
 0.71
 0.75
0.31-1.65
0.30-1.90
0.72
1.00
1.54
2.48
0.86-2.76
1.36-4.51
0.001
BMI
 < 25  kg/m2
 25-29 kg/m2
 ≥ 30  kg/m2
 1.00
 1.21
 2.02
0.57-2.56
0.76-5.37
0.37
1.00
1.46
1.36
0.99-2.17
0.73-2.54
0.16
T-stage
 T1 + T2
 T3 + T4
 1.00
 5.28 2.23-12.5
<0.001
1.00
2.86 2.00-4.10
<0.001
N-stage
 N0
 N1
 N2
 1.00
 6.34
13.61
2.82-14.5
6.05-30.6
<0.001
1.00
1.89
6.62
1.27-2.81
4.63-9.48
<0.001
CRM
 Negative
 Positive
 1.00
 4.89 2.67-8.94
<0.001
1.00
3.03 2.23-4.13
<0.001
Maximum tumour 
diameter
 ≤ 3.0    cm
 3.1-4.0 cm
 4.1-5.0 cm
 5.1-6.0 cm
 > 6.0    cm
 1.00
 1.08
 1.17
 0.96
 1.69
0.44-2.65
0.45-3.04
0.29-3.18
0.64-4.51
0.82
1.00
1.19
1.06
1.64
1.59
0.76-1.88
0.64-1.76
0.96-2.81
0.95-2.68
0.21
Distance tumour from 
anal verge
 ≤ 2.0    cm
 2.1-4.0 cm
 > 4.0    cm
 1.00
 0.51
 0.41
0.25-1.04
0.16-1.07
0.06
1.00
0.72
0.67
0.50-1.03
0.43-1.05
0.09
Tumour location
 Anterior
 Lateral
 Posterior
 Circular
 Unspecified
 1.00
 0.70
 0.90
 0.35
 0.47
0.26-1.86
0.44-1.83
0.08-1.49
0.16-1.38
0.42
1.00
0.85
0.71
0.51
0.54
0.54-1.36
0.48-1.05
0.27-0.96
0.32-0.90
0.05
HR = hazard ratio; CI = confidence interval; BMI = body mass index; CRM = circumfential resection margin.
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performed. Data were derived from the TME trial that investigated the efficacy of short-
term preoperative RT in patients with rectal cancer treated by TME. Stratification for type 
of surgery took place, but the trial was not set up to answer any question regarding 
problems related to APR. Therefore, any statement based on data from the trial must 
be regarded with care. However, the present analysis is informative and identified risk 
factors for adverse outcome of patients treated with an APR. It showed that tumour 
location is an independent risk factor for nonradical resections in APR patients. Recently, 
other studies have been published in which tumour location in rectal cancer was studied. 
In these studies, however, patients with a LAR were also included. Lee et al. published 
a retrospective study of ultrasound localisation of rectal tumour, but could not show 
table 6. Results of the multivariate Cox regression analyses for local recurrence and overall survival.
Variable Local recurrence Overall survival
HR 95% CI P-value HR 95% CI P-value
Radiotherapy
 No
 Yes
1.00
0.61 0.31-1.21
0.16
 1.00
0.95 0.68-1.33
0.77
Sex
 Female
 Male
1.00
0.61 0.31-1.19
0.15
 
1.00
0.96 0.67-1.38
0.82 
Age
 ≤ 50  years
 51-70 years
 > 70  years
----
1.00
1.91
2.98
0.98-3.72
1.49-5.93
0.003
T-stage
 T1 + T2
 T3 + T4
1.00
4.13 1.58-10.8
0.004
 
1.00
2.22 1.48-3.33
<0.001
N-stage
 N0
 N1
 N2
1.00
3.16
8.04
1.32-7.57
3.40-19.0
<0.001
1.00
1.54
5.23
0.99-2.40
3.48-7.86
<0.001
CRM
 Negative
 Postive
1.00
2.41 1.20-4.87
0.01
1.00
1.66 1.14-2.40
0.008
Distance tumour from 
anal verge
 ≤ 2.0   cm
 2.1-4.0 cm
 > 4.0   cm
1.00
0.49
0.44
0.23-1.03
0.17-1.17
0.08
1.00
0.66
0.55
0.45-0.96
0.34-0.88
0.02
Tumour location
 Anterior
 Lateral
 Posterior
 Circular
 Unspecified
----
1.00
0.81
0.88
0.63
0.67
0.49-1.36
0.57-1.35
0.32-1.26
0.38-1.18
0.53
HR = hazard ratio; CI = confidence interval; CRM = circumferential resection margin.
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an effect of tumour location on recurrence or survival.16 Chan et al. used a prospective 
hospital register to study location of rectal tumours.17 They found that if part of the 
tumour was located anteriorly the LR rate was 15.9%, compared with 5.8% if the tumour 
was not located anteriorly (P = 0.009). Although we could not demonstrate a significant 
association between tumour location and LR, a significant correlation between tumour 
location and CRM was found.
The outcome for patients undergoing an APR has improved less than for patients 
who are treated with a LAR.2,10,11 In low rectal cancer, CRM is positive in more than 30% 
of patients if an APR and in 10.7% if a LAR is performed.11 CRM involvement increases 
the more distally the tumour is located.11 The present analysis showed that CRM is of 
prognostic value for both LR and OS in patients treated with an APR, similar to previ-
ously published results demonstrating the importance of CRM for all patients.14 In the 
present analysis, the definition as described by Quirke et al. was used to define CRM 
involvement in which both distance from tumour and metastatic lymph nodes were 
regarded.6,15 However, if CRM involvement was defined as ≤ 1 mm from tumour only, 
the results of the analyses were similar (data not shown). Glynne-Jones et al. recently 
performed a literature search studying alternative clinical end-points in rectal cancer.5 
They concluded that CRM is an acceptable alternative end-point, predicting the risk of 
both LR and disease-free survival. Consequently, the large proportion of CRM positive 
resections found in the TME trial after an APR is an important explanation of the poor 
outcome of these patients.
Remarkably, our results showed a difference between men and women. In the 
univariate analysis, it was found that women treated with an APR were more likely to 
have a positive CRM than men (P = 0.002). In women, less frequently an APR procedure 
was performed and more often for a T4 tumour, suggesting that in women a T4 tumour 
was considered to be primarily resectable. Although the TME trial was primarily aimed 
at resectable tumours, patients with T4 tumours that were considered to be resectable 
could be included. We have previously shown that the schedule of preoperative 5 x 5 
Gy RT followed by surgery within 1 week (short-course) does not lead to downstag-
ing and downsizing.13 In addition, we demonstrated that short-course preoperative RT 
cannot compensate for positive CRM.12 Our present results reveal that margin positivity 
in women with vaginal wall involvement is a relatively common problem. Apparently, 
vaginal wall involvement merely reflects a large tumour as CRM is often positive at other 
sites than the vagina itself. From the previous results, it cannot be expected that 5 x 5 
Gy is an appropriate RT schedule for these patients. Therefore, if vaginal wall involve-
ment is suspected on MRI or digital rectal/vaginal examination, the tumour should be 
downstaged and/or the resection widened.
Several different treatment options have been described to achieve downstaging. 
The effect of delaying surgery on downstaging was studied in the Lyon R90-01 trial.18 
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The results of this trial demonstrated that delaying surgery for 6 to 8 weeks after 13 x 3 
Gy RT was more efficient in terms of downstaging than operating within 2 weeks after 
completion of the RT (P = 0.007). Bujko et al. showed in a randomised trial that delayed 
chemoradiotherapy with surgery after 4 to 6 weeks was superior for downstaging com-
pared with short-course RT followed by immediate surgery.19 Finally, both the EORTC 
22921 and the FFCD 9203 trial demonstrated that chemoradiotherapy is more efficient 
than RT alone in downsizing and downstaging rectal cancer, resulting in improved local 
control in the chemoradiotherapy arm.20,21 These results indicate that preoperative treat-
ment aiming at downstaging should consist of chemoradiotherapy with an interval of 
several weeks between RT and surgery. Currently, a trial is being conducted in Sweden, 
addressing the issue of postponing surgery after 5 x 5 Gy. In this trial, patients are ran-
domised between 5 x 5 Gy RT with a short (<1 week) interval between RT and surgery, 5 
x 5 Gy RT followed by surgery after a delay and 25 x 2 Gy RT with delayed surgery.
Apart from neoadjuvant treatment, an improvement could be made in the surgi-
cal treatment. Preliminary results of the MRC CR07 trial showed that the rate of CRM 
involvement from 1998 to 2005 gradually declined from above 20% to below 10%.22 
Furthermore, the plane of the surgical dissection was related to CRM, LR, and disease-
free survival, which is in accordance with our previous results.11 Clearly, a strong associa-
tion exists between the quality of surgery on one hand and CRM, the rates of LR, and 
disease-free survival on the other hand. Therefore, the resection in APR patients should 
be widened to resect the complete mesorectal plane and aim for a free CRM. Besides, 
evidence is available that patients with rectal cancer should be treated in specialised 
centres.23 From a national audit in Sweden, it was concluded that survival of patients 
with rectal cancer treated in a designated centre improved and is currently better than 
survival of patients with colon cancer, which is not treated in such designated centres.9 
The improvement in outcome was thought to be a combination of increased quality of 
the resections after the introduction of TME surgery and the introduction of preoperative 
RT in a multidisciplinary team setting. Therefore, it might be advisable to treat patients 
with rectal cancer by specialised surgeons, especially if they have to undergo an APR.
Although both downstaging with chemoradiotherapy and widening of the resection 
might be used in patients with a threatened CRM, both treatments cause associated 
morbidity. Short-term side effects of chemoradiotherapy have been often described, but 
long-term complications are not extensively studied.24 Bujko et al. compared chemo-
radiotherapy with 5 x 5 Gy RT in 351 patients and found a borderline non-significant 
lower complication rate after chemoradiotherapy (22% versus 31% overall postopera-
tive complications, expressed in number of events, P = 0.06).25 However, in the same trial, 
acute irradiation toxicity was significantly higher after chemoradiotherapy than after 
the short scheme (85% versus 24% for all complications, P < 0.001; 18% versus 3% for 
serious complications including death, P < 0.001). More complications will also be seen 
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after a widened resection, mainly problems associated with perineal wound healing and 
closure. Hence, preoperative imaging should be used to select patients for whom 5 x 5 
Gy is sufficient and for whom advanced treatment is necessary.
conclusion
Anterior tumour location, advanced T-stage, and higher N-stage were independent risk 
factors for CRM. Positive CRM, higher T-stage, and higher N-stage were risk factors for LR. 
In addition to the risk factors for LR, distal tumour location, and older age were associ-
ated with reduced OS. To further improve the outcome of patients treated with an APR, 
tumours should be properly preoperatively staged, including an assessment of CRM. 
The surgical treatment should primarily be aimed at adequate resection margins. For 
patients with a threatened CRM preoperatively, 5 x 5 Gy RT alone is insufficient and treat-
ment should preferentially consist of chemoradiotherapy and/or extended resection.
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aBstract
Purpose
The present analyses aimed to determine risk factors for rectal cancer patients associated 
with circumferential resection margin (CRM) and number of examined lymph nodes and 
to correlate these parameters of surgical quality with local recurrence (LR), disease-free 
and overall survival (DFS and OS).
Material and methods
Data of 884 eligible patients, who underwent a resection and had no metastases at time 
of surgery, were analysed.
results
Age, period of treatment, distance, and pT-stage were associated with surgical quality. 
CRM involvement, but not number of examined lymph nodes, was associated with a 
higher risk of a LR, reduced DFS and OS. An abdominoperineal resection (APR) was a risk 
factor for adverse outcome.
conclusion
Surgical quality is an important predictor of outcome, also for patients treated with 
conventional RT or chemoradiotherapy (CRT). Preoperative CRT results in downstaging 
and downsizing of the tumour, but not in less CRM involvement.
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introDuction
Surgery is the cornerstone of the curative treatment of rectal cancer. However, in 1991, 
McArdle and Hole reported that surgical variability could influence outcome to a large 
extent.1 Afterwards, several groups reported that the surgeon is an important prognos-
tic factor for outcome in patients with rectal cancer.2-4 Havenga and colleagues studied 
cohorts of patients treated with different surgical techniques.5 Standardised surgery 
resulted in 30% survival and 25% local control benefit. Quality assurance aims to reduce 
this variability and can be defined as the systematic measures required to achieve a 
treatment result that meets a certain standard.
From the end of the eighties, surgeons and pathologists started to be interested in 
the lateral spread of rectal cancer.6,7 Quirke and colleagues observed that the amount of 
excised tissue varied from surgeon to surgeon and found that circumferential resection 
margin (CRM) involvement was an important predictor for local recurrence (LR) and 
described a method to study CRM.6,7 Also in the standardised TME trial, CRM was found 
to be an important predictor of outcome.8 Consequently, CRM can be considered as a 
determinant of surgical quality. Another prognostic factor for outcome of rectal cancer 
is the number of examined lymph nodes.9-11 Although the pathologist also influences 
the number of reported lymph nodes,12 the number of removed and examined lymph 
nodes could be considered as a measure of the extent of surgery. Recently, Quirke and 
colleagues found that CRM and the number of examined lymph nodes were related, 
and therefore number of examined lymph nodes can be regarded as a measurement of 
quality of surgery as well (P. Quirke, St James’s University Hospital, Leeds).
The EORTC 22921 trial studied the addition of pre- and/or postoperative chemo-
therapy (CT) to preoperative radiotherapy (RT) followed by surgery in T3 or resectable 
T4 rectal cancer.13 The present analyses aimed to determine risk factors associated with 
quality of surgery in EORTC 22921 trial, defined by CRM and the number of examined 
lymph nodes, and to correlate these parameters of surgical quality with LR, disease-free 
and overall survival (DFS and OS) in RT or chemoradiotherapy (CRT) treated patients.
Patients anD MethoDs
trial design
The trial design and eligibility criteria are reported previously13 and therefore only the 
main features are summarised. Patients were randomised between preoperative RT or 
CRT and to either postoperative CT or no further treatment (Figure 1). Inclusion criteria 
were T3 or resectable T4 M0 adenocarcinoma of the rectum located within 15 cm from 
the anal verge, aged 80 years or less, and a WHO performance status of 0 or 1. The study 
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was approved by the ethics committees of the participating centres. Informed consent 
was obtained from all patients before their inclusion. The present analyses were re-
stricted to eligible patients who underwent a resection and had no distant metastases at 
the time of surgery. Patients treated with a Hartmann’s procedure (n = 22) were excluded 
from some analyses due to small patient numbers.
RT consisted of 45 Gy delivered in 25 fractions of 1.8 Gy to the posterior pelvis.14 
Variability of the treated volume and dose homogeneities have previously been studied 
and reported.15 Preoperative CT (fluorouracil, 350 mg/m2/d and leucovorin, 20 mg/m2/d) 
was administered in two 5-day courses. Surgery was planned 3-10 weeks after the end 
of the preoperative treatment. It was recommended to maintain the surgical technique 
that was planned upfront (low anterior resection (LAR) or abdominoperineal resection 
(APR)), to perform a total mesorectal excision (TME; included in the recommendations 
in 1999), to create a protective colostomy in the case of a low-lying anastomosis, and to 
primarily close the perineum after an APR. When allocated, four courses of postopera-
tive CT had to be delivered starting between 3 and 10 weeks after surgery.
Pathology procedures
Macroscopic and microscopic characteristics of the resected specimen were prospec-
tively recorded by the local pathologists on a standard case report form. Macroscopic 
examination was performed on the fixated specimen. The total number of lymph nodes 
examined and total number of lymph nodes involved were registered. Tumour staging 
was performed according to TNM classification 4 (UICC,1987).16 For pathological (p)T3-4 
Preoperative RT Preoperative CRT Preoperative RT Preoperative CRT
Surgery Surgery Surgery Surgery
Postoperative CT Postoperative CT
Randomisation
figure 1. Treatment groups in the trial. RT = radiotherapy; CT = chemotherapy; CRT = chemoradiotherapy.
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tumours (beyond the muscularis propria), the status of the CRM was determined ac-
cording to the recommendations of Quirke and colleagues.6 In this study, CRM was con-
sidered positive only if the tumour was microscopically abutting the resection margin.
end-points studied and variables considered
All recurrences were confirmed with radiological or histological examination. DFS is 
defined as the time from the day of surgery to the first event of loco-regional or dis-
tant recurrence or death of any cause, or to the date of the most recent follow-up for 
censored cases. Local control was calculated from the day of surgery to the day of LR, 
defined as tumour regrowth within the pelvis or perineum. OS is calculated from the 
day of surgery to the day of death of any cause or the day of most recent information if 
alive. The end-points and variables studied are shown in Table 1. In the analysis for the 
number of examined lymph nodes as end-point, this variable was analysed as a numeri-
cal variable, whereas in analyses where the number of examined lymph nodes was used 
as covariate, this variable was analysed as a categorical variable.
table 1. Relationships that were assessed during the analyses.
End-points Variables
Ran-
domised 
treatment
Sex Age Distance 
tumour 
to anal 
verge
Period of 
treat-
ment
Type of 
surgery
CRM Patho-
logical 
T-stage
Pathologi-
cal N-stage
Number of 
examined 
lymph nodes 
(categorical)
Type of surgery 
(LAR versus APR)
yes yes yes yes yes n.a. no no no no
CRM yes yes yes yes yes yes n.a. no no no
Number of 
examined lymph 
nodes (numerical)
yes yes yes yes yes yes no yes no n.a.
Local recurrence yes yes yes yes yes yes yes yes yes yes
Disease-free 
survival
yes yes yes yes yes yes yes yes yes yes
Overall survival yes yes yes yes yes yes yes yes yes yes
LAR = low anterior resection; APR = abdominoperineal resection; CRM = circumferential resection margin; 
n.a. = not applicable.
statistics
Data were analysed with Statistical Analysis Software (SAS®, Cary, NC, USA). A multi-
variate backward selection model was used for all analyses whereby all variables were 
initially in the model and then the least significant variables were sequentially removed 
from the model until all remaining variables were significant at the 0.05 level. All models 
were adjusted for allocated treatment. Local control, DFS, and OS were studied by Cox 
regression models. Logistic regression was used to study the probability of APR surgical 
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procedure and CRM involvement, whereas rank ANOVA was used to study the number of 
examined lymph nodes. The two-sided 0.05 significance level was used for all analyses.
results
Patients
From April 1993 to March 2003, 1011 patients entered the trial, of whom 884 were 
included in the present analyses. The reasons for excluding patients were distant metas-
tases at surgery (n = 46), unknown status of distant metastases (n = 62), no resection (n = 
11), and ineligibility (n = 8). The characteristics of the 884 patients are shown in Table 2. 
table 2. Patient characteristics.
Variable Preoperative RT Preoperative 
CRT
Preoperative 
RT and 
postoperative CT
Preoperative CRT 
and postoperative 
CT
Total
n (%) n (%) n (%) n (%) n (%)
Sex
 Male
 Female
162 (73)
 59 (27)
163 (73)
 61 (27)
159 (72)
 62 (28)
161 (74)
 57 (26)
645 (73)
239 (27)
Age
 Median
 Range
63.0
23.0-79.0
62.0
36.0-79.0
63.0
31.0-78.0
62.0
22.0-78.0
62.0
22.0-79.0
pT-stage
 T0
 T1
 T2
 T3
 T4
 Tx
 15  (7)
 16  (7)
 69 (31)
107 (48)
 13  (6)
  1  (1)
 32 (14)
 24 (11)
 80 (36)
 77 (34)
  7  (3)
  4  (2)
 10  (5)
 17  (8)
 66 (30)
116 (53)
  9  (4)
  3  (1)
 28 (13)
 25 (12)
 71 (33)
 84 (39)
  6  (3)
  4  (2)
 85 (10)
 82  (9)
286 (32)
384 (43)
 35  (4)
 12  (1)
pN-stage
 N0
 N+
 Nx
144 (65)
 73 (33)
  4  (2)
157 (70)
 61 (27)
  6  (3)
143 (65)
 74 (34)
  4  (2)
165 (76)
 46 (21)
  7  (3)
609 (69)
254 (29)
 21  (2)
Distance tumour to 
anal verge
 ≤ 3.0   cm
 3.1-6.0 cm
 6.1-9.0 cm
 > 9.0   cm
 51 (23)
 88 (40)
 46 (21)
 36 (16)
 58 (26)
 79 (35)
 48 (21)
 39 (17)
 52 (24)
 79 (36)
 57 (26)
 33 (15)
 55 (25)
 83 (38)
 46 (21)
 34 (16)
216 (24)
329 (37)
197 (22)
142 (16)
Surgical procedure
 APR
 LAR
 Hartmann
 93 (42)
122 (55)
  6  (3)
 94 (42)
125 (56)
  5  (2)
 92 (42)
122 (55)
  7  (3)
 84 (39)
130 (60)
  4  (2)
363 (41)
499 (56)
 22  (2)
Percentages may not sum to 100 because of rounding. T-stage and N-stage are pathological stages. RT = 
radiotherapy; CT = chemotherapy; CRT = chemoradiotherapy; APR = abdominoperineal resection; LAR = 
low anterior resection.
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The median follow-up at the time of analysis was 5.0 years (range 0.3-10.6 years). The 22 
cases with a Hartmann resection were excluded from all further analyses.
type of surgery
An APR was performed in 363 patients (41%), whereas 499 (56%) and 22 (2%) were 
treated with a LAR and a Hartmann’s procedure, respectively. To evaluate prognostic 
factors determining the type of surgery, preoperative treatment (RT or CRT), age, sex, 
distance between tumour and anal verge, and period of treatment were included in the 
initial step of the multivariate analysis. Preoperative treatment was kept in the model to 
adjust for trial design. All variables but age were retained in the final model (Table 3). 
Compared to LAR, APR was more frequently applied in males, in patients treated in the 
period 1993-1996, and in tumours located within 3 cm from the anal verge.
table 3. Final model of multivariate logistic regression analysis for the probability of an abdominoperineal 
resection (APR) compared to a low anterior resection (LAR).
Variable OR 95% CI P-value
Preoperative treatment
 RT*
 CRT
1.00
0.83 0.60-1.16
0.28
Sex
 Male*
 Female
1.00
0.67 0.46-0.98
0.03
Period of treatment
 1993-1995*
 1996-1999
 2000-2003
1.00
0.51
0.54
0.33-0.79
0.33-0.86
0.008
0.003
0.010
Distance
 ≤ 3.0   cm*
 3.1-6.0 cm
 6.1-9.0 cm
 > 9.0   cm
1.00
0.21
0.05
0.01
0.14-0.32
0.03-0.08
0.01-0.03
<0.001
<0.001
<0.001
<0.001
* Reference group; RT = radiotherapy; CRT = chemoradiotherapy; OR = odds ratio; CI = confidence 
interval; OR < 1 indicates an increased likelihood of LAR and decreased likelihood of an APR.
circumferential resection margin (for pt3-4 tumours)
CRM involvement was studied pathologically only in pT3-4 tumours, whereas patients 
with a pT0-2 tumour were assumed to have a negative CRM. Information on the status of 
the resection margin was unknown for 115 patients (14%) who were treated with a LAR 
or APR. In total, 778 patients could be analysed, of whom 42 patients (5.4%) had a posi-
tive CRM; 6.5% for patients treated with preoperative RT and 4.9% for patients treated 
with preoperative CRT (P = 0.35). In the multivariate analysis, treatment after 1999 was 
associated with a significantly lower risk of margin involvement (Table 4). In Figure 2, the 
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relation between CRM and period of treatment is shown (P = 0.01 in univariate analysis, 
χ2 for trends).
number of examined lymph nodes
The lymph node status was known for 831 patients treated with a LAR or APR. The 
median number of examined lymph nodes was 8 (range 0-45). The results of the mul-
tivariate analysis are displayed in Table 5. Younger age, treatment after 1995, proximal 
tumour location, and advanced tumour stage (pT3-4) were independently associated 
with a larger number of examined lymph nodes.
table 4. Final model of multivariate logistic regression analysis for the probability of a positive CRM in 
patients with LAR or APR.
Variable OR 95% CI P-value
Preoperative treatment
 RT*
 CRT
1.00
0.73 0.39-1.37
0.33
Period of treatment
 1993-1995*
 1996-1999
 2000-2003
1.00
0.81
0.29
0.40-1.71
0.10-0.75
0.04
0.56
0.01
* Reference group; RT = radiotherapy; CRT = chemoradiotherapy; OR = odds ratio; CI = confidence 
interval; OR < 1 indicates a decreased risk of positive circumferential resection margin compared to the 
reference level.
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figure 2. CRM involvement, 1-year and 3-year local recurrence (LR) rate shown per period of treatment. 
P-value for CRM involvement is 0.01 (χ2-test), for LR 0.79 (log-rank test).
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table 5. Final model of multivariate rank ANOVA analysis for the number of examined lymph nodes.
Variable Difference in number of 
examined lymph nodes
95% CI P-value
Preoperative treatment
 RT*
 CRT
0.00
-0.38 -1.28 to 0.51
0.41
Age
 ≤ 50  years*
 51-60 years
 61-70 years
 > 70  years
0.00
-0.87
-1.77
-1.73
-2.29 to 0.55
-3.11 to -0.43
-3.31 to -0.14
0.04
Period of treatment
 1993-1995*
 1996-1999
 2000-2003
0.00
2.65
3.58
1.47 to 3.83
2.31 to 4.85
<0.001
Distance
 ≤ 3.0   cm*
 3.1-6.0 cm
 6.1-9.0 cm
 > 9.0   cm
0.00
0.87
1.18
0.99
-0.39 to 2.13
0.06 to 2.30
0.98 to 4.87
0.02
Pathological T-stage
 T0-T2*
 T3-T4
0.00
1.90 0.99 to 2.80
<0.001
RT = radiotherapy; CRT = chemoradiotherapy; CI = confidence interval. The average number of examined 
lymph nodes for a reference patient aged ≤50 years, treated with preoperative RT, year of entry before 
1996 and a pT1-2 tumour located within 3 cm from the anal verge was 4.86.
Prognostic factors for outcome
Most LR were found in the group treated with preoperative RT alone13 and were located 
in the presacral area (42%). LR occurred in 99 (12%) of the 862 patients with a LAR or 
APR. The local recurrence rate per period is shown in Figure 2 (P = 0.14). The results of the 
multivariate analysis are presented in Table 6: younger age, APR surgery, advanced pT-
stage, and positive CRM were independent predictors of an increased risk of LR. Of the 
862 patients treated with a LAR or an APR, 346 (40%) had a local or distant recurrence 
or died during follow-up. The results of the multivariate analysis stratified for treatment 
are presented in Table 6 and show that an APR procedure, advanced pT-stage, positive 
lymph node status, and positive CRM are independent prognostic factors for a shorter 
DFS. During follow-up, 247 patients treated with an APR or a LAR died (29%). The final 
multivariate model for OS is presented in Table 6. The same variables as for DFS were 
independent prognostic factors for OS.
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Discussion
In this analysis, we investigated risk factors associated with quality of surgery in EORTC 
22921 trial, which assessed the efficacy of adding pre- and/or postoperative CT to a 
conventional schedule of preoperative RT for T3 and resectable T4 rectal cancer. In the 
present analyses, it was found that the period of treatment was associated with CRM and 
the number of examined lymph nodes. Besides, preoperative treatment was not found 
to be associated with CRM involvement.
The results indicate that the quality of the surgical resections improved during 
the trial. In the second half of the eighties, both surgeons and pathologists became 
interested in the lateral spread of rectal cancer and consequently CRM.6,7 In addition, 
results from the TME trial demonstrate that RT is even beneficial for tumours located >1 
cm from the CRM, indicating that lateral tumour spread is present in these tumours.17 
In the mid-1990s, after the start of EORTC 22921 trial, it became evident that excision 
of the total mesorectum should be considered as the gold standard.18 In EORTC 22921 
trial, CRM involvement decreased in the period 2000-2003 compared to the period 
1993-1999, which correlates with the addition of the recommendation to perform a TME 
procedure in the protocol in 1999. A limitation of the present analyses was that CRM 
status was determined only for pT3-4 tumours; all tumours that were downstaged to 
pT0-2 were considered to have a negative margin. Although patients with T0-2 tumours 
in general will have a negative CRM, a few patients might have had a positive CRM 
similar to findings in the Dutch trial (18% overall margin involvement; 2% margin in-
volvement for T1-2 tumours).8 Another parameter of surgical quality also improved: over 
time more lymph nodes were examined. However, in the period 2000-2003, 8.4 lymph 
nodes were on average examined, whereas in the 5th TNM-classification (UICC, 1999), it 
was recommended to remove at least 12 lymph nodes.19 Part of this difference could be 
explained by the use of preoperative (chemo)radiotherapy, which might have resulted 
in a reduced number of examined lymph nodes.20 In daily clinical practice, patients in 
whom no sufficient lymph nodes are removed are often considered as high risk stage 
II patients and consequently treated with postoperative chemotherapy. However, by 
examining an adequate number of lymph nodes, a number of these patients could be 
considered as low risk patients, without the need to be treated with chemotherapy.
Surgical quality has been shown to be an important predictor of outcome in TME 
operated patients.21,22 For patients in the TME trial, an incomplete mesorectum at patho-
logical examination was associated with an increased risk of local and distant recur-
rence.21 These results were confirmed in the MRC CR07 trial: an incomplete mesorectum 
was associated with more CRM involvement and subsequently with decreased local 
control.22 However, in the present trial, recommendations to perform a TME were in-
cluded in the protocol halfway through the trial in 1999. Consequently, in many patients, 
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no TME surgery was performed. Compared to before 2000, CRM involvement decreased 
in the period 2000-2003. Patients in this trial were treated with preoperative 45 Gy RT 
with or without pre- and/or postoperative CT. Several studies have investigated CRM 
involvement after CRT,23-25 whereas only few studies report on the association between 
CRM involvement and outcome after preoperative CRT.23 As far as we know, the associa-
tion between CRM and outcome for curatively treated patients in whom postoperative 
chemotherapy has been administered in addition to preoperative RT or CRT, has not 
been reported before. Our analyses for LR, DFS and OS, which were stratified for the four 
treatment arms, indicated that CRM involvement was still an independent predictor of 
outcome, even though patients were treated with RT and/or pre- or postoperative CT. 
Moreover, the highest hazard ratio for OS was found for CRM, indicating that CRM was 
the most important prognostic factor for survival.
The type of surgical resection was found to be a prognostic factor for LR, DFS and OS. 
Factors which increased the likelihood to undergo an APR were male sex, inclusion in 
the trial in the period 1993-1995, and tumour location within 3 cm from the anal verge. 
In the nineties, it was shown that a tumour free distal margin of 5 cm was unneces-
sary, and that a clear margin of at least 1 cm was sufficient in TME operated patients.26 
Consequently, less patients were treated with an APR and more with a LAR since the 
introduction of TME surgery.27 In addition, an APR was associated with a higher risk of 
CRM involvement and reduced local control and DFS.28,29 Therefore, it is often advised to 
treat patients preoperatively with CRT before an APR. Significant more downstaging and 
downsizing was observed after CRT compared with RT.14 Despite this downstaging, no 
significant difference for CRM status could be found when comparing CRT with RT in the 
present multivariate analysis. Apparently, increased downstaging and downsizing after 
CRT did not result in more radical resections. To reduce CRM involvement, the surgical 
procedure should change, especially for APR. For this procedure, it could be an option to 
perform a so-called cylindrical resection by widening the resection near the sphincter, 
an area were the resection is often incomplete.29
In the early 1990s, endo-rectal ultrasound was commonly used for rectal cancer. 
Consequently, endo-rectal ultrasound was advised in the EORTC trial protocol. In the 
same time period, the importance of a negative CRM became clear. However, it is found 
that CRM involvement cannot be appropriately assessed with ultrasound.30 Nowadays, 
it is possible to predict CRM involvement preoperatively with a MRI-scan.30 In patients 
who are found to have an involved or threatened CRM on a MRI scan, treatment could 
be adapted. CRT, for example, could be administered to downstage and downsize the 
tumour and subsequently the resection should be widened to obtain a negative CRM. 
In that way, individualisation of treatment with preoperative imaging could improve 
surgical resection quality.
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In conclusion, important surgical parameters improved over time: less APR pro-
cedures were performed, the rate of CRM involvement decreased and the number of 
examined lymph nodes increased. However, an APR procedure was still a risk factor for 
an adverse outcome, even though all patients were preoperatively treated with 45 Gy 
RT (or CRT) followed by delayed surgery after 6 weeks. Although downstaging might be 
helpful in the treatment of these advanced tumours, the ultimate aim of the treatment 
should still be to perform a radical operation.
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aBstract
Purpose
European Organisation for Research and Treatment of Cancer (EORTC) 22921 trial com-
pared adjuvant fluorouracil-based chemotherapy (CT) to no adjuvant treatment in a 2 
x 2 factorial trial with randomisation for preoperative (chemo)radiotherapy in patients 
with resectable T3-4 rectal cancer. The results showed no significant impact of adjuvant 
CT on progression-free or overall survival, although a difference seemed to emerge at 
approximately, respectively, 2 and 5 years after the start of preoperative treatment. We 
further explored the data with the aim of refining our understanding of the long-term 
results.
Patients and methods
Data of 785 of the 1011 randomly assigned patients whose disease was M0 at curative 
surgery were used. Using meta-analytic methods, we investigated the homogeneity of 
the effect of adjuvant CT on the time to relapse or death after surgery (disease-free 
survival [DFS]) and survival in patient subgroups.
results
Although there was no statistically significant impact of adjuvant CT on DFS for the 
whole group (P > 0.5), the treatment effect differed significantly between the ypT0-2 
and the ypT3-4 patients (heterogeneity P = 0.009): only the ypT0-2 patients seemed to 
benefit from adjuvant CT (P = 0.011). The same pattern was observed for overall survival.
conclusion
Exploratory analyses suggest that only good-prognosis patients (ypT0-2) benefit from 
adjuvant CT. This could explain why, in the whole group, the progression-free and over-
all survival diverged only after the poor-prognosis patients (ypT3-4) had experienced 
treatment failure. Patients in whom no downstaging was achieved did not benefit. This 
also suggests that the same prognostic factors may drive both tumour sensitivity for the 
primary treatment and long-term clinical benefit from further adjuvant CT.
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introDuction
The European Organisation for Research and Treatment of Cancer (EORTC) 22921 trial 
was a 2 x 2 factorial plan, four-arm, randomised trial that questioned the value of preop-
erative radiochemotherapy (RT-CT) versus preoperative radiotherapy (RT) alone and the 
value of adjuvant chemotherapy (CT) versus none with respect to overall survival and 
progression-free survival in patients with potentially resectable cT3-4 M0 rectal cancer.
From April 1993 to March 2003, 1011 patients were allocated to one of the following 
treatment arms: arm 1, preoperative RT; arm 2, preoperative RT-CT; arm 3, preoperative 
RT and adjuvant CT; and arm 4, preoperative RT-CT and adjuvant CT.
The main trial results were recently published with a median follow-up of 5.4 years.1 
A first analysis showed that the addition of CT to preoperative RT induced a significant 
increase of the downstaging rate.2 The long-term results1 failed to demonstrate a signifi-
cant impact of CT (either before or after surgery) on progression-free or overall survival, 
the primary trial end-points. The 5-year overall survival rate was 63.2% in the no-adjuvant 
CT and 67.2% in the adjuvant CT arms (P = 0.12) with a hazard ratio (HR) of 0.85 for ad-
juvant CT (95% confidence interval (CI), 0.68-1.04). The 5-year progression-free survival 
rates were 52.2% and 58.2% in the no-adjuvant and adjuvant arms, respectively (P = 
0.132; HR = 0.87; 95% CI, 0.72-1.04). However, the progression-free and overall survival 
curves started to diverge at approximately, respectively, 2 and 5 years after entry onto 
study, suggesting that a subset of patients of better prognosis who survive 2 to 5 years 
after the initiation of the first treatment might benefit from the adjuvant treatment in 
the long-term.
We now further explore the data with the aim of refining our understanding of the 
long-term results. For that purpose, we will focus on the group of eligible patients whose 
disease had not spread to distant sites before or at surgery and in whom a complete 
resection was performed. This subgroup should be disease free after surgery. We will 
then investigate whether we can identify, on the basis of baseline patient and treatment 
factors as well as of preoperative and surgical treatment and outcome characteristics, 
a subgroup of patients who benefit significantly from the adjuvant treatment in the 
long-term.
Patients anD MethoDs
trial design
The trial design and eligibility criteria have been reported previously,1 and we will sum-
marise only the main features herein. Patients age up to 80 years with resectable T3 or 
T4 M0 (1987 International Union Against Cancer (UICC) staging) adenocarcinoma of the 
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rectum,3 located within 15 cm of the anal margin, with a WHO performance status of 0 
or 1, and without previous history of cancer, angina pectoris, or inflammatory disease of 
the ileum or colon were eligible for the trial. Disease staging was by clinical examination, 
rigid sigmoidoscopy, chest X-ray, and abdominopelvic computed tomography scan. 
Endorectal ultrasonography was optional.
The trial was approved by the medical ethics committees of all participating centres. 
Informed consent was obtained from all patients before random assignment. The pa-
tients were centrally randomised at the EORTC Data Centre to RT or RT-CT as preopera-
tive treatment and to CT or nil as adjuvant treatment.
RT consisted of a 45-Gy dose delivered in 25 fractions of 1.8 Gy to the posterior pel-
vis.2,4 Irradiation techniques and treatment volumes have been reported previously.2,4 
Preoperative CT was delivered in two 5-day courses during the first and fifth weeks of 
RT. Surgery was planned 3 to 10 weeks thereafter, and total mesorectal excision was 
recommended from 1999 onwards. When allocated, the four 3-week courses of adjuvant 
CT had to start 3 to 10 weeks after surgery. Preoperative and adjuvant CT consisted 
of fluorouracil (350 mg/m²/d) and leucovorin (20 mg/m²/d) administered as a short 
intravenous infusion.
The toxicity was monitored during treatment.4 Patients were then followed at 
6-month intervals for at least 5 years by clinical examination, abdominal ultrasound, 
and chest x-ray; coloscopy was performed annually. Recurrences were confirmed radio-
logically or histologically. Local recurrence was defined as a tumour regrowth within the 
pelvis or perineum.
analysis set and end-points
Only the 785 eligible patients whose disease did not spread to distant sites before or 
at surgery and in whom a microscopically complete (R0) resection was performed are 
included in the analysis (77.6% of 1011). Complete resection was defined in this study as 
resection with negative resection margin by both macroscopic and microscopic exami-
nation. Disease-free survival (DFS) is defined as the time from the date of surgery to the 
first event of locoregional or distant recurrence or death resulting from any cause; or to 
the date of the most recent follow-up for excluded cases. This end-point corresponds to 
progression-free survival in the study protocol, but is counted from the date of surgery. 
Survival is counted from the date of surgery to the date of death resulting from any 
cause or the date of most recent information if alive.
statistical methods
The analysis is exploratory. The association between classifications and outcome are 
assessed by log-rank test for heterogeneity and effects represented on forest plots,5 and 
the distribution of time-to-event end-points is estimated by means of Kaplan-Meier.6 
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Interaction between factors and treatment effects is summarised by the interaction HR 
and its associated 95% CI.7 The interaction HR represents the ratio of the treatment HR 
for one level of the explanatory variable to the treatment HR in the reference level of 
the covariate, and thus measures how much the relative treatment effect is modulated 
by the covariate. For grouping patients, continuous variables were dichotomised at the 
sample median or at published values. Adjacent levels of discrete variables with small 
numbers were lumped together. Two-sided tests were used with a 5% significance level. 
All analyses but those of the preoperative treatment were stratified for the allocated 
preoperative treatment.
results
A total of 226 patients were excluded from the analysis (102 initially allocated to no 
adjuvant CT and 124 to adjuvant CT): 15 were ineligible, 45 had metastatic progres-
sion before surgery, 57 have unknown metastatic status, 10 were not resected despite 
disease being M0, and 78 had an incomplete resection; in 21, the information regarding 
completeness of the resection was unknown.
Of the 785 patients included in the analysis, 199 had been randomly assigned to the 
RT arm without adjuvant CT, 204 to RT-CT arm without adjuvant CT, 190 to the RT arm 
with adjuvant CT, and 192 to the RT-CT arm with adjuvant CT. In the analysed set, all 
patients allocated adjuvant CT received at least one adjuvant CT cycle. The four adjuvant 
CT cycles were delivered to 140 (73.7%) of 190 patients and 142 (73.9%) of 192 patients 
allocated adjuvant CT in the RT and RT-CT arms, respectively.
Of the patients in the RT arm, 233 (57.8%) were alive and free of disease at a median 
follow-up of 5.2 years from surgery, compared with 237 (62.0%) in the RT-CT arm (Figure 
1). The first relapse was locoregional in 37 patients receiving RT versus 19 patients re-
ceiving RT-CT, distant relapse occurred in 98 versus 91 patients, the two types of events 
occurred concurrently in five versus eight patients, a death without relapse occurred in 
28 versus 25 patients, and relapse at unspecified localisation occurred in two patients 
in each arm.
The patients and the potential predictors considered in the analysis are described 
in Table 1. Because only 5.2% of the cases had mucinous tumours, this variable was not 
analysed. Although the treatments were randomly assigned, some factors were slightly 
imbalanced between the two adjuvant treatment groups: WHO performance status 
more than 1 was more frequent in the adjuvant treatment group (32.2% versus 25%), 
whereas in the no-adjuvant group, treatment downstaging to ypT0-2 was less frequent 
(51.8% versus 55.8%) and pN+ cases were less common (25.4% versus 29.5%). The imbal-
ances in prognostic factors seemed to average out: The adjuvant treatment HR for DFS 
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was very similar with (HR = 0.94; 95% CI 0.73-1.20; P = 0.262) or without (HR = 0.92; 95% 
CI 0.73-1.14; P = 0.443) adjustment for the covariates; as was the adjuvant treatment HR 
for overall survival with (HR = 0.93; 95% CI 0.69-1.25; P = 0.623) or without adjustment 
for the covariates (HR = 0.92; 95% CI 0.70-1.19; P = 0.514).
The univariate interaction tests for DFS and overall survival are also presented in 
Table 1 with the HRs and the CIs. Only the downstaging (ypT0-2 versus ypT3-4) statisti-
cally significantly influenced the magnitude of the adjuvant treatment effect (P = 0.008, 
Figure 2), with an interaction HR of 1.87 (95% CI 1.18-2.98) indicating a significantly 
larger treatment benefit for the group with downstaging. In the group of patients with 
downstaging to ypT0-2 at the time of surgery, the treatment HR for DFS was 0.64 (95% 
CI 0.45-0.91) in favour of adjuvant CT (P = 0.013); the DFS rate was 65.6% (95% CI 58.3%-
72.0%) without CT and 76.7% (95% CI 69.4%-82.5%) with CT (Figure 3). In patients 
without downstaging, there was no statistically significant benefit of adjuvant CT (HR = 
1.18; 95% CI 0.89-1.57; P = 0.244). For that group, the 5-year DFS rate was 48.9% without 
CT (95% CI 40.8%- 56.5%) and 45.1% with adjuvant CT (95% CI 37.3%-52.5%; Figure 3).
For survival, the downstaging also significantly influenced the effect of the adjuvant 
treatment (heterogeneity test P = 0.024, Figure 4), with an interaction HR of 1.89 (95% CI 
1.09-3.27; Table 1). In the group with downstaging, adjuvant CT significantly prolonged 
survival time after surgery (P = 0.030; HR=0.64; 95% CI 0.42-0.96), whereas the group 
without downstaging did not seem to benefit (P = 0.337; HR = 1.19; 95% CI 0.84-1.68). 
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figure 1. Progression-free survival (PFS) and overall survival (OS) from the date of surgery by adjuvant 
treatment. O = number of events; N = number of patients; CT = chemotherapy.
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Events Patients
Adjuvant CT No adjuvant CT Statistics
O-E Variance HR and CI
Downstaging
ypT0-2 45 198 77 225 -13.9 30.4
ypT3-4 100 183 92 176 7.2 47.8
Total 145 381 169 401 -6.7 78.2
(38.1 %) (42.1 %)
Heterogeneity χ21 = 6.91; P < 0.01
Tumour distance to anal verge
Distance ≤ 5 cm 84 185 90 198 1.8 43.3
Distance > 5 cm 61 197 80 205 -8.5 35.2
Total 145 382 170 403 -6.8 78.5
(38.0 %) (42.2 %)
Heterogeneity χ21 = 1.16; P > 0.1
Type of surgery
APR 70 149 75 163 3.2 36.0
AR or other 75 233 95 240 -10.0 42.4
Total 145 382 170 403 -6.8 78.3
(38.0 %) (42.2 %)
Heterogeneity χ21 = 2.08; P > 0.1 0.25 0.50 1.00 2.00 4.00
Adjuvant CT No adjuvant CT
better better
Treatment effect: P = 0.5
Events Patients
figure 2. Forest plot of the univariate interactions between the effect of adjuvant chemotherapy (CT) 
on disease-free survival after surgery and downstaging by preoperative treatment, tumour localisation, 
and type of surgical procedure. Solid vertical line represents no effect. Dashed vertical line and diamond 
represent the overall hazard ratio (HR) and confidence interval (CI). Centre of squares indicates HR in 
each group with 95% CI (horizontal bars). Square size is proportionate to the amount of information in 
each group. O = number of events observed; E = number of events expected in the absence of treatment 
effect; APR = abdominoperineal resection; AR = anterior resection.
0 2 4 6 8 10
0
10
20
30
40
50
60
70
80
90
100
O N Number of patients at risk
77 225 157 101 57 22
45 196 150 111 59 16
92 176 107 63 42 15
100 183 94 62 42 17
No adjuvant CT
Adjuvant CT
ypT3-4
No adjuvant CT
Adjuvant CT
ypT0-2
Time (years)
ypT0-2
No adjuvant CT
Adjuvant CT
ypT3-4
No adjuvant CT
Adjuvant CT
figure 3. Kaplan-Meier curve of disease-free survival after surgery by adjuvant treatment and 
pathological down staging to ypT0-2. O = number of events; N = number of patients; CT = chemotherapy.
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Unlike for DFS, the benefit from adjuvant CT was significantly increased in patients with 
tumour located more than 5 cm from the anal verge compared to the benefit seen in 
patients with a tumour located at 5 cm from the anal verge (low rectum; heterogeneity 
test P = 0.026; interaction HR = 0.54; 95% CI 0.31-0.98; Figure 4). For tumours in the low 
rectum, adjuvant CT was not beneficial (P = 0.353; HR = 1.18; 95% CI 0.83-1.66), whereas it 
was beneficial in patients with tumours located higher up in the rectum (P = 0.033), with 
a treatment HR of 0.64 (95% CI 0.42-0.96) indicating prolonged survival with adjuvant 
treatment. Similarly, the type of surgical procedure also influenced the effect of adjuvant 
chemotherapy (interaction HR = 0.54; 95% CI 0.31-0.93; P = 0.026). Patients who had 
undergone an abdominoperineal resection (APR) did not seem to benefit from adjuvant 
CT (HR = 1.26; P = 0.222), whereas those with another type of surgical procedure did 
(HR = 0.68; P = 0.046; Figure 4). This is not surprising, because tumour localisation in the 
rectum is the major driver of choice of the surgical procedure, and 68% of the patients 
with a tumour in the low rectum underwent APR, compared with only 12% in those with 
tumours located higher in the rectum.
Events Patients
Adjuvant CT No adjuvant CT Statistics
O-E Variance HR and CI
Downstaging
ypT0-2 33 198 60 225 -10.8 23.1
ypT3-4 69 183 59 176 4.9 31.9
Total 102 381 119 401 -5.9 55.0
(26.8 %) (29.7 %)
Heterogeneity χ21 = 5.17; P = 0.02
Tumour distance to anal verge
Distance ≤ 5 cm 67 185 63 198 5.4 32.5
Distance > 5 cm 35 197 56 205 -10.4 22.7
Total 102 382 119 403 -5.0 55.1
(26.7 %) (29.5 %)
Heterogeneity χ21 = 5.21; P = 0.02
Type of surgery
APR 58 149 55 163 6.5 28.0
AR or other 44 233 64 240 -10.6 26.9
Total 102 382 119 403 -4.1 54.9
(26.7 %) (33.5 %)
Heterogeneity χ21 = 5.39; P = 0.02 0.25 0.50 1.00 2.00 4.00
Adjuvant CT No adjuvant CT
better better
Treatment effect: P = 0.4
Events Patients
figure 4. Forest plot of the univariate interactions between the effect of adjuvant chemotherapy (CT) 
on survival after surgery and downstaging by preoperative treatment, tumour localisation and type of 
surgical procedure. Solid vertical line represents no effect. Dashed vertical line and diamond represent 
the overall hazard ratio (HR) and confidence interval (CI). Centre of squares indicates HR in each group 
with 95% CI (horizontal bars). Square size is proportionate to the amount of information in each group. O 
= number of events observed; E = number of events expected in the absence of treatment effect; APR = 
abdominoperineal resection; AR = anterior resection.
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Because the type of surgical procedure and the tumour localisation in the rectum are 
strongly correlated,8,9 only the tumour localisation was combined with tumour down-
staging for a multivariate predictive factor analysis of overall survival. The four-group 
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Adjuvant CT No adjuvant CT Statistics
O-E Variance HR and CI
ypT0-2
Distance ≤ 5 cm 21 98 32 115 -4.1 13.1
Distance ≤ 5 cm 12 100 28 110 -7.6 9.6
Subtotal 33 198 60 225 -11.7 22.7
(16.7 %) (26.7 %)
Heterogeneity χ21 = 1.29; P = 0.3
ypT3-4
Distance ≤ 5 cm 48 86 31 83 8.5 19.1
Distance > 5 cm 23 97 28 93 -2.5 12.7
Subtotal 69 183 59 176 5.8 31.8
(37.7 %) (33.5 %)
Heterogeneity χ21 = 3.25; P = 0.07
Events Patients
40% ± 16
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better better
Treatment effect: P = 0.4
Total 102 381 119 401 -5.9 54.5
(26.8 %) (29.7 %)
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Events Patients
Adjuvant CT No adjuvant CT Statistics
O-E Variance HR and CI
ypT0-2
Distance ≤ 5 cm 28 98 41 115 -6.8 16.6
Distance ≤ 5 cm 19 100 36 110 -8.4 13.3
Subtotal 45 198 77 225 -15.2 29.9
(22.7 %) (34.2 %)
Heterogeneity χ21 = 0.38; P = 0.5
ypT3-4
Distance ≤ 5 cm 58 86 49 83 8.6 26.3
Distance > 5 cm 42 97 43 93 0.1 21.1
Subtotal 100 183 92 176 8.8 26.3
(54.6 %) (52.3 %)
Heterogeneity χ21 = 1.22; P = 0.3
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40% ± 14
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20% ± 16
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8% ± 11
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Adjuvant CT no Adjuvant
better better
Treatment effect: P = 0.5
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(38.1 %) (42.1 %)
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χ23 = 10.38; P = 0.01
Test for interaction
χ21 = 8.78; P = 0.01
[1-HR]
% ± SD
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figure 5. Forest plot of the effect of adjuvant chemotherapy (CT) by downstaging and tumour 
localisation on (A) overall survival and (B) disease-free survival after surgery. Solid vertical line represents 
no effect. Dashed vertical line and diamond represent the overall hazard ratio (HR) and confidence 
interval (CI). Centre of squares indicates HR in each group with 95% CI (horizontal bars). Square size is 
proportionate to the amount of information in each group. O = number of events observed; E = number 
of events expected in the absence of treatment effect; SD = standard deviation.
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classification combining tumour downstaging (ypT0-2 versus ypT3-4) and tumour lo-
calisation (≤ 5 cm versus > 5 cm from the anal verge) statistically significantly influenced 
the treatment effect (heterogeneity test P = 0.012; 3 df; Figure 5A). However, within the 
subgroup with ypT0-2, the treatment effect seemed not to significantly vary according 
to tumour localisation (heterogeneity P = 0.255) whereas it seemed to differ more within 
the subgroup with ypT3-4, although not statistically significantly (heterogeneity P = 
0.071). Nevertheless, the three-way interaction amongst ypT, tumour localisation, and 
treatment was not statistically significant (P = 0.731). In the patients with ypT0-2, the 
HR favoured adjuvant CT (HR = 0.73; 95% CI 0.43-1.26; and HR = 0.45; 95% CI 0.24-0.85 
for low and middle/high rectum, respectively). In the patients with ypT3-4 disease, the 
treatment HRs were not in favour of adjuvant CT: the treatment HR was 1.55, pointing 
against adjuvant CT for patients with a tumour in the low rectum (95% CI 0.99-2.44; P = 
0.053), and it was 0.81 for patients with tumours located in the middle or high rectum 
(95% CI 0.47-1.41).
The impact of this classification on DFS after surgery is represented in Figure 5B and 
shows that only the classification by ypT influences the treatment effect on this end-
point. The study could not demonstrate a statistically significant behaviour according 
to the type of preoperative treatment administered, but the predictive effect remained 
significant even if patients had no preoperatively CT.
Discussion
Overall, the EORTC trial 22921 could not demonstrate that delivering adjuvant CT to all 
patients with resectable T3-T4 rectal cancer would prolong progression-free or overall 
survival.1 In the present analysis, we focused on those patients whose tumour could be 
resected completely and whose disease had not extended to metastatic sites by the 
time of the surgery. We then showed that, in the subgroup of patients whose disease 
had been downstaged to ypT0-2 by preoperative treatment, the delivery of adjuvant CT 
prolonged both the time to relapse and the survival time.
These findings should not, however, be misinterpreted: It is a common mistake to 
conclude causality when only associations have been demonstrated. We did not show 
that it is because tumour downstaging was achieved that these patients also benefited 
of further CT, but rather that those same patients who achieved downstaging have a 
disease that is responsive to both the preoperative and the adjuvant treatment. This 
suggests that the same good prognostic factors induce both an increased likelihood 
of downstaging from preoperative treatment and increased likelihood of a benefit 
from adjuvant CT. These findings are no proof of surrogacy of the downstaging for the 
long-term end-points,10 but are in line with Valicenti et al.’s statement that heterogene-
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ity of tumour behaviour exists, which identification may be promoted by preoperative 
treatment.11
One could then ask which factors drive the sensitivity to pre- and postoperative treat-
ment. In this database, the factors predicting an increased likelihood of downstaging 
were preoperative treatment,4 along with tumour length and the use of modern staging 
by endorectal ultrasonography (data not shown). The factors predicting for progression-
free survival after surgery were type of surgical procedure, pN status, microscopic surgi-
cal margin status, and tumour downstaging by preoperative treatment.9 We therefore 
focused on curatively resected patients. We believe, however, that other factors more 
closely related to sensitivity to RT and/or CT and to the biology of the disease are prob-
ably more relevant to the definition of the “good prognostic” patient group. However, 
these factors are not known from the data collected in the trial. We can therefore only 
identify this subgroup a posteriori, on the basis of the pathologic downstaging after 
preoperative treatment.
The other factors that seemed to influence the effect of the adjuvant treatment on 
overall survival (tumour localisation and type of surgery) were not confirmed to influ-
ence the effect of the treatment on progression-free survival. These factors are known 
prognostic factors of outcome,8,9 but in our study, they were not confirmed to be predic-
tive for a benefit from adjuvant treatment regarding progression-free survival.
This analysis is exploratory in nature: neither the end-point nor the hypotheses stud-
ied were planned in the study protocol. The hypothesis that a subgroup might benefit 
from adjuvant treatment emerged from the first trial results that were suggestive of 
mixture of patients in the sample, with varying sensitivity to and potential benefit from 
the tested adjuvant treatment. These findings must, therefore, be validated on an inde-
pendent set of patients with cT3-4 rectal cancer who received preoperative treatment, 
were operated on, and were downstaged to pT0-2 and are then randomly assigned to 
receive or not receive fluorouracil-based adjuvant CT.
Despite the lack of evidence to support the routine use of adjuvant CT for all patients 
with resectable T3-4 rectal cancer after preoperative treatment,1 adjuvant chemo-
therapy is regarded by some as standard adjuvant treatment.12-16 The present report, 
however, confirms that, at least in patients presenting with poorer risk features (i.e., 
without tumour downstaging after preoperative radiotherapy or radiochemotherapy), 
adjuvant chemotherapy with fluorouracil and leucovorin may be an ineffective treat-
ment, causing extra burden and toxicity to the patients without evidence, so far, of any 
clinical benefit. Our findings contrast with the recommendations by Das et al.14 who 
suggest, rather, that adjuvant chemotherapy might benefit more higher-risk patients 
but are in line with those of Janjan et al.,17 who report higher rates of relapse despite 
adjuvant chemotherapy in patients showing no response to preoperative treatment. 
However, they suggest the use of FOLFOX for high-risk patients, which includes oxali-
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platin in addition to the fluorouracil and leucovorin used in EORTC 22921 trial. In a study 
of 95 rectal cancer patients who all underwent preoperative radiochemotherapy and a 
microscopically complete resection, Frietkau et al.13 concluded that postoperative che-
motherapy may not be necessary in patients with ypN0. Their conclusions are based on 
the observation that ypN was the most important and sole independent prognostic fac-
tor for disease-free survival in their study and that there was no significant impact of the 
type, if any, of postoperative treatment on outcome. EORTC 22921 trial confirmed that 
ypN was a strong independent prognostic factor for overall survival and DFS;9 however, 
we demonstrated in the present report that ypN status after preoperative treatment did 
not show an interaction with the benefit from postoperative CT. The findings reported 
by Frietkau may well have resulted from lack of power in their analyses, in relation to the 
limited number of patients in their study.
We can therefore conclude that newer agents are worth investigating either alone or 
in combination as (neo)adjuvant treatment of rectal cancer, but predictive factors such 
as tumour responsiveness to preoperative treatment must be taken into account in the 
design of future phase III trials. Separate treatment strategies may be devised for patients 
with differing sensitivity to classical chemotherapeutic agents. Finally, the analysis of 
gene expression profiles of the primary tumour may be relevant to identify patients who 
may benefit from preoperative radiochemotherapy16 and adjuvant fluorouracil-based 
chemotherapy.18,19
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aBstract
Purpose
The association between a diverting stoma and the rate of symptomatic anastomotic 
leakage following rectal cancer surgery was studied here. Furthermore, the impact of 
anastomotic leakage on the rate of local recurrence, distant metastases, disease-free 
survival, overall survival, and cancer-specific survival was investigated.
Patients and methods
The Swedish Rectal Cancer trial, TME trial, CAO/ARO/AIO-94 trial, EORTC 22921 trial, 
and Polish Rectal Cancer trial were pooled (n = 5187). All eligible patients treated with 
a low anterior resection and without distant metastases at the time of surgery were 
selected (n = 2726). In the Swedish Rectal Cancer trial no data on stomas were available. 
The patients from that trial were thus excluded from all analyses related to stomas (n = 
430). Overall survival was studied in the selected patients aged ≤ 75 years (n = 2480). 
Multivariable models were used to study the association between a diverting stoma and 
anastomotic leakage and the association between anastomotic leakage and recurrence 
or survival.
results
In total 264 of 2726 (9.7%) patients were diagnosed with a symptomatic anastomotic 
leak; a diverting stoma was negatively associated with leakage (11.7% for patients 
without and 7.9% for patients with a diverting stoma, P = 0.002). Anastomotic leakage 
was negatively associated with overall survival in the multivariable analysis even after 
excluding patients who died within 90 days of surgery (hazard ratio (HR) 1.29; 95% CI 
1.02-1.63; P = 0.034), but not with cancer-specific survival (HR 1.12; 95% CI 0.83-1.52; P 
= 0.466).
conclusion
Diverting stomas were associated with less symptomatic anastomotic leakage. Although 
oncological outcome was not significantly influenced by a leak, overall survival (both 
short- and long-term) was reduced.
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introDuction
Surgery is the cornerstone in the treatment of rectal cancer. Widespread use of stan-
dardised total mesorectal excision (TME) improved overall survival.1,2 However, TME 
surgery might be associated with an increased risk of developing anastomotic leakage3 
with attendant morbidity and mortality in the postoperative period.4,5 Leaks might be 
associated with decreased local control6-11 and survival7,12,13. Therefore, the rate of (symp-
tomatic) anastomotic leakage has been considered as one of the quality indicators of 
surgical performance.14
Studies to identify risk factors for anastomotic problems and methods to reduce 
symptomatic leaks are clearly important.15,16 At the end of last century, two small ran-
domised trials tested the hypothesis that a diverting stoma reduces the incidence of 
anastomotic leakage.17,18 Although both trials showed fewer anastomotic leaks with 
stoma use, the difference was not statistically significant. A larger randomised trial con-
cluded that a diverting stoma significantly reduces the risk of symptomatic anastomotic 
leakage.19
In this study, 5 large European randomised clinical trials were pooled to study the 
association between the creation of a diverting stoma and the rate of symptomatic 
leakage after a (low) anterior resection for rectal cancer. In addition, the impact of anas-
tomotic leakage on the rate of local recurrence, distant metastasis, disease-free survival, 
overall survival, and cancer-specific survival were investigated.
Patients anD MethoDs
trials and patients
Patient and treatment variables of the following 5 trials were pooled: Swedish Rectal 
Cancer trial20, Dutch TME trial21, German CAO/ARO/AIO-94 trial22, EORTC 22921 trial23, 
and the Polish Rectal Cancer trial24. The period of inclusion, randomisation arms and 
number of included patients are shown in Table 1. Of this pooled database of treatment 
variables, all eligible patients treated with a low anterior resection and without distant 
metastases at the time of surgery were selected. In the Swedish Rectal Cancer trial no 
data on stomas were available, although stomas in that trial were rarely used as mostly 
high anastomoses were created. The patients from that trial were thus excluded from all 
analyses related to stomas. The 5th edition of TNM classification of malignant tumours 
was used to determine the TNM stage.25 The analyses of overall survival, disease-free 
survival, and cancer-specific survival were restricted to patients aged 75 year or less, to 
control those analyses for different age limits allowed in the various trials.
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table 1. Period of inclusion, randomisation arms and number of patients per trial.
Trial Period Randomisation n
Swedish Rectal Cancer trial 1987-1990 preoperative 5 x 5 Gy RT
surgery alone
1180
Dutch TME trial 1996-1999 preoperative 5 x 5 Gy RT with TME surgery
TME surgery alone
1861
German CAO/ARO/AIO-94 trial 1995-2002 preoperative CRT
postoperative CRT
 823
EORTC 22921 trial 1993-2003 preoperative 45 Gy RT
preoperative CRT
preoperative 45 Gy RT and postoperative CT
preoperative CRT and postoperative CT
1011
Polish Rectal Cancer trial 1999-2002 preoperative 5 x 5 Gy RT with TME surgery
preoperative CRT with TME surgery
 312
Total 5187
RT = radiotherapy; CRT = chemoradiotherapy; CT = chemotherapy.
end-points, variables and statistics
In  the included trials, only symptomatic anastomotic leakages were documented. 
Anastomotic leakage was defined as clinically apparent leakage such as faecal discharge 
from pelvic drain or abdominal wound, or radiologically, endoscopically or surgically 
proven anastomotic leakage in symptomatic patients such as those with peritonitis.
The χ2 test was used for comparisons of categorical variables. Univariate and mul-
tivariable logistic regression analyses were performed with the following variables to 
study their association with anastomotic leakage: gender, age, distance of the tumour 
from the anal verge, TNM stage, and the presence of a stoma. The multivariable analysis 
was adjusted for trial and randomisation arm.
To study the effects of anastomotic leakage on local recurrence, distant metastasis, 
overall survival, disease-free survival, and cancer-specific survival, Cox regression analy-
ses were used, stratified for trial and randomisation arm. The following confounders were 
first studied by univariate analyses: gender, age, distance of the tumour from the anal 
verge, TNM stage, and circumferential resection margin (CRM) involvement. Variables 
with a P-value of ≤ 0.10 were then entered in the multivariable Cox regression models. 
A positive CRM was defined as microscopic or macroscopic tumour in the resection 
margin (unavailable in the Swedish Rectal Cancer trial). Time to local recurrence, distant 
metastases, and overall survival were calculated as the time from surgery to respectively 
local recurrence, distant metastases, and death. For overall survival, the analyses were 
performed first for all selected patients. These analyses were then repeated with a 
landmark selection, excluding all patients who died within 90 days postoperatively to 
correct for short-term mortality associated with anastomotic leakage itself. Disease-free 
survival, defined as time from surgery to first event of local recurrence, distant metas-
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tases or death, and cancer-specific survival, defined as the time from surgery to death 
due to rectal cancer, were studied only using the landmark selection excluding patients 
with 90-day postoperative mortality. The probability of local recurrence is reported as 
cumulative incidences with death as competing risk; cancer-specific survival is reported 
as one minus cumulative incidence with death due to other causes than rectal cancer as 
competing risk.26
Data were analysed with the SPSS package (SPSS 14.0 for Windows; SPSS Inc., Chi-
cago, IL, USA). A two-sided P-value of ≤ 0.05 was considered to be statistically significant.
results
Patients
In total, 5187 patients were included in the Swedish Rectal Cancer trial, Dutch TME trial, 
German CAO/ARO/AIO-94 trial, EORTC 22921 trial, and the Polish Rectal Cancer trial. 
Reasons for exclusion and number of patients are shown in Figure 1. Of 1962 patients 
with another than a low anterior resection, 1749 were treated with an abdominoperineal 
resection. For the analyses, 2726 patients (52.6%) were included. Patient and disease 
characteristics of these patients are shown in Table 2. The median follow-up of patients 
alive was 5.9 years (range 0.2-14.9 years). Overall, disease-free and cancer-specific sur-
vival were studied in 2480 of these 2726 patients who were aged ≤ 75 years.
anastomotic leakage
In total, 264 patients (9.7%) were diagnosed with anastomotic leakage. No information 
on stoma construction was available for the Swedish Rectal Cancer trial (n = 430). There-
fore, these patients were excluded in the analyses related to stomas: 2296 patients were 
studied. In 1226 patients (53.5%) a stoma was constructed; in 1067 patients (46.5%) no 
stoma was created; for 3 patients (0.1%), the stoma status was unknown. Symptomatic 
anastomotic leakage occurred in 124 patients (11.7%) without a stoma, whereas it was 
diagnosed in 96 patients (7.9%) with a stoma (P = 0.002).
In Table 3, the results of the univariate and multivariable analysis for risk factors as-
sociated with anastomotic leakage are shown. From the univariate analyses, both gen-
der and the presence of a diverting stoma were selected for entry in the multivariable 
analysis due to a P-value ≤ 0.10. Trial and treatment arm were entered in the analysis as 
adjustment. Female gender and the presence of a diverting stoma were both indepen-
dently associated with a reduced chance to develop symptomatic anastomotic leakage.
The anastomotic leakage rates per trial and randomisation arm are shown in Table 4. 
None of the trials showed a significant difference between the randomised treatment 
arms.
134 Chapter 9
1.3% of patients without anastomotic leakage (33 of 2446) died within 30 postopera-
tive days, whereas the 30-day mortality rate after anastomotic leakage was 5.7% (15 of 
263 patients; P < 0.001). For one patient with anastomotic leakage, no details on death 
status were available.
anastomotic leakage and local recurrence
Anastomotic leakage was not associated with local recurrence in the univariate analysis 
and therefore not entered in the multivariable analysis: 5-year local recurrence rate 8.8% 
(95% confidence interval (CI) 7.6%-10.0%) for patients without anastomotic leakage 
and 12.0% (95% CI 7.4%-16.5%) for patients with anastomotic leakage (P = 0.103). The 
cumulative incidence of local recurrence with death as competing risk for patients with 
and without anastomotic leakage is depicted in Figure 2A.
5187 patients included 
in the 5 trials
5063 eligible patients
124 ineligible patients
4688 patients with no 
distant metastases at 
time of surgery
375 patients with distant 
metastases at time of 
surgery
1962 patients treated with 
another procedure than a 
low anterior resection
2726 patients treated 
with a low anterior 
resection
246 patients aged > 75 
years
2480 patients aged ≤ 75 
years
figure 1. Flow diagram of selected and excluded patients.
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table 2. Patient and tumour characteristics of the patient population after selection of all eligible patients 
treated with a low anterior resection and without distant metastases at time of surgery.
Variable  n (%)
Sex
 Female 1018 (37.3)
 Male 1708 (62.7)
Age
 ≤ 60  years 1008 (37.0)
 61-70 years 1007 (36.9)
 > 70  years  711 (26.1)
Trial
 Swedish Rectal Cancer trial  430 (15.8)
 Dutch TME trial 1132 (41.5)
 German CAO/ARO/AIO-94 trial  495 (18.2)
 EORTC 22921 trial  502 (18.4)
 Polish Rectal Cancer trial  167  (6.1)
Distance of tumour to anal verge
 ≥ 5.0 cm 2197 (80.6)
 < 5.0 cm  500 (18.3)
 Unknown   29  (1.1)
TNM stage
 TNM stage 0/I  951 (34.9)
 TNM stage II  804 (29.5)
 TNM stage III  954 (35.0)
 Unknown   17  (0.6)
CRM involvement
 No 2070 (75.9)
 Yes   87  (3.2)
 Unknown  569 (20.9)
Stoma*
 No 1067 (46.5)
 Yes 1226 (27.2)
 Unknown    3  (0.1)
Anastomotic leakage
 No 2452 (89.9)
 Yes  264  (9.7)
 Unknown   10  (0.4)
CRM = circumferential resection margin. * Excluding 430 patients in the Swedish Rectal Cancer trial in 
which no data on stoma construction was available.
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anastomotic leakage and distant metastases
The univariate analysis for the association between anastomotic leakage and distant 
metastases was not significant: rate of distant metastases at 5 years 25.6% (95% CI 
23.7%-27.3%) and 27.5% (95% CI 21.4%-33.6%), respectively for patients without and 
with anastomotic leakage (P = 0.480). Therefore, no multivariable analysis with anasto-
motic leakage was performed for distant metastases.
anastomotic leakage and overall survival
First, the analyses were performed with all selected patients. Anastomotic leakage was 
significantly associated with a worse overall survival rate (hazard ratio (HR) 1.49; 95% 
CI 1.20-1.84; P < 0.001 univariate analysis and HR=1.48; 95% CI 1.19-1.83; P < 0.001 
multivariable analysis). Five-year overall survival rate was 74.4% (95% CI 72.4%-76.4%) 
within the group of patients without anastomotic leakage compared to 66.4% (95% CI 
60.1%-72.7%) for patients with anastomotic leakage (P < 0.001).
In Table 5, the results of both the univariate and multivariable analyses for risk factors 
associated with overall survival are shown, excluding patients who died within 90 days 
after surgery (n = 52): 5-year overall survival rate 75.5% (95% CI 73.4%-77.4%) for pa-
tients without anastomotic leakage versus 71.5% (95% CI 62.2%-77.8%) for patients with 
table 3. Univariate and multivariable analyses of risk factors associated with anastomotic leakage.
Variable Univariate analyses Multivariable analysis
OR 95% CI P-value OR 95% CI P-value
Gender 0.002 0.002
 Female 1.00 1.00
 Male 1.56 1.18-2.07 1.64 1.20-2.24
Age 0.956 ----
 ≤ 60   years 1.00
 61-70 years 1.00 0.74-1.34 0.975
 > 70   years 0.95 0.69-1.32 0.780
Distance from tumour to anal verge 0.949 ----
 ≥ 5.0 cm 1.00
 < 5.0 cm 0.99 0.71-1.38
TNM stage 0.608 ----
 TNM stage 0/I 1.00
 TNM stage II 1.14 0.83-1.57 0.418
 TNM stage III 1.15 0.85-1.57 0.362
Stoma 0.002 0.001
 No 1.00 1.00
 Yes 0.65 0.49-0.85 0.62 0.47-0.82
OR = odds ratio; CI = confidence interval.
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anastomotic leakage (P = 0.030). Male gender, age above 70 years, advanced TNM stage, 
and postoperative anastomotic leakage were both in the univariate and multivariable 
analyses associated with diminished overall survival. The Kaplan-Meier curves for overall 
survival are presented in Figures 2B and 2C, respectively for all patients and excluding 
the patients who died in the first 90 postoperative days.
anastomotic leakage, stomas and overall survival
If the analyses for overall survival were repeated with both the variables anastomotic 
leakage and stoma in the model, both were significantly associated with a worse over-
all survival (data not shown). However, no statistical significant interaction between 
anastomotic leakage and the presence of a stoma could be demonstrated (P = 0.255). 
Patients with a stoma had an increased risk of death (HR=1.24; 95% CI 1.04-1.48; P = 
0.015; multivariable model). Figure 3A shows the Kaplan-Meier curves for overall sur-
vival separately for patients with/without anastomotic leakage and with/without stoma. 
table 4. Anastomotic leakage rate and univariate logistic regression analyses per trial and randomisation 
arm.
Variable n Anastomotic 
leakage (%)
Univariate analyses
OR 95% CI P-value
Swedish Rectal Cancer trial 0.283
 Surgery alone 209 18  (8.6) 1.00
 5 x 5 Gy RT + surgery 221 26 (11.8) 1.41 0.75-2.67
TME trial* 0.418
 TME surgery alone 578 65 (11.2) 1.00
 5 x 5 Gy RT + TME surgery 553 54  (9.8) 0.85 0.58-1.25
CAO/ARO/AIO-94 trial& 0.609
 Preoperative CRT 241 39 (16.2) 1.00
 Postoperative CRT 248 36 (14.5) 0.88 0.54-1.44
EORTC 22921 trial ----
 Preoperative RT 122  0  (0.0) n.e.
 Preoperative CRT 125  0  (0.0) n.e.
 Preoperative RT + postoperative CT 122  4  (3.3) n.e.
 Preoperative CRT + postoperative CT 133  4  (3.0) n.e.
Polish Rectal Cancer trial† 0.657
 Preoperative CRT  81  8  (9.9) 1.00
 Preoperative 5 x 5 Gy RT  83 10 (12.0) 1.25 0.47-3.35
Due to differences in trial design and data collection, anastomotic leakage rates are not comparable 
between trials. Odds ratio (OR) not estimated (n.e.) for EORTC 22921 trial due to the small number of 
patients reported with anastomotic leakage. RT= radiotherapy; CRT=chemoradiotherapy. * Unknown for 1 
patient; & unknown for 6 patients; † unknown for 3 patients.
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Figure 3B shows the Kaplan-Meier curves for overall survival excluding the patients who 
died within 90 postoperative days. The difference between Figures 3A and 3B is caused 
by early postoperative mortality. Patients without anastomotic leakage and without a 
stoma fared better than the other three groups in the long-term. For patients without 
anastomotic leakage and without a stoma, without anastomotic leakage and with a 
stoma, with anastomotic leakage and without a stoma, and with anastomotic leakage 
and with a stoma, the 90-day mortality was 1.3%, 1.9%, 8.9%, and 5.8%, respectively. The 
difference in 90-day postoperative mortality was significant only between patients with 
and those without anastomotic leakage (P < 0.001).
table 5. Univariate and multivariable analyses for overall survival excluding patients with 90-day 
postoperative mortality.
Variable n Univariate analyses Multivariable analysis
HR 95% CI P-value HR 95% CI P-value
Gender <0.001 <0.001
 Female  902 1.00 1.00
 Male 1526 1.43 1.23-1.67 1.33 1.14-1.56
Age <0.001 <0.001
 ≤ 60  years  997 1.00 1.00
 61-70 years  984 1.16 0.98-1.38 0.084 1.23 1.04-1.46 0.016
 > 70  years  447 1.86 1.54-2.25 <0.001 2.06 1.70-2.49 <0.001
Distance of tumour to anal verge* 0.466 ----
 ≥ 5.0 cm 1939 1.00
 < 5.0 cm  464 1.08 0.88-1.32
TNM stage& <0.001 <0.001
 TNM stage 0/I  845 1.00 1.00
 TNM stage II  712 2.11 1.70-2.63 <0.001 2.08 1.67-2.26 <0.001
 TNM stage III  858 3.93 3.21-4.81 <0.001 4.02 3.28-4.92 <0.001
CRM involvement 0.045 0.704
 No 1848 1.00 1.00
 Yes   81 1.63 1.11-2.39 0.013 1.17 0.79-1.72 0.442
 Unknown  499 1.09 0.76-1.56 0.651 0.94 0.64-1.40 0.774
Anastomotic leakage† 0.030 0.034
 No 2199 1.00 1.00
 Yes  220 1.29 1.02-1.63 1.29 1.02-1.63
HR = hazard ratio; CI = confidence interval. * Unknown for 25 patients; & unknown for 13 patients; 
† unknown for 9 patients.
The association between diverting stomas and symptomatic anastomotic leakage 139
anastomotic leakage and disease-free and cancer-specific survival
Anastomotic leakage was associated with a worse DFS rate: HR 1.26 (95% CI 1.02-1.56; 
P = 0.033) in the univariate analysis and HR 1.24 (95% CI 1.01-1.56; P = 0.040) when 
adjusted for gender, age, and TNM stage. The disease-free survival curve is shown in 
Figure 2D. The 5-year disease-free survival rate was 66.9% (95% CI 64.9%-68.9%) for 
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figure 2. Local recurrence (A), overall survival for all patients (B) and after exclusion of patients with 
90-day postoperative mortality (C), disease-free survival (D), and cancer-specific survival (E) shown as 
cumulative incidence (A), Kaplan-Meier survival (B, C, D), and one minus cumulative incidence (E) curves 
separately for patients with and without anastomotic leakage.
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figure 3. Kaplan-Meier curves for overall survival shown separately for patients with/without anastomotic 
leakage and with/without a stoma, for all patients (A) and after exclusion of patients who died within 90 
postoperative days (B).
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patients without anastomotic leakage and 60.6% (95% CI 53.7%-67.5%) for patients 
with anastomotic leakage (P = 0.033). The estimates of the cumulative incidence for 
cancer-related mortality with death due to causes other than rectal cancer as competing 
risk, are shown in Figure 2E. No significant association could be found between cancer-
specific survival and anastomotic leakage (HR=1.12; 95% CI 0.83-1.52; P = 0.466); the 
5-year cancer-specific survival rate was 80.6% (95% CI 78.8%-82.4%) for patients without 
and 79.5% (95% CI 73.6%-85.4%) for patients with anastomotic leakage (P = 0.466).
Discussion
In the present study, patient data of 5 large randomised European trials for rectal cancer 
were pooled. Although the decision to create a stoma was left to the discretion of the 
surgeon, and each individual trial was not designed to study anastomotic leakage, the 
present results are interesting due to the large number of patients included from several 
European countries with a long and well documented follow-up. However, the results 
should be considered with caution. Patients with a diverting stoma had significantly 
less anastomotic leakage. Interestingly, leaks were associated with decreased disease-
free and overall survival, but oncological outcome measures (local recurrence, distant 
metastases and cancer-specific survival) were not affected.
Apart from the early consequences after a leak, such as sepsis-related mortality, 
anastomotic failure has been reported to be associated with decreased local control6-11 
and survival7,12,13. However, the association between anastomotic leakage and local con-
trol cannot be confirmed in all studies: in a population-based cohort study in Norway 
(1958 patients), anastomotic leakage did not result in an increased local recurrence 
rate.27 In the present study, anastomotic leakage was associated with both impaired 
disease-free survival and overall survival. When excluding early postoperative mortality, 
overall survival in the groups with and without anastomotic leakage is very similar in 
the first 4 years. After 4 years, however, overall survival in the group of patients who 
leaked, significantly decreased. In the present analysis, no association between anas-
tomotic leakage and cancer-specific survival was found, although in other studies such 
an association was demonstrated.7,12,13 Apparently, patients in the pooled database who 
developed anastomotic leakage had a higher chance of dying than those without anas-
tomotic leakage, but mainly due to other causes rather than rectal cancer. The observed 
consequences of anastomotic leakage - early and late morbidity and mortality - stress the 
importance of decreasing the incidence of (symptomatic) anastomotic leakage. One 
of the options is to create a diverting stoma. Recently, Matthiessen et al. performed a 
randomised trial in 234 patients who underwent a low anterior resection.19 Patients were 
randomised between a diverting loop stoma and no stoma. In this study it was found 
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that a diverting stoma decreased the rate of symptomatic anastomotic leakage. Hüser 
et al. did a systematic review and meta-analysis on the role of a diverting stoma in low 
rectal cancer surgery.28 In total 27 relevant retrospective and 4 randomised clinical trials 
were studied. The authors concluded that a diverting stoma reduces the rate of clinically 
relevant anastomotic leakage and is thus recommended in surgery for low rectal cancer. 
Nevertheless, stoma closure is also associated with morbidity and mortality.29,30 Besides, 
one out of five diverting stomas is never closed.31
In this analysis, patients without leakage and without a stoma had a better survival 
than those without leakage and with a stoma. As the pooled studies did not randomise 
between a stoma and no stoma (the decision to create a stoma was left at the discretion 
of the surgeon), there is likely a selection bias here. However, this reflects daily clinical 
practice and one can hypothesise that patients with a stoma had more comorbidity than 
those without a stoma. Even so, patients with a stoma had less symptomatic leakage. 
Besides, postoperative mortality after anastomotic leakage tends to be lower with a 
stoma (5.8% versus 8.9%), though this was not statistically significant. Due to the afore-
mentioned bias, the question whether the presence of a stoma (as an isolated variable) 
might improve overall survival, cannot be answered by this study.
Many observational studies have examined the association between preoperative 
treatment and anastomotic leakage. In national population-based studies in both 
Sweden and Norway, preoperative radiotherapy was found to be associated with 
anastomotic leakage.27,32 Similarly, in a case-control study using the Swedish Cancer 
Registry, preoperative radiotherapy was found to be a risk factor for anastomotic leak-
age.15 However, there is no association between an anastomotic leak and short-course 
radiotherapy in randomised trials.16,33 Due to different treatment protocols and other 
variance, anastomotic leakage rates cannot be fairly compared across trials, although 
comparison within each trial is valid. In none of the 5 randomised trials discussed here 
was a significant difference found in the anastomotic leak rate due to preoperative treat-
ment, but trials are notorious for not necessarily reflecting real practice. Indeed, based 
on the real life observational studies,15,27,32 other (confounding) factors that affect the 
selection of patients for preoperative radiotherapy contribute to the observed higher 
leak risk.
Anastomotic leakage cannot be avoided but their consequences can be limited by a 
diverting stoma.28,34 Apart from a diverting stoma, some have found that the placement 
of a pelvic drain limited the consequences of anastomotic leakage,16 although others 
could not find such an association.35 Nevertheless, prompt diagnosis and treatment 
of anastomotic leakage are necessary to limit morbidity and mortality. Standardised 
postoperative surveillance results in early identification of and reduced mortality from 
symptomatic anastomotic leakage.4
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aBstract
aim
This study aimed at testing feasibility of a standardised postoperative surveillance pro-
tocol to reduce delay in the diagnosis of anastomotic leakage (AL) and, subsequently, 
mortality.
Material and methods
Patient files of patients operated between 1996 and 1999 were reviewed and used as 
historical controls (n = 1066). As a result, a protocol for standardised postoperative 
surveillance was designed using easily accessible, clinical parameters. Between August 
2004 and August 2006, all operated patients with a colorectal anastomosis (n = 223) 
were prospectively subjected to this standardised surveillance.
results
AL was diagnosed in 7.0% of patients in the historical control group and 9.4% of patients 
in the standardised surveillance group. AL mortality decreased from 39% to 24% with 
standardised surveillance (n.s.). The delay in AL diagnosis was significantly reduced dur-
ing standardised surveillance (4 versus 1.5 days, P = 0.01), which was confirmed in the 
multivariate analysis.
conclusion
With non-standardised postoperative monitoring, AL was associated with a high mortal-
ity rate. Patients were subjected to several additional tests, which were not primarily 
useful to diagnose AL. Standardised postoperative surveillance for AL was introduced 
successfully and resulted in a shorter delay between the first signs and symptoms to the 
confirmation of AL.
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introDuction
Anastomotic leakage (AL) is a feared complication after colorectal surgery causing 
morbidity and mortality.1 Different percentages are published for the incidence of AL, 
varying between 1 and 25%, partly depending on the method of evaluation and the 
level of the anastomosis.2-5 AL does not only result in increased and serious morbidity 
and mortality,6-9 but has also been associated with a higher local recurrence rate after 
curative treatment of colorectal malignancies.10,11
In literature, different mortality rates after AL are reported.8,12,13 In the evaluation 
of surgery, slowly, more attention is focussed on adverse events such as postopera-
tive morbidity and mortality.14 AL can never be reduced to zero and therefore it is of 
relevant importance to control the negative and sometimes fatal sequelae in case an 
AL occurs. Consequently, not only the occurrence but also the clinical outcome after 
AL might be considered as a performance indicator of surgical care. Firstly, this study 
aimed at investigating the occurrence of AL and associated mortality in several training 
hospitals in the Netherlands. Secondly, we hypothesised that the interval between first 
signs or symptoms and action on AL can influence the clinical outcome. As a result, a 
standardised postoperative surveillance protocol was designed which aimed at reduc-
ing the delay in the diagnosis of AL and subsequently at reducing the mortality rate. The 
feasibility of this surveillance protocol was studied prospectively.
Patients anD MethoDs
retrospective analysis
Patient files from all patients of three training hospitals (Haga Hospital location Leyen-
burg (The Hague), Haga Hospital location Red Cross (The Hague) and Albert Schweitzer 
Hospital (Dordrecht)) in whom a colorectal anastomosis was created were reviewed 
(part of the data previously published15 and presented at the Surgical Infection Society 
Meeting in 200316). As AL is an issue after both resections for malignant and benign 
diseases, we included all resections in this period in the study. Malignancies were colon 
or rectal cancer, whereas benign diseases included resections for polyps, ulcerative coli-
tis, diverticulosis, Crohn’s disease, and continuity restoration after a stoma. Delay in the 
diagnosis of AL was calculated as the period from the first signs of clinical deterioration 
to confirmation of the diagnosis. These signs consisted of the presence of fever (tem-
perature >38.0°C), ileus (absence of passage of faeces or air after the third postoperative 
day) or an elevated number of leukocytes in the blood count (>12.0 x 109/l).
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Design of the protocol for standardised postoperative surveillance for al
The results of the retrospective study led to the design of a protocol for standardised post-
operative monitoring aiming to reduce the delay in the diagnosis of AL and subsequently 
to reduce AL related mortality. Literature was used to select postoperative variables which 
are prognostic for AL. Furthermore, the items had to be easily available during normal 
patient visits. The final selection process was done by MdD, MB and WS and are shown in 
Table 1. The items related to laboratory tests were checked at least every other day. For 
each item, points were given as shown in Table 1. If an item was scored as normal or if an 
item was not scored (such as items related to laboratory investigation), no points were 
given, whereas if the item was scored as abnormal, 1 or 2 points were given. The weight 
of an abnormal score was depending on the diagnostic importance of that specific item 
(determined by MdD, MB and WS). The sum of all items gave a score: the leakage-score. In 
case of more than one score determined within 24 h, the worst score was used.
table 1. Items scored in the prospective study.
Item Normal value Score 
(points)
Abnormal value Score 
(points)
General
 Fever ≤ 38.0°C 0 > 38.0°C 1
 Heart rate ≤ 100/min 0 > 100/min 1
 Respiratory rate ≤ 30/min 0 > 30/min 1
 Urinary production ≥ 30 ml/h or 700 ml/day 0 < 30 ml/h or 700 ml/day 1
 Mental status Normal mental status 0 Agitation or lethargic 2
 Clinical condition Stable or improving condition 0 Deterioration 2
Local physical examination
 Signs of ileus No ileus 0 Ileus 2
 Gastric retention No gastric retention 0 Gastric retention 2
 Fascial dehiscence No fascial dehiscence 0 Fascial dehiscence 2
  Abdominal pain, other 
than wound pain
No pain other than wound 
pain
0 Pain other than wound 
pain
2
Laboratory investigation
 Signs of infection No increase in leukocyte 
number or CRP
0 Increase of ≥ 5% in 
leukocyte number or CRP
1
 Kidney function No increase in urea and 
creatinine
0 Increase of ≥ 5% in urea or 
creatinine
1
Diet
 Nutritional status Normal diet 0 Tube feeding/TPN 1/2
The leakage-score is the sum of all points. If a patient receives both tube feeding and total parental 
nutrition (TPN), only tube feeding is scored (1 point). CRP = C-reactive protein.
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the prospective cohort study
All patients, in whom an intra-abdominal colorectal anastomosis was created in Haga 
Hospital location Leyenburg from 1 August 2004 to 1 August 2006, were monitored 
using the standardised postoperative surveillance protocol. Resections were performed 
both for malignant and benign diseases. Daily, all patients were scored by the treating 
surgical resident or surgeon (Table 1). The leakage-score was linked to a decision tree 
indicating the diagnostic and treatment actions that had to be taken (Figure 1). Patients 
with clinically proven AL (faecal leakage through drains or wounds) bypassed the diag-
nostic part of the decision tree. Patients were followed until one of the three end-points 
was reached: AL, postoperative mortality or discharge from the surgical ward. The first 
symptomatic day of AL was defined as the day after the last day with zero leakage-points 
before AL was diagnosed. The difference between the first symptomatic day and the day 
of confirmation of AL was considered to be the delay in the diagnosis of AL.
≤ 3 points 4 –7 points ≥ 8 points
No action Re-evaluation and 
laboratory investigation 
within 12 hours; CT-
scan with rectal 
contrast?
CT-scan with
rectal contrast
Positive CT-scan 
(confirmed AL):
Initiate treatment. 
Relaparotomy?
Negative CT-scan (no AL):
Other focus?  Relaparatomy? 
If not, re-evaluation with laboratory
investigation after 12 hours.
Clinically proven 
AL
Leakage-score
figure 1. Decision tree of the leakage-score indicating which actions should be taken with each score. 
Clinically proven anastomotic leakage (AL; faeces in a drain or wound) was treated identically as a positive 
CT-scan.
statistical analyses
Data were analysed with the SPSS package (SPSS 14.0 for Windows; SPSS Inc., Chicago, 
IL). In the analysis for delay, patients from the retrospective analysis were used as his-
torical controls. Univariate analyses with categorical variables were performed with a χ2 
test. Delay and leakage-score were univariately studied using the non-parametric Mann-
Whitney test. The multivariate analysis for delay was performed with a ranked ANOVA. A 
two-sided P-value of ≤ 0.05 was considered statistically significant.
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results
historical controls
In total 1066 resections were performed between 1996 and 1999. Demographic data 
are shown in Table 2. In this period, 29 patients were treated twice during separate 
admissions. As these patients were subjected to a risk of AL during each procedure, 
each admission was considered as a separate patient. AL was diagnosed in 75 patients. 
Overall mortality was 7.4%. Mortality after the diagnosis AL was 39%.
Before the diagnosis AL was made, several additional diagnostic investigations were 
performed to exclude other complications such as pneumonia or urosepsis. In 58 of AL 
patients the following imaging and laboratory studies were performed in the period 
before confirmation of AL: chest X-ray (n = 48), urine sediment test (n = 22), ultrasound 
table 2. Demographic data of patients.
Variable Historical controls Patients with 
standardised 
surveillance
n = 1066 n = 223
Gender
 Male
 Female
509
557
115
108
Age
 < 70 years
 ≥ 70 years
480
586
 95
128
Primary disease*
 Malignancy
 Benign disorder
736
314
147
 76
Timing of procedure
 Elective
 Emergency
906
160
189
 34
Procedure+
 Right sided resection
 Left sided resection
 Other procedure
391
643
 32
101
106
 16
Hospital
 A
 B
 C
335
290
441 223
* Missing for 16 patients; + Right side resection includes ileocecal resection, right sided hemicolectomy, 
transversectomy, and removal of a stoma in ascending or transverse colon; left sided resection includes 
left sided hemicolectomy, sigmoid resection, low anterior resection, proctocolectomy, and removal of 
a stoma in descending colon or sigmoid; other procedure includes subtotal colectomy or unspecified 
procedures.
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investigation (n = 25), CT-scan without contrast enhancement (n = 10), and plain X-ray 
of the abdomen without contrast (n = 8). In 21, 19 and 18 patients, respectively one, 
two and more than two of these additional diagnostic tests were used to exclude other 
complications before AL was diagnosed.
Prospective cohort study with standardised surveillance
In total 224 consecutive resections were performed in the period with standardised 
postoperative follow-up. During this period 6 patients underwent two resections during 
separate procedures. One patient was transferred to another hospital and was lost to 
follow-up and was excluded from all analyses. Demographic details of the remaining 
223 patients are shown in Table 2. Twenty-one patients were diagnosed with AL. In total 
14 patients died postoperatively. Nine patients died of causes not related to AL: respira-
tory complications (n = 3), cardio-vascular complications (n = 4), and progression of the 
malignant disease (n = 2). In all these cases AL was excluded as cause of death. Five 
patients died after AL was diagnosed.
leakage-score
The leakage-score was determined daily for every patient. The median score for patients 
diagnosed with and without AL per day is shown in Figure 2. A significant higher score 
for patients with AL was found from day 5 to 9. When comparing the median of the 
highest leakage-score for patients with and without AL, this difference was significant: 7 
points (range 0-13) versus 3 points (range 0-10), P < 0.001.
*
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figure 2. Median scores of patients with and without anastomotic leakage per day. * Indicates a 
significant difference between patients with and without anastomotic leakage (Mann-Whitney test).
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the effects of standardised surveillance on the diagnosis of anastomotic 
leakage
In the period of standardised surveillance, three patients were dismissed from the 
hospital without any signs or symptoms on day 6, 7 and 17, respectively. These patients 
were later readmitted and AL was diagnosed, of whom one patient eventually died. As 
no information about delay is available for these patients, these patients could not be 
considered in the analysis for delay. However, these patients were included in all other 
analyses.
In Table 3 the univariate comparison is shown between patients subjected to 
standardised monitoring compared with patients without standardised postoperative 
surveillance. If the three patients who were discarded from the hospital and readmitted 
before AL was diagnosed were included in the analysis for the day of the diagnosis, no 
significant difference could be found (median 8 days in the historical control group ver-
sus median 6 days after standardised surveillance, P = 0.22). However, if these patients 
were excluded from the analysis, as these patients were not monitored after discharge, 
the difference was statistically significant (median 8 days versus 6 days, P = 0.02). Never-
theless, the delay in the diagnosis of AL was significantly shorter for patients monitored 
with standardised postoperative surveillance (median 4.0 versus 1.5 days, P = 0.01). 
If the analysis was performed using the same definition of delay in the standardised 
surveillance group as was used for the historical controls (temperature above 38.0°C, 
ileus after day 3 or leukocytes blood count >12.0 x 109/l), the delay was still significantly 
shorter (median delay 4.0 days (range 0-21) for historical controls and 3.0 days (range 
0-14) after standardised surveillance, P = 0.03). In the multivariate analysis, in which 
patients from both periods are combined, the effects of gender, age, primary disease, 
timing, procedure, and hospital of treatment were not found to be significantly related 
to delay (data not shown). Treatment during the period with standardised postoperative 
surveillance was the only variable that was independently associated with an earlier 
diagnosis (P = 0.03). If for the calculation of delay in the prospective study a cut-off 
table 3. Univariate comparison between controls without standardised postoperative surveillance and 
patients with standardised surveillance.
Historical controls Standardised 
surveillance
P-value
Time to diagnosis since surgery (days) 0.22
 Median
 Range
8.0
1–58
6.0
4-47
Delay in the diagnosis of AL (days) 0.01
 Median
 Range
4.0
0–21
1.5
0–21
Mortality rate of AL diagnosed patients 29/75 5/21 0.21
AL = anastomotic leakage.
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point of 4 leakage-points was used instead of 1 point or if the definition of delay as used 
for the historical controls was used for the group with standardised surveillance, the 
results were comparable (data not shown). The mortality rate decreased when patients 
were monitored with standardised surveillance, but this difference was not statistically 
significant (Table 3).
Discussion
Delay in the diagnosis of anastomotic leakage
AL after colorectal surgery is a frequently occurring, important, postoperative complica-
tion, associated with a relatively high mortality rate.8,9,12,13,17,18 Several studies indicated 
that delay was associated with increased mortality.13,19 We studied AL in a retrospec-
tive study and developed a protocol for standardised postoperative surveillance, to 
reduce the delay in the diagnosis and treatment of AL and subsequently to reduce AL 
associated mortality. AL is found both after malign and benign diseases, although the 
majority of resections is performed for malignancies. Consequently, a complete cohort 
of patients was studied, which included both patients with benign and malign diseases, 
to prevent patient selection. In the present analysis, it is shown that it is feasible to 
introduce and perform postoperative standardised surveillance for AL after colorectal 
surgery. This standardised surveillance resulted in a shorter period of delay (median 1.5 
day compared to 4 days), independent from gender, age, primary disease, timing of the 
procedure, type of resection, and hospital of treatment. It should be noted, that it can-
not be excluded that the implementation of a standardised postoperative surveillance 
for AL also increased the awareness of AL, resulting in an earlier diagnosis. However, also 
in the period 1996-1999 surgeons were familiar with AL. Apparently, awareness of AL 
alone was insufficient to result in a earlier diagnosis of AL, as it was found not to be easy 
to notice clinical deterioration in an early stage without the standardised postoperative 
surveillance protocol.
Mortality after anastomotic leakage
Seven percent of patients treated in the period 1996-1999 were diagnosed with AL, 
which is in accordance with the percentage reported in literature.2-5 The observed 
mortality rate after AL was 39%. Although differences exist in the diagnosis of AL (symp-
tomatic AL versus radiologically proven AL) the highest mortality rate found in literature 
was reported by the West of Scotland and Highland Anastomosis Study Group.12 In this 
study, 40 patients of 1004 had symptomatic AL, of whom 33% died. In general, a mor-
tality rate below 22% is reported in literature.8,9,13,17,18 In our historical control patients, 
the relatively large delay could have contributed to the high mortality rate, similar to 
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findings by others.13,19 In all patients who died after AL, their death was considered to 
be related to the AL, which might have resulted in a higher mortality rate than reported 
in other studies. In the standardised surveillance group five patients died resulting in 
a decreased mortality rate of 24%, including one patient who died 19 days after the 
diagnosis of AL due to an aspiration pneumonia and myocardial infarction and one 
patient who died 125 days after AL due to a palliative treatment setting. Due to this 
small patient population (n = 5) and differences in the definition of AL mortality, a safe 
comparison of the mortality rate of the last period with literature can hardly be made.
Variability in diagnostic management
One of the possibilities that might explain the delay in diagnostic management, which 
was observed in patients treated between 1996 and 1999, is the finding that in 77% of 
patient various diagnostic procedures were performed to exclude other complications 
instead of an appropriate diagnostic test for AL, such as a CT-scan with rectal contrast.20 
These additional tests might have resulted in additional delay in the diagnosis of AL. 
According to the adage “treat first what kills first”, exclusion or confirmation of the diag-
nosis AL (and subsequent treatment) have to take priority in patients with any suspicion 
of AL after colorectal surgery.
Development of the leakage-score
To reduce variability, a standardised postoperative surveillance protocol was developed 
which aimed at reducing delay in the diagnosis of AL and subsequently at reducing 
mortality. Literature was studied to select postoperative variables which have been 
associated with AL before. In 1991, the Surgical Infection Study Group described the 
clinical signs of AL which included fever, increased leukocyte count and increased CRP 
level.21 Furthermore, Systemic Inflammatory Response Syndrome (SIRS) was indicated 
to be a sign of AL.21,22 The following signs could also occur with SIRS: changed mental 
status, oliguria, increased levels of serum creatinine, and ileus.23 Finally, the following 
other postoperative signs were associated with AL: pelvic pain24, renal failure13, and 
peritonitis25. Although various groups have described different postoperative param-
eters that were associated with AL, no scoring system was yet designed nor tested 
prospectively in a clinical setting. We designed a scoring list, in which most of the above 
mentioned parameters were included. As no literature was available on the weight of 
the variables, we determined the weight of the variable based on our opinion of clinical 
relevance. Most items used to determine the “leakage-score” could be easily obtained 
during history taking and physical examination, and should normally be recorded daily 
in the patient’s file.
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limits of the analysis
A limit of the present analysis is that prospectively collected data from a single centre 
are compared with historical controls from three centres. Ideally, a randomised trial 
is performed, however this is not possible as the investigators will be biased by their 
knowledge of the protocol when treating a patient in the “conventional” arm. Perform-
ing a study in different centres raises the question whether observed differences could 
be explained just by differences between these centres. If in the present study the 
analyses were repeated with results from Haga Hospital location Leyenburg only, the 
results were similar (data not shown). Therefore, the present study using historical data 
is the best available evidence, although the results should be interpreted with caution.
A difference in the data collection existed between the two periods: retrospective 
versus prospective. In the historical controls the presence of fever, ileus or an elevated 
number of leukocytes were considered to be reliably recorded and used in the definition 
of delay. For comparison, in the prospective study any sign or symptom was considered 
in the calculation of delay. Therefore, it is likely that signs for anastomotic leakage were 
detected earlier in the prospective trial, which could have resulted in a relatively longer 
period of delay in the group followed with standardised surveillance. However, using the 
definition of delay of the retrospective analysis for the standardised surveillance group 
still resulted in a significant decrease in delay (median 4 days compared with median 3 
days, P = 0.03). Apart from that, the period of delay in the historical control group could 
be underestimated. For this group, patient’s files were reviewed, in which the first signs 
could have been underreported. During a prospective study, this problem is less likely. 
Due to these differences in data collection the delay could have been underestimated 
in the historical control group, resulting in an underestimation in the decrease in delay 
with standardised surveillance.
further improvements of the leakage-score
In the leakage-score several items were considered. It could however be questioned 
whether the used cut-off values were chosen optimally. Besides, the present analysis did 
not study whether all items were weighted properly in the scoring system. Neverthe-
less, in Figure 2 is shown, that the leakage-score as currently defined, could be used to 
distinguish the group of patients with and without AL. In order to optimise the leakage-
score, a registration project has been launched in several Dutch centres, in which various 
parameters are collected prospectively for a large number of patients with a colorectal 
anastomosis in order to come to a more validated scoring system. Eventually, this might 
result in a modified DUtch LeaKage (DULK) scoring list.
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conclusion
AL is a serious complication after colorectal surgery. With non-standardised postopera-
tive monitoring, AL was associated with a high mortality rate. Patients were subjected 
to several additional tests, which were not useful to diagnose AL. Standardised postop-
erative surveillance for AL was introduced successfully and resulted in a shorter delay 
between the first signs and symptoms to the confirmation of AL. In the daily clinical 
practice, standardised postoperative surveillance after colorectal surgery could be 
a guide for surgical residents who are developing clinical experience. Its usage could 
result in improved postoperative care. To further validate the scoring list and decision 
model, a larger group of patients is necessary. Recently, we started a registration project 
in several Dutch hospitals. In this project patients are postoperative monitored as nor-
mal, without usage of the decision model. Of all patients, various parameters are scored 
to determine which set of parameters is an early predictor of AL. Eventually, this project 
will result in an improved and validated DUtch LeaKage scoring list and decision model.
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aBstract
Background
In many patients with rectal cancer, defunctioning stomas are created to limit the con-
sequences of anastomotic leakage. Although intended to be temporary, a substantial 
proportion of these stomas might never be reversed for various reasons. We aimed to 
describe stoma policy by use of data from the total mesorectal excision (TME) trial in 
patients with rectal cancer and to identify factors that limit stoma reversal.
Methods
924 Dutch patients with rectal cancer who underwent a low anterior resection were 
selected from the TME trial, a prospective, randomised multicentre trial studying the 
effects of short-term preoperative radiotherapy in 1861 patients who underwent TME. 
Creation of stomas and time to stoma reversal were analysed retrospectively by use of 
multivariate analysis.
findings
In 523 of 924 (57%) patients, a primary stoma (defined as a stoma created at the time 
of TME) was constructed after a low anterior resection. Geographical differences in the 
number of primary stomas constructed were reported throughout the Netherlands. 19% 
of stomas that were created were never reversed. Postoperative complications and sec-
ondary constructed stomas (defined as a stoma created during a second or subsequent 
procedure after TME) were associated with a high likelihood of a permanent stoma. 
However, perioperative complications were not a limiting factor for stoma closure.
interpretation
Postoperative complications are an important limiting factor for stoma reversal because, 
after occurrence of these complications, patients and surgeons might be reluctant to 
reverse the stoma, so a substantial proportion of these stomas are never closed. Future 
guidelines for stoma creation and closure should consider these factors.
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introDuction
Stomas are created frequently in patients undergoing surgery for rectal cancer to limit 
the consequences of anastomotic leakage. Colostomies created after abdominoperi-
neal resections are permanent. However, after a low anterior resection, a defunctioning 
stoma -such as a diverting colostomy- is constructed to protect the healing anastomosis, 
and these stomas are intended to be temporary. Although studies have not shown a 
substantial difference in the incidence of anastomotic leakage when comparing patients 
with and without a diverting stoma,1,2 we have previously reported a substantial de-
crease in clinically evident anastomotic leakage in patients with stomas.3 Furthermore, 
defunctioning stomas might mitigate the consequences of symptomatic anastomotic 
leakage, a notion that is supported by the decreased proportion of patients with a leak 
needing secondary surgery.1-3
The decision to create a stoma is affected by factors such as availability of high-quality 
stoma care, capability of stoma handling, and risk of stoma-related complications. Stoma 
complications occur in up to 30% of patients with a stoma.4 These complications affect 
patients’ daily activities and a relation between the number of stoma-care problems and 
the amount of restriction in social activities has been reported.5 These stoma-related 
difficulties might be permanent because some of these stomas will never be closed.6 The 
quality of life of a patient with a stoma is decided by multiple factors, such as patients’ 
preferences and sociodemographical characteristics. Engel and coworkers found that 
patients undergoing a low anterior resection without creation of a stoma had better 
quality of life than did patients treated with an abdominoperineal resection and given a 
stoma.7 By contrast, we previously reported that overall perceived health in patients who 
had undergone an abdominoperineal resection was not lower than that in patients who 
had been treated with a low anterior resection.8 A recent Cochrane review9 suggested 
that published studies challenged the assumption that patients who had undergone 
anterior resection fare better, but that data from larger, better designed and executed 
prospective trials are needed to answer the question of whether anterior resected pa-
tients had a better quality of life.
We aimed to describe the policy of stoma formation in patients entered into the TME 
trial for rectal cancer and to identify factors that limit reversal of these stomas.
MethoDs
Patients and procedures
The TME trial included 1861 patients between 1 January 1996 and 31 December 1999.10 
This randomised multicentre trial asessed TME surgery with or without preoperative 5 
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x 5 Gy radiotherapy. Patients aged 18 years or over with clinically resectable adenocar-
cinoma of the rectum were randomly assigned to either radiotherapy followed by TME, 
or TME alone. The trial had no age limit. Radiotherapy, surgery, and pathology were 
standardised and strictly quality controlled, as described previously.11 Both the decision 
to construct a stoma and the type of stoma were at the discretion of the surgeon, as 
defined in the protocol. A stoma created at the time of the TME procedure was defined 
as a primary stoma, and a secondary stoma was defined as a stoma created during a 
second (or following) procedure after the TME procedure. Follow-up of all patients was 
done according to trial protocol. The study was approved by all participating institutes 
and central and local ethics committees. All patients gave informed consent.
For the current analysis, all relevant data were collected at the time of trial. Only 
patients undergoing low anterior resection who were eligible for trial participation were 
studied in this analysis. Inclusion criteria have been reported previously.10 Only Dutch 
patients were included because detailed and reliable information on patient and treat-
ment characteristics was available for these patients, and data checking with hospital 
reports was done for these patients. Stomas created after a local recurrence were not 
included in the analysis. Exclusion criteria have been reported previously.10
statistical analysis
Data were analysed with the SPSS package (version 12.0 for Windows; SPSS Inc., Chi-
cago, IL, USA). Time to stoma reversal was analysed by use of the Kaplan-Meier method. 
Univariate log-rank and multivariate Cox regression analyses were used to study limit-
ing factors for stoma reversal. The initial list of prognostic factors was based on clinical 
importance decided by the investigators (MdD, TW, CvdV). Each of these variables was 
retained for the multivariate analysis if either the univariate effect of that variable was 
significant or if the interaction with timing of stoma (primary versus secondary) was 
significant. In this selection process of variables, a P-value of ≤ 0.100 was deemed to be 
significant. For significant interactions, the results are presented separately for primary 
and secondary stomas, and the interaction was included in the multivariate Cox regres-
sion analysis. For non-significant interactions, the overall hazard ratio is shown. Except 
in the above mentioned selection process, a two-sided P-value of ≤ 0.050 was deemed 
to be statistically significant.
The following variables were studied as limiting factors for stoma closure: preopera-
tive radiotherapy; sex; age; body-mass index; timing of stoma (primary versus second-
ary); type of stoma (ileostomy versus colostomy for primary stomas; end colostomy 
or ileostomy versus diverting stoma for secondary stomas); tumour-node-metastasis 
(TNM) stage; distance of the tumour to the anal verge; perioperative complications (in-
cluding bleeding, organ injury, and tumour spill); postoperative infective complications 
(including wound infection, urinary tract infection, abscess, sepsis, and fever without 
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known cause); postoperative general complications (including thrombosis, embolism, 
cholecystitis, pulmonary, renal, neurological, and cardiac problems); postoperative sur-
gical complications (for primary stomas only, including wound dehiscence, anastomotic 
leakage, ileus, postoperative bleeding, fistula, and perforation); and recurrence (either 
local recurrence defined as evidence of a tumour within the lesser pelvis or perineal 
wound, or distant recurrence defined as evidence of a tumour in any other area) after 
stoma creation as identified by: clinical assessment every 3 months in the first year and 
annually thereafter for at least 2 years; also, annual liver imaging and endoscopy. Overall 
recurrence status was entered as a time-dependent covariate.
results
Median follow-up of patients who were alive at the time of analysis was 7.1 years (range 
2.5 to 9.8 years). Primary stomas were created in 523 of 924 (57%) patients who under-
went low anterior resections (Figure 1). 329 (63%) of these stomas were ileostomies, and 
the remaining 194 patients (37%) received a colostomy. Characteristics of the patients 
924 patients had low anterior resection
174 
ileostomy
1530 patients enrolled
50 inelegible
7   no adenocarcinoma
26   other or previous malignancy
3   previous treatment
1   transanal resection
6   double tumour
5   sigmoid carcinoma
2   irresectable at randomisation
1480 patients assessable
37 no resection
519 other than low anterior 
resection
459 preoperative radiotherapy
275 primary stoma 184 no stoma 248 primary stoma 217 no stoma
101 
colostomy
142 
no stoma
42 
secondary 
stoma
155 
ileostomy
93 
colostomy
166 
no stoma
51 
secondary 
stoma
465 no preoperative radiotherapy
figure 1. TME trial profile. Patients were randomised to TME surgery alone and TME surgery with 
preoperative radiotherapy at the time of inclusion.
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and tumours are shown in Table 1. The Netherlands comprises nine comprehensive 
cancer centre regions, each serving a different part of the country. The geographical 
differences in primary stoma construction within the rectal cancer TME trial are shown 
in Figure 2.
Stomas were created at a secondary surgical procedure in 93 of 401 (23%) patients 
for reasons other than a recurrence. Stomas were created after a recurrence in four 
patients (0.4%), which were not included in this analysis. In one patient, a secondary 
stoma was created in conjunction with an abdominoperineal resection, which was done 
because of a positive resection margin. This patient was deemed to have had a perma-
nent stoma and was, therefore, discarded from all further analyses. Of the 93 patients 
who had temporary stomas created at a secondary surgical procedure, 58 of 93 (62%) 
had diverting stomas, whereas 29 of 93 (31%) had end ileostomies or colostomies. The 
type of secondary stoma was unknown in six (6%) patients. The reasons for formation of 
secondary stomas are shown in Table 2. These secondary procedures were undertaken 
because of clinical anastomotic leakage in 61 of 93 (66%) patients. Taken together, 616 
of 924 (67%) patients initially treated with a low anterior resection received a temporary 
stoma, either at initial or at secondary surgery.
table 1. Characteristics of patients included in the analysis.
Variable No primary stoma (%) Primary stoma (%)
Preoperative radiotherapy
 No
 Yes
217 (54)
184 (46)
248 (47)
275 (53)
Sex
 Male
 Female
234 (58)
167 (42)
336 (64)
187 (36)
Age at randomisation (years)
 Mean
 Standard deviation
63.3
11.2
63.7
10.6
TNM stage
 TNM Stage 0
 TNM Stage I
 TNM Stage II
 TNM Stage III
 TNM Stage IV
 11  (3)
120 (30)
106 (26)
141 (35)
 23  (6)
  9  (2)
165 (32)
124 (24)
204 (39)
 21  (4)
Distance tumour to anal verge
 < 5.0   cm
 5.0-9.9 cm
 ≥ 10.0  cm
 18  (4)
174 (43)
209 (52)
 49  (9)
288 (55)
186 (36)
Type of anastomosis*
 End-to-side
 End-to-end
 Pouch
257 (64)
 55 (14)
 87 (22)
293 (56)
 52 (10)
174 (33)
* Data missing for six patients. Percentages might not add up to 100% due to rounding.
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97% (95% CI 95%-98%) of stomas that were reversed were closed within the first 
year after surgery. The median time to stoma reversal was 4.1 months (range 1.3-33.1 
months). 19.0% (16%-22%) of all stomas were not removed during follow-up. No sig-
nificant difference was found between closure rate of ileostomies (15% not reversed 
[11%-19%]) and colostomies (13% not reversed [7%-18%]; P = 0.474; Figure 3).
Table 3 shows the univariate and multivariate analyses on limiting factors for stoma 
closure. In the univariate analysis, a relation between timing of the stoma, preopera-
n=141 n=69 n=48 n=56 n=73 n=135 n=13 n=141 n=248
0
10
20
30
40
50
60
70
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90
100
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n = 141
Comprehensive cancer centre region
P
rim
ar
y
st
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a 
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)
IKL
n = 69
IKMN
n = 48
IKN
n = 56
IKO
n = 73
IKR
n = 135
IKST
n = 13
IKW
n = 141
IKZ
n = 248
figure 2. Primary stomas per comprehensive cancer centre region in the TME trial. IKA = comprehensive 
cancer centre Amsterdam; IKL = comprehensive cancer centre Limburg; IKMN = comprehensive cancer 
centre Middle Netherlands; IKN = comprehensive cancer centre North Netherlands; IKO = comprehensive 
cancer centre East; IKR = comprehensive cancer centre Rotterdam; IKST = comprehensive cancer centre 
Stedendriehoek Twente; IKW = comprehensive cancer centre West; IKZ = comprehensive cancer centre South.
table 2. Reasons for secondary-stoma creation.
Reason for secondary-stoma formation n (%)
Anastomotic leakage 61 (66)
Abscess, sepsis or peritonitis 18 (19)
Fistula  6  (6)
Bleeding  1  (1)
Stenosis or ileus  2  (2)
Other  3  (3)
Unknown  2  (2)
Percentages might not add up to 100% due to rounding.
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tive radiotherapy, and TNM stage was found. The results for these variables are shown 
separately for primary and secondary stomas in Table 3. Figure 4 shows the rate of stoma 
closure per age group (P = 0.046), and the rate of stoma closure for primary and second-
ary stomas. During follow-up, the closure rate was 86% (83%-89%) for primary stomas 
and 49% (37%-61%) for secondary stomas (P < 0.0001).
In the multivariate analysis, preoperative radiotherapy was significantly associated 
with a decreased likelihood of stoma reversal for secondary stomas, but not for primary 
stomas. Older age, secondary stoma construction, an end colostomy or ileostomy, any 
postoperative complication, and a recurrence were identified as limiting factors for 
stoma reversal. By contrast, no significant difference was reported for perioperative 
complications.
Discussion
This study describes the policy on stoma construction used in the TME trial. As 84 of 
102 hospitals in the Netherlands participated in this trial, the present study indicates 
common practise in the Netherlands. However, all extrapolations should be made care-
fully, because no information on treatment policy in the nontrial setting was studied 
and only Dutch patients entered into the TME trial are included in this analysis. We can 
assume that surgeons did not want to increase the risk of symptomatic anastomotic 
leakage, and so created more stomas in patients treated with preoperative radiotherapy 
Numbers at risk
Ileostomy 329 48         36          32          30          24
Colostomy  194 26         15          12          12 10 
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figure 3. Kaplan-Meier curve for stoma reversal of primary ileostomies and colostomies.
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table 3. Univariate log-rank and multivariate Cox regression analyses for factors limiting stoma reversal.
Variable n Univariate analyses Multivariate analysis
   HR 95% CI P-value HR 95% CI P-value
Radiotherapy, primary stoma
 No
 Yes
248
275
1.00
1.00 0.82 – 1.21
0.960
 
1.00
1.13 0.92 – 1.38
0.244
 
Radiotherapy, secondary stoma
 No
 Yes
 51
 42
1.00
0.41 0.19 – 0.87
0.021
 
1.00
0.34 0.15 – 0.77
0.010
 
Sex*
 Female
 Male
220
396
1.00
1.01 0.83 – 1.23
0.923
   
----
 
Age
 < 60  years
 60-69 years
 ≥ 70  years
204
226
186
1.00
1.03
0.77
0.82 – 1.28
0.61 – 0.99
0.046
0.815
0.038
1.00
1.10
0.79
0.88 – 1.38
0.62 – 1.02
0.029
0.394
0.071
Body mass index*†
 < 25.0    kg/m2
 25.0-29.9 kg/m2
 ≥ 30.0    kg/m2
240
213
 50
1.00
1.17
1.08
0.94 – 1.47
0.75 – 1.55
0.369
0.158
0.681   
----
 
Distance*
 < 5.0     cm
 5.0 – 9.9 cm
 ≥ 10    cm
 57
330
229
1.00
1.01
1.12
0.72 – 1.42
0.79 – 1.59
0.608
0.939
0.536   
----
 
TNM stage, primary stoma
 0-II
 III-IV
298
225
1.00
0.88 0.72 – 1.08
0.226
 
1.00
0.90 0.73 – 1.10
0.309
 
TNM stage, secondary stoma
 0-II
 III-IV
 57
 36
1.00
1.79 0.91 – 3.52
0.090
 
1.00
1.71 0.85 – 3.45
0.134
 
Type of primary stoma*
 Colostomy
 Ileostomy
194
329
1.00
0.93 0.76 – 1.14
0.474
   
----
 
Type of secondary stoma‡
 Diverting stoma
 End ileostomy or colostomy
 58
 29
1.00
0.13 0.03 – 0.55
0.006
 
1.00
0.14 0.03 – 0.59
0.008
 
Perioperative complication
 No
 Yes
422
194
1.00
0.84 0.68 – 1.03
0.089
 
1.00
0.84 0.68 – 1.04
0.103
 
Infectious postoperative complication
 No
 Yes
439
177
1.00
0.50 0.39 – 0.63
<0.0001
 
1.00
0.65 0.51 – 0.83
0.0005
 
General postoperative complication
 No
 Yes
429
187
1.00
0.61 0.49 – 0.77
<0.0001
 
1.00
0.73 0.57 – 0.93
0.012
 
Surgical postoperative complication,
primary stoma only
 No
 Yes
350
173
1.00
0.58 0.46 – 0.72
<0.0001
 1.00
0.62 0.49 – 0.79
0.0001
Local or distant recurrence§
 No
 Yes
431
156
1.00
0.46 0.28 – 0.75
0.002
 
1.00
0.36 0.22 – 0.59
0.0001
 
Timing of stoma
 Primary
 Secondary
523
 93
1.00
0.30 0.21 – 0.43
<0.0001
 
1.00
0.06 0.01 – 0.24
0.0001
 
HR = hazard ratio. HR < 1 indicates decreased likelihood of stoma reversal, whereas HR > 1 indicates 
increased likelihood of stoma reversal. *Multivariate analysis not done. †Data on height or weight were 
missing for 113 patients. ‡Unspecified for six patients. §Entered as time-dependent covariate, data missing 
for 29 patients (recurrence status unknown for one; recurrence status not applicable because of M1 
disease in 28 at the time of surgery).
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and for distally located tumours with, consequently, distally located anastomoses. Large 
geographical differences in primary stoma policy were detected -and similar findings 
have been reported in the UK12- but that such large differences exist is remarkable.
We report that 19% of temporary created stomas were not closed during follow-up. 
Of the stomas that were closed during follow-up, 97% were closed in the first year after 
construction. Therefore, if a stoma was not closed in the first year, it would probably 
become permanent. Although the outcome of temporary stomas in terms of the num-
bers closed has been studied before,13,14 little is known about risk factors associated with 
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figure 4. Kaplan-Meier curves for stoma reversal per age group (A) and for primary and secondary 
stomas (B).
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stoma closure. To our knowledge, this study is the first to analyse systematically factors 
that limit stoma reversal in a large population with a long follow-up.
Age was found to be a significant risk factor associated with a decreased likelihood 
of stoma reversal. In the TME trial, an upper age limit was not set, whereas most other 
randomised trials studying neoadjuvant treatment restricted the age of older partici-
pants.15,16 Consequently, only few researchers report on older age as a limiting factor 
for stoma reversal. However, Kairaluoma and co-workers13 also reported that age above 
70 years was associated with fewer stoma closures due to fear of increased morbidity 
in older patients. Age has also been associated with increased morbidity and mortal-
ity after stoma closure,17 although such an association could not be found in another 
study.18 Fear of increased comorbidity in the elderly and patients’ refusals to undergo 
more surgery might have resulted in the decreased frequency of stoma reversal in these 
patients. Additionally, patients with stomas who have had postoperative complications, 
such as infection, had their stomas reversed less frequently. By contrast, perioperative 
complications, such as bleeding, which were not perceived directly by the patient, 
could not be identified as a risk factor. Generally secondary stomas, which were created 
after complications, were less frequently removed. A reason for this could be that older 
patients and patients who have had postoperative complications after initial (curative) 
treatment of rectal cancer are more willing to accept a stoma than other patients. 
We have previously reported a similar finding for faecal incontinence:19 a substantial 
proportion of patients treated with a low anterior resection had faecal incontinence. In 
our opinion, few secondary stomas are constructed in such patients, suggesting that 
patients accept faecal incontinence.
Other risk factors for not having stomas reversed might not be related directly to 
patients’ or surgeons’ motivation, but more related to surgical problems. The decision 
to create an end ileostomy or colostomy instead of a diverting stoma also highlights 
expected technical difficulties in creating a primary anastomosis. Accordingly, reversal 
of an end ileostomy or colostomy is less probable, and so these stomas are often perma-
nent. Obviously, the development of a recurrence shifted treatment focus to a palliative 
setting in which the aim was to optimise quality of life and to prevent unnecessary 
surgery. Remarkably, other factors that might be associated with technical difficulties in 
reversing stomas, such as distance and TNM stage, were not identified as limiting factors 
in this study.
Although a side-to-end or colonic pouch anastomosis is recommended as an at-
tempt to minimise the risk of anastomotic dehiscence,20 an end-to-end anastomosis 
was created in only 107 of 924 patients. We previously showed that anastomosis type 
was not an independent factor for anastomotic dehiscence in the TME trial.3 Similarly, 
in this study, the type of anastomosis was not associated with the necessity to create a 
secondary stoma (data not shown). However, the type of anastomosis and the decision 
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to create a stoma were left to the surgeons’ discretion, which might have resulted in 
biased data. Preoperative radiotherapy was a risk factor for secondary stomas becoming 
permanent, but not for primary stomas -suggesting that the combination of preopera-
tive radiotherapy and serious complications after primary surgery that necessitated a 
secondary stoma resulted in fewer stoma reversals.
The large difference in stoma reversal in patients having primary and secondary 
stomas might raise the question of whether all patients should have a stoma in the first 
operation. However, based on the findings in this study, we would not support this idea. 
Almost one-third of all patients treated with a low anterior resection in the rectal cancer 
TME trial never had a stoma. Also, only about 81% of stomas were reversed. Further-
more, the stomas themselves and second procedures to reverse stomas are associated 
with morbidity and mortality. Patients’ preferences, morbidity -which sometimes even 
results in a new stoma- and mortality were not included in this analysis. Moreover, the 
costs associated with the stoma and its reversal are a burden for health-care systems.
A temporary diverting stoma is often created in an attempt to decrease the risk of 
clinical anastomotic leakage. However, data in published studies are inconsistent about 
the relation between defunctioning stoma usage and prevention of anastomotic leak-
age after surgical treatment of rectal cancer. Some studies have reported no significant 
difference in the frequency of anastomotic leakage if a diverting stoma is created,1,2 
whereas we and others have found a decreased incidence of clinically evident leak-
age.3,21,22 More consistent evidence is available that suggests a diverting stoma reduces 
the clinical consequences of anastomotic leakage, for example, the finding that fewer 
patients with diverting stomas than those without such stomas need surgery when 
anastomotic leakage occurs.1-3
Other factors might support the argument for stoma construction. In the TME trial, 
patients with a stoma were more satisfied with their bowel function than those without a 
stoma (174 of 235 [74%] versus 199 of 362 [55%], P < 0.001).19 Others, however, reported 
lower quality of life with a stoma.7 Obviously, patients’ preferences and sociodemo-
graphical characteristics, such as the availability of good stoma care and cultural ac-
ceptance of stomas, will decide the individual patient’s quality of life to a certain extent. 
Eventually, the loss of quality of life due to a stoma needs to be counterbalanced with 
the patient’s comorbidity, which might limit successful stoma reversal. Only in this way 
can an individualised decision be made on stoma reversal.
Our results do not suggest that the unreversed stomas should not have been made, 
but show that temporary stomas should be created as if they are permanent stomas; 
correct placement that helps life-long handling is of utmost importance. In an attempt 
to lower clinical anastomotic leakage and variability in surgical management of patients 
with rectal cancer, a working party has been developed in the Netherlands. This party will 
document prospectively surgical procedures in colorectal surgery in the Netherlands, 
A multivariate analysis of limiting factors for stoma reversal 171
including the incidence of stoma formation and anastomotic leakage. This prospective 
audit should provide data that will guide surgeons towards a more standardised and 
evidence-based approach in stoma formation. Only then can treatment be further 
tailored to the individual patient with rectal cancer.
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General Discussion
Colorectal cancer is the cancer with the second highest cancer incidence in Europe.1 
Roughly, one out of three patients with a colorectal malignancy has a rectal carcinoma. 
Surgery is the cornerstone in the curative treatment of rectal cancer. In the 1980s with 
conventional surgery, the 5-year local recurrence rate was over 20% and the 5-year over-
all survival rate around 50%.2,3 In the Swedish Rectal Cancer trial in which 1168 patients 
were included, preoperative radiotherapy in addition to conventional surgery resulted 
in a reduction of more than 50% in the 5-year local recurrence rate in comparison to 
conventional surgery alone (11% versus 27%; P < 0.001).2 Besides, the 5-year overall 
survival rate improved from 48% to 58% if patients were treated with preoperative 
radiotherapy in addition to conventional surgery (P = 0.004).2 With the total mesorectal 
excision (TME), by which the rectum with its mesorectum and visceral fascia are dissect-
ed sharply and under direct vision,4 local recurrence rates dropped and overall survival 
improved.5,6 In the Dutch TME trial, 5 x 5 Gy preoperative radiotherapy in combination 
with TME surgery was compared to TME surgery alone (1861 patients). In this trial, the 
5-year local recurrence rate for patients treated with TME surgery alone was similar to 
patients treated in the Swedish Rectal Cancer trial with blunt dissection in combination 
with preoperative 5 x 5 Gy radiotherapy (11%)2,7 If preoperative radiotherapy was added 
to TME surgery, 5-year local recurrence rate was reduced to 5.6%7 The overall survival 
rate at 5 year was 64% for both patients treated with TME surgery alone and patients 
treated with preoperative radiotherapy followed by TME surgery,7 compared to 48% 
for patients treated with blunt dissection alone in the previously mentioned Swedish 
trial.2 TME surgery is now considered the standard surgical procedure for rectal cancer.4 
However, even if TME surgery is performed, surgical quality varies.8,9 First, these results 
indicate that improvements in the surgical procedure itself can result in major progress 
regarding long-term oncological outcome such as decreased local recurrence rates and 
improved overall survival. Second, it illustrates that variation in surgical quality could 
lead to large differences in outcome. Recently, it was shown that surgical variation is not 
only important for patients with rectal cancer, but also plays an important role for the 
outcome of patients with colon cancer.10,11
surGical Quality assurance
In 1991, McArdle and Hole wrote that “some surgeons perform less than optimal sur-
gery… If by meticulous attention to detail the results of surgery could be improved, 
and our results suggest that this would not be difficult, the impact on survival might be 
greater than that of any of the adjuvant treatment therapies currently under study”.12 
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Quality assurance aims at reducing variability and can be defined as the systematic 
measures required to achieve a treatment result that meets a certain standard. These 
measures include training of all participating surgeons to reduce the variation in skill 
level, presence of an instructor surgeon during the first procedures of each surgeon, and 
pathological quality control of the resected specimen on, for example, the number of 
resected lymph nodes or circumferential resection margin involvement.
Several studies showed that circumferential resection margin involvement is a risk 
factor for increased local recurrence and reduced overall survival.13-15 Some even con-
sider circumferential resection margin involvement as an early (surrogate) end-point.16,17 
Furthermore, it has been shown that preoperative radiotherapy could not compensate 
for circumferential resection margin involvement.18 The predictive value of the circumfer-
ential resection margin for local recurrence is significantly higher if preoperative therapy 
has been applied compared to no preoperative treatment (hazard ratio 6.3 versus 2.0, 
respectively; P < 0.05).19 Consequently, circumferential resection margin involvement is 
not only prognostic for oncological outcome, but also influences the studied effects of 
the (neo)adjuvant treatment. This illustrates the necessity to document circumferential 
resection margin involvement in randomised trials. Feedback from the pathologist to the 
surgeon on, for example, circumferential resection margin involvement could eventually 
improve the number of radical resections. In the MRC CR07 trial, which compared short 
course preoperative radiotherapy with selective postoperative chemoradiotherapy in 
case of involvement of the circumferential resection margin, quality of the resection 
specimen was prospectively assessed and reported to the surgeons.8 During this trial, 
the frequency of involved circumferential resection margins decreased. Furthermore, 
both this trial and the Dutch TME trial showed that poor quality of surgery, defined as 
resection in the muscularis plane, was associated with poor local control and disease-
free survival.8,9 This feedback could also improve the surgical resection quality in the 
daily clinical practice: distance of the tumour to the circumferential resection margin 
should be a standard parameter in the pathology report of a rectal resection specimen.
considerations after the introduction of tMe surgery
Although in general the outcome for patients improved since the introduction of the 
TME procedure,5,20 outcome for some groups of patients improved less than for oth-
ers.9,21,22 In the Netherlands, TME surgery was nationwide introduced during the TME trial 
(1996-1999).23 For patients under 75 years, the population-based 5-year overall survival 
rate in the Netherlands was 60% in the period before the TME trial, 67% in the period of 
the trial and 70% in the period after the TME trial.21 However, in the same study, patients 
aged ≥ 75 years had a 5-year overall survival rate of respectively 41%, 40% and 43% in 
these periods.21 In the elderly patients, the 1-month and 6-month postoperative mor-
tality rates are much higher compared to the rates of younger patients.21,22 Treatment 
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related mortality is probably an important competitive risk factor, which obscures the 
positive effects of TME surgery in patients aged ≥ 75 years.21,22
Another group of patients who used to have a worse outcome, is the group of pa-
tients treated with an abdominoperineal resection compared with the group of patients 
treated with a low anterior resection. These patients have higher rates of circumferential 
resection margin involvement, worse local control, and a reduced overall survival rate.24 
At the beginning of the 1990s, it became clear that the distal margin of 5 cm from the 
tumour could be safely reduced to 2 cm or less.25 Simultaneous, the TME technique was 
introduced as standard treatment.4,26 Consequently, the frequency of abdominoperineal 
resections decreased, whereas more low anterior resections were performed.27 Marr and 
collegues studied the abdominoperineal resection before and after the introduction of 
the TME procedure in Leeds.24 They found that patients treated with an abdominoperi-
neal resection had more involved circumferential resection margins, an increased local 
recurrence rate, and a reduced overall survival rate.24 Interestingly, since the introduc-
tion of the TME technique the frequency of involved circumferential resection margins 
after an abdominoperineal resection did not change: 43% involved margins between 
1997 and 2000 compared to 36% in the period 1986 to 1997.24 Over time less patients 
were treated with an abdominopereneal resection compared to an low anterior resec-
tion.24 This difference in patient selection could have influenced the results, as nowadays 
only the more difficult, distal tumours are treated with an abdominoperineal resection. 
Nevertheless, also in the Dutch TME trial, high rates of circumferential resection margin 
involvement were found after an abdominoperineal resection.9 In general, with TME 
surgery overall survival is still 10% worse for patients treated with an abdominoperineal 
resection in comparison to patients treated with a low anterior resection.9,28,29
The above mentioned examples are indicating the importance of performing con-
tinuous research and quality monitoring to identify the areas where treatment results 
are not as expected. The findings for the elderly patients question the benefit of the 
“standard” TME procedure for some frail elderly patients with a limited tumour: neo-
adjuvant treatment in combination with a smaller surgical procedure might be a good 
alternative for these patients.22 The results of the abdominoperineal resection did also 
lead to a change in practice in several institutes, where a wider, cylindrical resection is 
performed instead of the traditional conic excision.30,31
national cancer plans
In several countries, the importance of continuous research and quality assurance for 
improving oncological care has been recognised. In the United Kingdom, the National 
Health Service (NHS) Cancer Plan was formulated in 2000, which gave cancer services 
high priority. The plan aimed to reduce death rates and improve prospects of survival 
and quality of life for patients with cancer and to guarantee high quality treatment and 
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care throughout the country. Also in France, a national cancer plan was introduced 
(2003). As a result the French National Cancer Institute was founded in 2004. Its mission 
is to direct the course of cancer care policy, to provide a network hub for research, and to 
act as a catalyst for European and international cooperation.32 In several other countries, 
including Australia, New Zealand and Canada, similar national cancer plans have been 
formulated. These plans emphasize the improvement of quality of care for the patient 
with cancer. Nevertheless, to structurally gain insight in the nationwide improvements 
of cancer care, and more importantly in the short and long-term results of the provided 
care, an audit is necessary.
auDits on rectal cancer
Several countries have organised a national audit, such as Norway and Sweden. Re-
cently, a national colorectal audit was also implemented in the Netherlands. In Norway, 
a national audit for the period 1986-1988 was performed. It was found that the 5-year 
local recurrence rate was 28% with a 5-year overall survival rate of 55% for patients 
aged younger than 75 years.33 The Norwegian Rectal Cancer Group was founded and 
established a national rectal cancer registry. Each department regularly received its own 
results together with the national average for comparison and quality control.33 From 
November 1993 until December 1999, 5382 patients with rectal cancer were included. 
TME surgery was rapidly implemented: 96% of patients were treated with this surgical 
technique in 1998.33 For patients younger than 75 years, the local recurrence rate was 
8% after a mean follow-up of 39 months, and the 5-year overall survival was 71%.33 Wibe 
and colleagues conclude the following: “The Rectal Cancer Registry has provided the 
opportunity for monitoring treatment standard in each department, and the routine 
reports of results to the departments are also believed to encourage every surgeon and 
pathologist to do his or her best. Moreover, it provides data which allow comparison of 
the results of individual units to the national average.”33
In Sweden, an audit for all patients with rectal cancer was launched in 1995: the Swed-
ish Rectal Cancer Registry. According to the Swedish healthcare system it is obligatory 
for pathologists and surgeons to report cancer diagnoses to the Swedish Cancer Regis-
try. All departments of surgery agreed to provide clinical data to the registry. Feedback 
is given to all centres on treatment outcome. Between 1995 and 2003, 13434 patients 
were documented in the Swedish Rectal Cancer Registry.28 The 5-year survival rate for 
rectal cancer improved significantly from 36.1% in the period 1960-1964 to 57.6% in the 
period 1995-1999.34 The survival rates for colon cancer were not included in the national 
audit and improved from 39.6% to 57.2% in these periods.34 These results indicate that in 
Sweden, survival for both rectal cancer and colon cancer have improved. Similar to the 
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Swedish results, in the regional database of the Dutch Comprehensive Cancer Centre 
West was found that, historically, patients with colon cancer had a better survival rate 
than patients with rectal cancer: hazard ratio 0.84; P = 0.001 for patients with colon 
cancer compared to patients with rectal cancer in the period 1990-1995, adjusted for 
age, gender, and TNM stage (unpublished data). However, due to the focus on rectal 
cancer in the last decade, the survival rate for patients with rectal cancer is now similar 
to patients with colon cancer. The concentration of patients with rectal cancer to a spe-
cialised hospital, the nationwide introduction of TME surgery, and the implementation 
of preoperative radiotherapy have probably contributed to these improvements.
The EUROCARE collaboration is an example of a collaboration between more than 
83 cancer registries across 23 countries.35 The data are obtained from some national 
registries, which cover 100% of the cases, and also from many regional registries. For 
colorectal cancer, the 5-year relative survival in the EUROCARE-4 study was 56.2% for 
patients diagnosed in the period 2000-2002.36 In general, the countries in Northern and 
Central Europe had the best survival rates, whereas countries in Eastern Europe, such 
as Poland and Czech Republic, had a 10% lower overall survival rate compared to the 
average.36 Furthermore, also the survival rate of the United Kingdom, a country with a 
Cancer Plan since 2000, was below the average survival rate in the EUROCARE study.36 A 
limitation of the EUROCARE study is that for some nations only regional registries were 
available and only a proportion of all cases was included in the database: for example in 
Poland and the Czeck Republic respectively only 9% and 8% of the national population 
is covered by the used registries.35 Nevertheless, the results indicate that large differ-
ences exists in survival rates of rectal cancer between nations. It is important to realise 
that not only survival differences between nations are present, but also within a nation 
due to different outcome in different centres.37,38 An audit such as the EUROCARE study 
helps to identify where the quality of care should and could be improved. However, 
interesting questions, such as why these differences exist and how the survival rate can 
be improved, cannot be answered by the EUROCARE database.
an european audit on colorectal cancer treatment outcome
In Europe, international initiatives for collaboration to improve cancer care outcome 
are limited. In the early 1980s, the Federation of European Cancer Societies (FECS) was 
founded, based on the vision that treating cancer is an effort of a multidisciplinary team. 
The European Society of Surgical Oncology (ESSO) took with support of the European 
Society for Therapeutic Radiology and Oncology (ESTRO) the initiative to officially dis-
band and replace the FECS in 2007 by the European CanCer Organisation (ECCO), which 
aims at taking an even wider approach to oncology. One of the goals of the ECCO is to 
uphold the right of all European cancer patients to the best possible treatment and care. 
The ECCO supported a recently initiated, European audit on colorectal cancer, which is 
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an outcome-based quality improvement project. The following outcomes will be con-
sidered: morbidity, mortality, loco-regional control, and survival. The aims of the audit 
are first to improve outcome for patients with cancer in Europe by quality assurance 
measures, and second to decrease the use of unproven treatments, which might cause 
side-effects without improving outcome. Regularly, collected data will be analysed to 
identify areas where further improvements in the quality of care are possible or neces-
sary. Additional data, such as TNM stage and other confounders, are collected so the 
analyses can be adjusted for confounders such as patient case-mix.
Furthermore, the audit could be used to identify centres which have the best (ad-
justed) outcome for colorectal cancer treatment: the “centres of excellence”. Studies why 
these centres have better results will contribute to the understanding of factors that 
influence colorectal cancer outcome. Apart from that, the audit could give insight in the 
actual number of procedures that are performed within each centre and by an individual 
surgeon each year. This could be important as Birkmeyer and colleagues showed that 
hospital volume was associated with operative mortality for colectomy in the United 
States (6.5% in hospitals with less than 33 resections per year compared to 4.5% for 
hospitals with more than 124 resections per year, P < 0.001).39 Besides, several groups 
showed that surgical caseload was associated with oncological outcome for rectal can-
cer.38,40 Surprisingly, in the Swedish Uppsula trial was found that 50% of patients were 
operated by surgeons who performed less than one rectal cancer operation per year.28,41 
As a consequence of above mentioned findings rectal cancer care in Sweden was eventu-
ally concentrated to centres with specialised surgeons. In the future, the outcome-based 
European audit for colorectal cancer could also result in reorganisation of colorectal 
cancer care in other countries in Europe: concentration of colorectal cancer care in the 
centres with the best outcome. It could be that these centres are high volume centres, 
but the decision should be based on outcome parameters and not solely on caseload.
costs of quality improvement
Every treatment costs money. Chemotherapeutic agents are relatively expensive, 
and the effects on outcome in the treatment of rectal cancer are currently limited. An 
example in which systemic treatment is used is metastatic colorectal disease. Due to 
the chemotherapeutic agents, the prognosis has improved from a median survival of 
eight months to more than 21 months (regimen including bevacizumab or cetuximab).42 
Although the progress is commendable, we should remember that these treatments 
costs over US$ 21,000 for the initial 8 weeks.
In the last decade, the largest improvements in survival of patients with rectal cancer 
resulted from a change in surgical technique: due to a change from blunt dissection to 
TME surgery the survival rates in several countries have improved.5,20,43 Professor Wibe 
showed during the Colorectal Conference 2007 in St. Gallen that the National Rectal 
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Cancer Audit in Norway, which started in 1993, costed € 120,000 per year including 
the costs of two secretaries and one statistician (50%). Until 2007, more than 14000 
patients were included in a country with 4.6 million inhabitants. During the audit each 
department was monitored. Feedback and, if necessary, counselling was given. The local 
recurrence rate decreased and the overall survival rate improved from 55% in the period 
1986-1988 to 71% in the period 1993-1999.33,44 Wibe estimated that since the introduc-
tion of the audit 2500 patients have been saved due to improved treatment. As the audit 
has cost around 1.6 million euros since 1993, the costs per saved life were around 700 
euros. This does not implicate that radiotherapy or chemotherapy should not be used. 
Rather, it indicates that quality assurance projects such as an audit have been shown to 
be very cost effective.
Although the costs of an audit are relatively low, it still has to be financed. One of the 
parties who could contribute towards the costs is the government: an audit fits within 
the national cancer plans as its helps to improve cancer care outcome. Consequently, an 
European audit might be supported by both the national government and the European 
Union. Moreover, an audit could result in reduction of the incidence of (expensive) com-
plications and a decreased use of unproven treatments, which could eventually result 
in a reduction of total expenses. Therefore, it is also interesting for medical insurance 
companies to invest in an outcome based audit. Finally, independent, grant-giving in-
stitutes such as cancer foundations might be willing to contribute to quality improving 
initiatives.
considerations for the audit
A registration project in which only data is collected for documentation purposes, will 
not lead to an improved quality of care. First of all, an audit should be an interactive 
system in which regularly feedback is given on performance, mirrored to the regional, 
national and European average. Besides, recommendations where further improve-
ments can be made should be given at least annually to the participants. Second, if only 
dedicated treatment teams register their data, a bias of the results will exist, eventually 
resulting in a failure to improve overall treatment outcome. Therefore, participation to 
the audit should be mandatory.
conclusions
Variability results in differences in outcome. Surgical variability can be minimised by 
extensive quality assurance. In several surgical randomised trials, the importance of 
quality assurance measurements are shown. However, the majority of patients is treated 
outside the framework of a trial. For patients treated in the daily clinical practice, quality 
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assurance by means of auditing is necessary. Registration of outcome-based quality 
measurements is cost effective and provides transparency, benchmarking, and internal 
feedback which will rapidly lead to improvements in cancer care.
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suMMary
In the last decade the surgical procedure for rectal cancer has been changed. At the 
end of the 1980s, a blunt dissection was performed. Several studies have shown that 
a total mesorectal excision (TME), which is a sharp removal under direct vision of the 
complete rectum with its intact mesorectum and visceral fascia with preservation of 
the autonomic nerves, resulted in better local control and overall survival.26,45 In the 
same period as the introduction of TME surgery, it became clear that the distal margin 
of 5 cm from the tumour could be safely reduced to 2 cm or less.25 Consequently, fewer 
abdominoperineal resections were performed.27
In the Netherlands, the TME trial introduced the TME technique nationwide.23 In this 
trial, radiotherapy, surgery, and pathology were extensively quality controlled. For the 
surgical procedure, several workshops were organised, videotapes with the procedure 
produced, trainings at the dissection table were given, and the first procedures of each 
participating surgeon were supervised by an instructor surgeon. This thesis focuses on 
quality assurance of rectal cancer treatment, in particular on the surgical treatment.
In chapter 1 the general introduction and outline of the thesis are described.
The effect of the introduction of TME surgery on population-based overall survival in the 
Netherlands is studied in chapter 2. In this study the cancer registries of the Compre-
hensive Cancer Centres South and West are used. In total 3179 patients were included. 
Three periods were studied: before, during and after the TME trial. Overall survival was 
respectively 56%, 62% and 65% in the pre-trial, trial and post-trial period (P < 0.001). 
Overall survival, adjusted for the confounders gender, age, pT-stage, lymph node 
involvement, and (neo)adjuvant treatment, improved in the trial period (P < 0.001), sug-
gesting that the introduction of TME surgery was successful. Preoperative radiotherapy 
was increasingly used over time. In the period of the TME trial, overall survival was similar 
for patients treated with preoperative radiotherapy and without (neo)adjuvant treat-
ment (P = 0.315). In the post-trial period, preoperative radiotherapy was significantly 
related to improved overall survival compared with no (neo)adjuvant treatment (P = 
0.002). The results indicate that population-based overall survival improved since the 
nationwide introduction of TME surgery. Besides, with standardised TME surgery, preop-
erative radiotherapy resulted in an improved overall survival rate, whereas withholding 
preoperative radiotherapy was associated with a poorer prognosis.
Although chapter 2 showed that in general overall survival increased since the introduc-
tion of TME surgery, in chapter 3 and 4 it was studied whether the outcome for the 
elderly patients with rectal cancer also improved. In most rectal cancer trials patients 
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aged over 75 years are underrepresented due to exclusion based on age or comorbidity. 
However, rectal cancer is a disease predominately occurring in the elderly patient. For 
both chapters 3 and 4, the Dutch TME trial and the cancer registries of Comprehensive 
Cancer Centres South and West were used. In chapter 3 it was shown that the 5-year 
overall survival was 60% before the introduction of TME surgery, 67% during the TME 
trial, and 70% after the TME trial in patients aged younger than 75 years (P < 0.0001). 
The survival for older patients did not improve and remained at 41%, 40% and 43% at 5 
years in the respective periods. Furthermore, mortality during the first 6-month period 
after treatment is significantly raised compared to younger patients: 14% in the elderly 
patients, compared to 3.9% in the younger TME study patient (P < 0.0001). In the data-
base of the Comprehensive Cancer Centres these figures were confirmed at 16% and 
3.9% (P < 0.0001). In chapter 4, the association between age, morbidity and 6-months 
mortality is shown. Treatment related mortality is probably an important competitive 
risk factor which obscures the positive effects of TME surgery in patients aged ≥ 75 
years. It is discussed that for elderly patients who retain a good physical and mental 
condition, treatment that is given to younger patients is regarded to be appropriate, 
whereas for those with diminished physiological reserves and comorbid conditions, 
alternative treatments that keep surgical trauma to a minimum and optimise the use of 
radiotherapy might be more suitable.
Another group of patients who had a worse outcome is the group of patients treated 
with an abdominoperineal resection compared with those treated with a low anterior 
resection. In chapter 5 it is studied which of the following is associated with circumferen-
tial resection margin involvement, local recurrence, overall survival, and cancer-specific 
survival: the abdominoperineal resection itself or the factors resulting in the decision 
to perform an abdominoperineal resection. Patient and treatment related variables of 
the Swedish Rectal Cancer trial, Dutch TME trial, CAO/ARO/AIO-94 trial, EORTC 22921 
trial and Polish Rectal Cancer trial were combined (5187 patients). A propensity score 
was calculated, which indicated the predicted probability of undergoing an APR given 
gender, age, and distance of the tumour to the anal verge. The results showed that an 
abdominoperineal resection was associated with an increased risk of circumferential 
resection margin involvement (odds ratio 2.52; P < 0.001), increased local recurrence 
rate (hazard ratio 1.53; P = 0.001), and a decreased cancer-specific survival rate (hazard 
ratio 1.31; P = 0.002), whereas the propensity score was not. The results suggest that 
the abdominoperineal resection itself is a significant predictor for nonradical resections 
and is associated with an increased risk of local recurrence and death due to cancer for 
patients with advanced rectal cancer.
chapter 6 focuses on patients treated with an abdominoperineal resection in the 
TME trial, to identify tumour and patient related risk factors associated with positive 
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circumferential resection margins, local recurrence, and overall survival. A positive 
circumferential resection margin was found in 29.6% of all patients: 44% for anterior, 
21% for lateral, 23% for posterior, and 17% for (semi)circular tumour location (P < 0.001). 
In a multivariate analysis, T-stage, N-stage, and tumour location were independent risk 
factors for circumferential resection margin involvement. If a (partial) resection of the 
vaginal wall was performed in women, 47.8% of patients still had a positive circumfer-
ential resection margin. T-stage, N-stage, and circumferential resection margin were risk 
factors for local recurrence and age, T-stage, N-stage, circumferential resection margin, 
and distance of the tumour to the anal verge for overall survival. The results indicate 
that the surgical treatment should primarily be aimed at adequate resection margins. 
To further improve the outcome of patients treated with an abdominoperineal resec-
tion, tumours should be properly preoperatively staged, including an assessment of the 
circumferential resection margin (mesorectal fascia). For patients with a threatened cir-
cumferential resection margin preoperatively, 5 x 5 Gy radiotherapy alone is insufficient 
and treatment should preferentially consist of chemoradiotherapy and/or extended 
resection.
The EORTC 22921 trial studied the addition of pre- and/or postoperative chemotherapy 
to preoperative radiotherapy followed by surgery in T3 or resectable T4 rectal cancer. 
The trial ran from April 1993 to March 2003. In 1999, an addition to the trial protocol was 
made in which it was recommended to perform a TME procedure. Circumferential resec-
tion margin involvement, local recurrence, overall survival, and disease-free survival in 
patients treated with a long schedule of (chemo)radiotherapy are studied in chapter 
7. Circumferential resection margin involvement was associated with the period of 
treatment: less circumferential margin involvement was found after 1999. Although 
preoperative chemoradiotherapy resulted in more downstaging and downsizing in 
comparison to preoperative radiotherapy alone in a previous analysis,46 the preopera-
tive treatment did not significantly affect circumferential resection margin involvement. 
A positive circumferential resection margin was associated with a higher risk of a local 
recurrence and a decreased disease-free and overall survival rate. Although downstag-
ing might be helpful in the treatment of these advanced tumours, the results suggest 
that the ultimate aim of the treatment should be to perform a radical operation.
In chapter 8, the data of EORTC 22921 trial are further explored, to study which pa-
tients might benefit from the addition of postoperative chemotherapy to a preoperative 
schedule of long (chemo)radiotherapy. Although there was no statistically significant 
impact of postoperative chemotherapy on disease-free survival for the whole group 
(P > 0.05),47 the treatment effect differed significantly between the patients showing 
downstaging (ypT0-2) and the patients that did not show downstaging after preopera-
tive therapy (ypT3-4): only the ypT0-2 patients seemed to benefit from postoperative 
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chemotherapy (P = 0.013). The same pattern was observed for overall survival. These 
results indicate that predictive factors such as tumour responsiveness to preoperative 
treatment must be taken into account in the design of future trials studying postopera-
tive treatments. Besides, tumour sensitivity for the primary treatment might be consid-
ered to tailor postoperative therapy and prevent ineffective treatments, which might 
cause addition burden and toxicity.
One of the feared complications after a low anterior resection is anastomotic leakage. In 
chapter 9, the data of the Swedish Rectal Cancer trial, Dutch TME trial, CAO/ARO/AIO-94 
trial, EORTC 22921 trial, and Polish Rectal Cancer trial were used to study the association 
between anastomotic leakage and long-term outcome. In total 2726 patients with a 
low anterior resection were selected. Anastomotic leakage occurred in 9.7% of patients. 
The presence of a diverting stoma was negatively associated with anastomotic leakage 
(P = 0.002). After exclusion of patients with early postoperative mortality, anastomotic 
leakage was independently associated with overall survival (HR 1.29; 95% CI 1.02-1.63; 
P = 0.034), but not with cancer-specific survival (HR 1.12; 95% CI 0.83-1.52; P = 0.466). 
These data indicate that patients who survived their anastomotic leakage still have a 
decreased long-term overall survival rate.
In the early postoperative period, anastomotic leakage is feared for its associated 
morbidity and mortality. In chapter 10 is focused on this period. First, historical data 
of 3 regional hospitals were collected (1066 patients). These data revealed that 7.0% of 
patients developed a symptomatic anastomotic leakage. The mortality rate of patients 
diagnosed with anastomotic leakage was 39%. It was considered that delay in the diag-
nosis of anastomotic leakage might have contributed to these findings: the diagnosis 
was made with a median delay of 4 days after the first symptoms were observed. As 
a result a protocol for standardised postoperative surveillance was made, using easily 
accessible clinical parameters such as temperature, heart rate, and physical examination 
of the abdomen. This protocol was then prospectively tested between August 2004 and 
August 2006 (223 patients). The anastomotic leakage rate was 9.4% in this period. Com-
pared to the historical controls, the delay between the first symptoms and the diagnosis 
of anastomotic leakage decreased significantly from a median of 4 days to 1.5 days (P = 
0.01). The mortality rate dropped, but this difference was not statistically significant. The 
results indicate that standardised postoperative surveillance for anastomotic leakage 
could result in a shorter delay between the first signs and symptoms to the confirmation 
of anastomotic leakage. At present a multicentre registration project is performed, to 
further improve and validate the scoring list and decision model (DUtch LeaKage score).
In chapter 9 and in other studies it was shown that the presence of a diverting stoma 
is associated with a lower rate of anastomotic leakage.48 However, part of the stomas 
constructed with temporary intent are never removed. In chapter 11, the data of the 
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Dutch TME trial were used to study the rate of stoma reversal and to identify factors 
that limit stoma closure. In 19% of patients, the stoma was never reversed. Postopera-
tive complications and secondary constructed stomas, for example after anastomotic 
leakage, were associated with a higher likelihood of a permanent stoma. The results 
show that temporary stomas should be created as if they are permanent stomas; correct 
placement that helps life-long handling is of utmost importance.
In chapter 12 this thesis is placed in a wider context. The importance of quality as-
surance is illustrated, using the results of the TME trial. To continuously improve the 
outcome of the oncological care it is necessary to monitor structurally. Quality assur-
ance should not only be used within randomised clinical trials, but be a part of the daily 
clinical practice. In several countries the efficiency of audits has been shown before. 
Recently, an European outcome-based audit was initiated, supported by the European 
CanCer Organisation (ECCO). Eventually, feedback of the audit will result in an improved 
outcome of the oncological treatment.
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neDerlanDse saMenVattinG
In het laatste decennium is de chirurgische behandeling van het rectumcarcinoom 
veranderd. Aan het einde van de jaren 80 van de vorige eeuw werd er een stompe dis-
sectie verricht. Verschillende studies hebben aangetoond dat een operatie waarbij het 
complete rectum met een intact mesorectum en viscerale fascie onder zicht en middels 
een scherp resectie werd verwijderd, resulteert in betere lokale controle en algehele 
overleving: de totale mesorectale excisie (TME).1,2 In dezelfde periode als de introductie 
van de TME procedure werd duidelijk dat de distale marge van 5 centimeter van de 
tumor gereduceerd kon worden tot (minder dan) 2 centimeter.3 Dit leidde ertoe dat er 
minder abdominoperineale resecties werden verricht.4
In Nederland werd met de TME studie de TME techniek landelijk geïntroduceerd.5 
In deze studie naar rectumcarcinoom werd de kwaliteit van radiotherapie, chirurgie en 
pathologie uitgebreid gecontroleerd: kwaliteitsborging of “quality assurance”. Het doel 
van deze kwaliteitscontrole was te garanderen dat radiotherapie, chirurgie en patho-
logie aan een bepaalde standaard voldeden. Voor de chirurgische kwaliteitsborging 
werden onder andere verschillende workshops georganiseerd, videobanden van de 
procedure verspreid, trainingen in de snijzaal gegeven en de eerste operaties van iedere 
deelnemende chirurg gesuperviseerd door een instructeur. Dit proefschrift richt zich op 
de kwaliteitsborging van de behandeling van het rectumcarcinoom, waarbij met name 
de chirurgische behandeling wordt bestudeerd.
hoofdstuk 1 is de inleiding van dit proefschrift. Daarnaast wordt in dit hoofdstuk de 
inhoud van het proefschrift op hoofdlijnen weergegeven.
Het effect van de introductie van TME chirurgie in Nederland op de algehele overle-
ving is onderwerp van studie in hoofdstuk 2. In deze studie met 3179 patiënten werd 
gebruik gemaakt van de kankerregistratie van de Integrale Kankercentra West (IKW) en 
Zuid (IKZ). Er werden drie perioden onderscheiden: voor, tijdens en na de TME studie. 
De algehele overleving was 56%, 62% en 65%, respectievelijk voor, tijdens en na de TME 
studie (P < 0,001). De algehele overleving, gecorrigeerd voor geslacht, leeftijd, patholo-
gisch T-stadium, lymfklier status en (neo)adjuvante therapie was significant verbeterd 
in de periode tijdens de TME studie in vergelijking met voor de TME studie (P < 0,001). 
Dit suggereert een succesvolle introductie van de TME procedure. Preoperatieve radio-
therapie werd in de opeenvolgende perioden steeds meer toegepast. In de periode van 
de TME studie was de algehele overleving van patiënten behandeld met preoperatieve 
radiotherapie gelijk aan de algehele overleving van patiënten die zonder (neo)adjuvante 
therapie werden behandeld (P = 0,315). In de periode na de TME studie had de groep 
patiënten die preoperatief behandeld werd met radiotherapie een significant betere 
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algehele overleving dan de groep die zonder (neo)adjuvante therapie werd behandeld 
(P = 0,002). De resultaten geven aan dat de algehele overleving is verbeterd sinds de 
introductie van TME chirurgie in Nederland. Daarnaast resulteert gestandaardiseerde 
TME chirurgie in combinatie met preoperatieve radiotherapie in een verbetering van 
de algehele overleving, terwijl de groep die niet wordt behandeld met preoperatieve 
radiotherapie een slechtere prognose heeft.
Alhoewel in hoofdstuk 2 is aangetoond dat voor de totale populatie van patiënten met 
een rectumcarcinoom de algehele overleving verbeterd is sinds de introductie van de 
TME procedure, werd in hoofdstuk 3 en 4 bestudeerd of de uitkomst ook voor de oudere 
patiënt is verbeterd. In de meeste studies die de behandeling van het rectumcarcinoom 
onderzoeken zijn patiënten ouder dan 75 jaar ondervertegenwoordigd door exclusie 
op basis van leeftijd of co-morbiditeit. Het rectumcarcinoom komt echter hoofdzakelijk 
voor bij oudere patiënten. Voor de hoofdstukken 3 en 4 werd gebruik gemaakt van de 
gegevens van zowel de TME studie als de Integrale Kankercentra West en Zuid. In hoofd-
stuk 3 werd aangetoond dat de 5-jaars overleving voor patiënten jonger dan 75 jaar 
60% was voor de introductie van de TME procedure in Nederland, 67% tijdens de TME 
studie en 70% na de TME studie (P < 0,0001). Voor patiënten van 75 jaar en ouder werd 
geen verbetering in de 5-jaars overleving gevonden: 41%, 40% en 43%, respectievelijk 
voor, tijdens en na de TME studie. Bovendien was de mortaliteit in de eerste 6 maanden 
postoperatief significant hoger voor de oudere patiënten in vergelijking met patiënten 
jonger dan 75 jaar: 14% voor oudere patiënten versus 3,9% voor jongere patiënten in de 
TME studie (P < 0,0001). In de database van het IKW en IKZ werden soortgelijke resulta-
ten gevonden (16% versus 3.9%; P < 0,0001). In hoofdstuk 4 werd de associatie tussen 
leeftijd, morbiditeit en 6-maanden mortaliteit aangegeven. Sterfte gerelateerd aan de 
behandeling is waarschijnlijk een belangrijke competitieve risicofactor, die de positieve 
effecten van TME chirurgie voor patiënten ouder dan 75 jaar doet vervagen. Voor oudere 
patiënten die een goede lichamelijke en geestelijke gezondheid hebben, lijkt de huidige 
therapie een goede behandeling. Echter, voor diegene met een verminderde fysiologi-
sche reserve door bijvoorbeeld co-morbiditeit, lijkt een alternatieve behandeling met 
gebruik van radiotherapie en minder uitgebreide chirurgie een meer geschikte optie.
Een andere groep met een relatief slechte uitkomst is de groep patiënten behandeld 
met een abdominoperineale resectie. In hoofdstuk 5 wordt een studie omschreven 
die onderzoekt of de abdominoperineale resectie zelf of de combinatie van patiënt- en 
tumorgerelateerde factoren die resulteerde in de keuze voor een abdominoperineale 
resectie resulteert in deze slechte uitkomst. De volgende eindpunten worden bestu-
deerd: radicaliteit (gedefinieerd als een tumor positief circumferentieel snijvlak), lokaal 
recidiefpercentage, algehele en kanker-specifieke overleving. Voor deze studie werden 
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de gegevens van de Swedish Rectal Cancer trial, de TME studie, de CAO/ARO/AIO-94 
studie, de EORTC 22921 studie en de Polish Rectal Cancer trial gecombineerd (5187 
patiënten). Er werd een “propensity score” berekend: de voorspelde kans om een abdo-
minoperineale resectie te ondergaan gegeven geslacht, leeftijd en afstand van de tumor 
tot de anus. De abdominoperineale resectie was geassocieerd met een toegenomen 
risico op een positief circumferentieel snijvlak (odds ratio 2,52; P < 0,001), een toege-
nomen kans op een lokaal recidief (hazard ratio 1,53; P = 0,001) en een afname van de 
kanker-specifieke overleving (hazard ratio 1,31; P = 0,002); een associatie tussen de “pro-
pensity score” en deze eindpunten werd niet gevonden. De resultaten suggereren dat 
de abdominoperineale resectie zelf een belangrijke voorspeller is voor een niet-radicale 
operatie met een toegenomen risico op een lokaal recidief en sterfte door kanker voor 
patiënten met een gevorderd rectumcarcinoom.
In hoofdstuk 6 werd de groep patiënten behandeld met een abdominoperineale 
resectie in de TME studie onderzocht om tumor- en patiëntgerelateerde risicofactoren 
te vinden voor irradicale resecties, lokaal recidief en algehele overleving. Een positief 
circumferentieel snijvlak werd gevonden bij 29,6% van alle patiënten: 44% bij een 
anterieur gelegen tumor, 21% bij een lateraal gelegen tumor, 23% bij een dorsaal gele-
gen tumor en 17% bij een (semi)circumferentiële tumor (P < 0,001). In de multivariate 
analyse waren T-stadium, N-stadium en tumorlocatie onafhankelijke risicofactoren voor 
een positief circumferentieel snijvlak. Van de vrouwen die een (partiële) resectie van 
de vagina-achterwand ondergingen, hadden 47,8% nog steeds een positief snijvlak. 
T-stadium, N-stadium en status van het circumferentiële snijvlak waren onafhankelijke 
risicofactoren voor een lokaal recidief. De volgende risicofactoren werden gevonden 
voor algehele overleving: leeftijd, T-stadium, N-stadium, status van het circumferentiële 
snijvlak en afstand van de tumor tot de anus. De resultaten geven aan dat de chirurgische 
behandeling erop gericht moet zijn om een adequate afstand tussen tumor en snijvlak 
te verkrijgen. Om de uitkomsten van patiënten behandeld met een abdominoperineale 
resectie te verbeteren, moet een adequate preoperatieve stadiëring worden verricht, 
inclusief een inschatting van de betrokkenheid van het circumferentiële snijvlak (me-
sorectale fascie). Voor patiënten bij wie de tumor tot in of vlakbij het circumferentiële 
TME snijvlak komt, is preoperatief 5 x 5 Gy radiotherapie alleen onvoldoende. De behan-
deling bestaat dan bij voorkeur uit preoperatieve behandeling met chemoradiotherapie 
en/of een uitgebreidere resectie.
In de EORTC 22921 studie werd de toevoeging van pre- en/of postoperatieve chemo-
therapie aan een schema van 6 weken preoperatieve radiotherapie bestudeerd voor 
patiënten met T3 of resectabele T4 rectumcarcinomen.6 De studie was open voor inclu-
sie van april 1993 tot maart 2003. Vanaf 1999 werd in het studieprotocol geadviseerd 
een TME procedure te verrichten. De betrokkenheid van het circumferentiële snijvlak, 
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het lokaal recidiefpercentage, de algehele en ziektevrije overleving voor patiënten met 
een lang preoperatief schema met (chemo)radiotherapie waren onderwerp van studie 
in hoofdstuk 7. Het percentage positieve snijvlakken was gerelateerd aan de periode 
van behandeling: er werden minder positieve snijvlakken gevonden na 1999. Alhoewel 
preoperatieve chemoradiotherapie in vergelijking met preoperatieve radiotherapie 
resulteerde in een lager TNM-stadium en kleinere tumoren,7 werd geen significant effect 
van het type preoperatieve behandeling op het percentage positieve circumferentiële 
snijvlakken gevonden. Een positief circumferentieel snijvlak gaf een hoger risico op een 
lokaal recidief en een afgenomen ziektevrije en algehele overleving. Alhoewel het nuttig 
kan zijn om een gevorderd rectumcarcinoom te “downstagen”, suggereren de resultaten 
dat het ultieme doel een radicale operatie is.
In hoofdstuk 8 werden de gegevens van de EORTC 22921 studie gebruikt om te 
bestuderen welke groep patiënten met een gevorderd rectumcarcinoom behandeld 
met een schema van 6 weken preoperatieve (chemo)radiotherpie voordeel kunnen heb-
ben van de toevoeging van postoperatieve chemotherapie. In de totale groep patiënten 
werd geen significant voordeel gevonden voor postoperatieve therapie op de ziektevrije 
overleving (P > 0,05).6 Het effect van postoperatieve chemotherapie op ziektevrije over-
leving verschilde echter significant tussen patiënten met een ypT0-2 stadium (“downsta-
ging”) na preoperatieve therapie en patiënten zonder “downstaging” (ypT3-4): alleen de 
patiënten met ypT0-2 leken een voordeel te hebben van postoperatieve chemotherapie 
(P = 0,013). Soortgelijke resultaten werden gevonden voor de algehele overleving. De 
resultaten tonen aan dat er onder andere rekening gehouden moet worden met de 
reactie van tumoren op preoperatieve therapie bij het ontwerpen en interpreteren van 
studies over postoperatieve therapie. Bovendien zou de tumorgevoeligheid voor de 
preoperatieve behandeling gebruikt kunnen worden om een eventuele postoperatieve 
behandeling aan te passen. Dit kan het gebruik van ineffectieve behandelingen, met de 
bijbehorende bijwerkingen, verminderen.
Eén van de gevreesde complicaties na een lage anterieure resectie is naadlekkage. In 
hoofdstuk 9 werden de databases van de Swedish Rectal Cancer trial, de TME studie, de 
CAO/ARO/AIO-94 studie, de EORTC 22921 studie en de Polish Rectal Cancer trial gecombi-
neerd om de associatie tussen naadlekkage en de gevolgen op lange termijn te bepalen. 
In totaal werden 2726 patiënten met een lage anterieure resectie geselecteerd. Naadlek-
kage trad op bij 9,7% van de patiënten. In de groep patiënten met een ontlastend stoma 
werd minder naadlekkage gevonden (P = 0,002). Na exclusie van patiënten die binnen 
90 dagen na de operatie stierven, was naadlekkage een onafhankelijke risicofactor voor 
verminderde algehele overleving (hazard ratio 1,29; 95% betrouwbaarheidsinterval 
1,02-1,63; P = 0,034), maar niet voor kanker-specifieke overleving (hazard ratio 1,12; 95% 
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betrouwbaarheidsinterval 0,83-1,52; P = 0,466). Patiënten die naadlekkage overleefden, 
hadden na enkele jaren nog steeds een afgenomen algehele overleving.
In de vroege postoperatieve periode wordt naadlekkage gevreesd door de geasso-
cieerde morbiditeit en mortaliteit. Het onderzoek in hoofdstuk 10 richtte zich op deze 
periode. Patiëntgegevens uit drie ziekenhuizen werden retrospectief verzameld (1066 
patiënten). Van deze groep patiënten werd bij 7,0% een symptomatische naadlekkage 
gediagnosticeerd. Het sterftecijfer voor patiënten met een naadlekkage was 39%. Ver-
traging in het stellen van de diagnose naadlekkage zou een bijdrage geleverd kunnen 
hebben aan dit hoge sterftecijfer: 4 dagen (mediaan) nadat de eerste symptomen aan-
wezig waren, werd de diagnose gesteld. Dientengevolge werd een protocol gemaakt 
waarin de postoperatieve zorg gestandaardiseerd werd en waarin gebruik werd gemaakt 
van gemakkelijk beschikbare klinische parameters, zoals temperatuur, hartfrequentie 
en lichamelijk onderzoek van het abdomen. Vervolgens werd dit protocol prospectief 
getest tussen augustus 2004 en augustus 2006 (223 patiënten). Naadlekkage werd bij 
9,4% van de patiënten in deze periode gediagnosticeerd. Vergeleken met de historische 
controles was de vertraging in het stellen van de diagnose naadlekkage na het optreden 
van de eerste symptomen significant korter in de periode waarin gebruik werd gemaakt 
van de gestandaardiseerde postoperatieve follow-up: de diagnose werd met een 
vertraging van 1,5 dag in plaats van 4 dagen (mediaan) gesteld (P = 0.01). Bovendien 
daalde de mortaliteit na het optreden van naadlekkage naar 24%, maar dit verschil was 
niet significant. Concluderend lijkt gestandaardiseerde follow-up voor naadlekkage te 
resulteren in een kortere periode tussen de eerste symptomen en het stellen van de 
diagnose naadlekkage. Op dit moment wordt er in meerdere centra in Nederland een 
registratieproject uitgevoerd om de scoringslijst en beslisboom verder te verbeteren en 
te valideren (de “DUtch LeaKage score”).
Zowel in hoofdstuk 9 als in andere studies werden bij ontlastend stoma’s minder 
naadlekkages gevonden.8 Een deel van deze tijdelijke stoma’s wordt echter nooit opge-
heven. In hoofdstuk 11 werden de gegevens van de TME studie gebruikt om het beleid 
ten aanzien van stoma’s te bestuderen en om factoren te identificeren die gerelateerd 
zijn aan het niet opheffen van stoma’s. Tijdens de eerste operatie werd bij 523 van de 924 
patiënten met een lage anterieure resectie (57%) een stoma aangelegd. Bij 19% van deze 
patiënten werd het stoma nooit opgeheven. Risicofactoren voor een permanent stoma 
waren onder andere postoperatieve complicaties en een stoma aangelegd tijdens een 
tweede of opeenvolgende operatie (bijvoorbeeld na het optreden van naadlekkage). 
De resultaten tonen aan dat ieder tijdelijk stoma aangelegd moet worden alsof het een 
permanent stoma is: een juiste plaatsing is dan vooral van belang.
In hoofdstuk 12 wordt dit proefschrift in een bredere context geplaatst. Het belang van 
kwaliteitsborgingprojecten wordt geïllustreerd, onder andere met de resultaten van de 
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TME studie. Om een continue kwaliteitsverbetering van de oncologische behandeling 
te bewerkstelligen, is monitoring nodig. Niet alleen binnen gerandomiseerde studies, 
maar ook als onderdeel van de dagelijkse praktijk. In diverse landen is de effectiviteit 
van een audit aangetoond. Recent is een Europese audit geïnitieerd, ondersteund door 
de European CanCer Organisation (ECCO). Door terugkoppeling van de resultaten van 
deze audit kan de zorg voor patiënten met kanker uiteindelijk verder worden verbeterd.
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